EXPRESS SCRIPTS INC, S-3/A, 2000-10-18

EXPRESS SCRIPTS INC
S-3/A, 2000-10-18
SPECIALTY OUTPATIENT FACILITIES, NEC

Previous: EXPRESS SCRIPTS INC, 8-K, EX-10.1, 2000-10-18

Next: EXPRESS SCRIPTS INC, S-3/A, EX-4.2, 2000-10-18

<PAGE> 1

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 17, 2000.
REGISTRATION NO. 333-47572
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
AMENDMENT NO. 1

FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------------

EXPRESS SCRIPTS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

<TABLE>
<S> <C>
DELAWARE 43-1420563
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
</TABLE>

13900 RIVERPORT DRIVE
MARYLAND HEIGHTS, MISSOURI 63043
(314) 770-1666

(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)

------------------------

THOMAS M. BOUDREAU, ESQ.
GENERAL COUNSEL AND SECRETARY
EXPRESS SCRIPTS, INC.
13900 RIVERPORT DRIVE
MARYLAND HEIGHTS, MISSOURI 63043
(314) 770-1666

(NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE,
OF AGENT FOR SERVICE)

------------------------

COPIES TO:

<TABLE>
<S> <C>
VINCENT PAGANO, JR., ESQ. JAMES J. CLARK, ESQ.
SIMPSON THACHER & BARTLETT CAHILL GORDON & REINDEL
425 LEXINGTON AVENUE 80 PINE STREET
NEW YORK, NEW YORK 10017-3954 NEW YORK, NEW YORK 10005
(212) 455-2000 (212) 701-3000
</TABLE>

------------------------

APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as
practicable after the effective date of this registration statement.

If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]

If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act,
other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [ ]

If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
--------

If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
--------

If delivery of the prospectus is expected to be made pursuant to Rule 434
under the Securities Act, please check the following box. [ ]
--------

------------------------

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON ANY DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE,
ON ANY DATE THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SECTION
8(a), MAY DETERMINE.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
<PAGE> 2

EXPLANATORY NOTE

This registration statement contains two forms of prospectus: (1) a
prospectus relating to an offer by NYLIFE LLC to sell outstanding shares of
Express Scripts Class A common stock; and (2) a prospectus relating to the
delivery by the Express Scripts Automatic Exchange Security Trust of shares of
Express Scripts Class A common stock owned by NYLIFE LLC that may be delivered
in exchange for the Trust Issued Automatic Exchange Securities offered by the
Trust. The prospectus to be used in connection with the stock offering is set
forth in full following this explanatory note. The prospectus to be used in
connection with the Trust offering is identical to the prospectus for the stock
offering except that the outside front and back covers and table of contents are
replaced with alternative versions, the subsections entitled "Concurrent
Offering" and "The Offering" contained in the section entitled "Prospectus
Summary" are replaced with alternative versions, the section entitled
"Underwriting" is replaced with an alternative section entitled "Plan of
Distribution", and a new section entitled "Trust Prospectus" is added after the
section entitled "Plan of Distribution", all included herein following the
prospectus for the stock offering.
<PAGE> 3

THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE
MAY NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT
AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY
THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.

SUBJECT TO COMPLETION, DATED OCTOBER 17, 2000.

6,000,000 Shares

[EXPRESS SCRIPTS LOGO]

Class A Common Stock
------------------

The shares of Class A common stock being offered by this prospectus are
being sold by NYLIFE LLC, the selling stockholder. We will not receive any
proceeds from the sale of the Class A common stock being offered by this
prospectus.

We have two classes of authorized common stock, our Class A common stock
and our Class B common stock. Our Class B common stock has ten votes per share,
and our Class A common stock has one vote per share. A subsidiary of NYLIFE is
currently the holder of all of our outstanding Class B common stock.

Our Class A common stock is quoted on The Nasdaq Stock Market's National
Market under the symbol "ESRX." On October 16, 2000, the last reported sale
price for our Class A common stock was $77.375 per share.

Concurrently with this offering, NYLIFE is offering up to 3,000,000 shares
of Class A common stock (or up to 3,450,000 shares if the underwriters'
over-allotment option is exercised in full) that may be delivered by the Express
Scripts Automatic Exchange Security Trust upon exchange of the Trust Issued
Automatic Exchange Securities on the exchange date as defined in the Trust
prospectus. The Trust Securities are being sold by the Trust in an offering
described in the Trust prospectus. We will not receive any proceeds from the
sale or exchange of Trust Securities offered in the Trust prospectus.

Immediately prior to the completion of this offering and the Trust
offering, each outstanding share of Class B common stock will be exchanged for
one share of Class A common stock and distributed to NYLIFE. A portion of these
shares will be sold in this offering. After this offering and the exchange and
distribution, NYLIFE will have 23.4% of the voting power of our Class A common
stock, and there will be no shares of Class B common stock outstanding.

The underwriters have an option to purchase a maximum of 900,000 additional
shares of our Class A common stock from NYLIFE to cover over-allotments of
shares. If the over-allotment option is exercised by the underwriters in full,
NYLIFE will have 21.1% of the voting power of our Class A common stock.

INVESTING IN OUR CLASS A COMMON STOCK INVOLVES RISKS. SEE "RISK FACTORS" ON
PAGE 8.

<TABLE>
<CAPTION>
UNDERWRITING
PRICE TO DISCOUNTS AND PROCEEDS TO
PUBLIC COMMISSIONS SELLING STOCKHOLDER
-------- ------------- -------------------
<S> <C> <C> <C>
Per Share............................................ $ $ $
Total................................................ $ $ $
</TABLE>

Delivery of the shares of Class A common stock will be made on or about
November , 2000.

Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.

Joint Bookrunners

CREDIT SUISSE FIRST BOSTON GOLDMAN, SACHS & CO.
------------------
BANC OF AMERICA SECURITIES LLC SALOMON SMITH BARNEY
CIBC WORLD MARKETS

The date of this prospectus is November , 2000.

<PAGE> 4

------------------

TABLE OF CONTENTS

<TABLE>
<CAPTION>
PAGE
----
<S> <C>
PROSPECTUS SUMMARY.................... 1
RISK FACTORS.......................... 8
RELATIONSHIP WITH NYLIFE ............. 14
USE OF PROCEEDS....................... 17
PRICE RANGE OF COMMON STOCK AND
DIVIDEND POLICY..................... 17
CAPITALIZATION........................ 18
SELECTED FINANCIAL AND OPERATING
DATA................................ 19
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS....................... 21
BUSINESS.............................. 33
</TABLE>

<TABLE>
<CAPTION>
PAGE
----
<S> <C>
MANAGEMENT............................ 46
PRINCIPAL STOCKHOLDERS................ 50
DESCRIPTION OF CAPITAL STOCK.......... 53
SELLING STOCKHOLDER................... 55
UNDERWRITING.......................... 56
NOTICE TO CANADIAN RESIDENTS.......... 59
FORWARD-LOOKING STATEMENTS............ 60
WHERE YOU CAN FIND MORE INFORMATION... 61
LEGAL MATTERS......................... 62
EXPERTS............................... 62
INDEX TO FINANCIAL STATEMENTS......... F-1
</TABLE>

------------------

YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS DOCUMENT OR TO
WHICH WE HAVE REFERRED YOU. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH
INFORMATION THAT IS DIFFERENT. THIS DOCUMENT MAY ONLY BE USED WHERE IT IS LEGAL
TO SELL THESE SECURITIES. THE INFORMATION IN THIS DOCUMENT MAY ONLY BE ACCURATE
ON THE DATE OF THIS DOCUMENT.

i
<PAGE> 5

PROSPECTUS SUMMARY

This summary highlights information contained elsewhere in this prospectus
and may not contain all of the information you should consider before investing
in the shares of Class A common stock offered by this prospectus. You should
read this entire prospectus carefully, including the risk factors and financial
statements.

You should also keep the following points in mind as you read this
prospectus:

- Unless the context otherwise indicates, references in this document to
"we," "us" and "our" refer to Express Scripts, Inc. and its subsidiaries.
References to "NYLIFE" refer to NYLIFE LLC.

- Unless we tell you otherwise, the information in this prospectus assumes
that the underwriters will not exercise their over-allotment option to
purchase additional shares of our Class A common stock from NYLIFE.

- Information regarding our relative size is based on estimates of our
management in light of their experience in the industry.

- Membership counts may not be comparable between us and our competitors,
although we believe they provide a reasonable estimate of the population
we serve.

THE COMPANY

We are the third largest pharmacy benefit management company in North
America, commonly referred to as a PBM. PBMs coordinate the distribution of
outpatient prescription pharmaceuticals through a combination of benefit
management services, including retail drug card programs and mail pharmacy
services. We provide these services for health care payors. We are independent
from pharmaceutical manufacturer ownership, and believe our independence is
important to our clients as it allows us to make unbiased formulary
recommendations to our clients, balancing both clinical efficacy and cost.

We have one of the largest managed care membership bases of any PBM. Before
1998, our internally generated growth was driven almost exclusively by the
ability to expand our product offerings and increase our client and membership
base. From 1992 through 1997, our net revenues and net income increased at
compound annual growth rates of 58% and 49%, respectively. While our internal
growth strategy remains a major focus, we have complemented our internal growth
strategy with two substantial acquisitions. In April 1998, we acquired ValueRx,
and in April 1999, we acquired Diversified Pharmaceutical Services, or DPS.
These acquisitions added to the scale of our membership base, broadened our
product offerings and enhanced our clinical capabilities and technologies.

As of October 1, 2000 we served approximately 41.5 million members,
excluding approximately 500,000 members served under our contract with United
HealthCare which expired on May 31, 2000. We developed a migration plan to
transition the United HealthCare members to their new provider throughout 2000.
The migration plan is now substantially complete. Some of our largest clients
include Aetna U.S. HealthCare, Oxford Health Plans, Blue Cross and Blue Shield
of Massachusetts, the State of Georgia, Blue Shield of California and the State
of New York Empire Plan Prescription Drug Program.

Our PBM services are delivered primarily through networks of retail
pharmacies that are under non-exclusive contract with us and through five mail
pharmacy service centers, which we own and operate. More than 55,000 retail
pharmacies, representing more than 99% of all U.S. retail pharmacies,
participate in one or more of our networks. In 1999, we processed approximately
211.3 million network pharmacy claims and 10.6 million mail pharmacy
prescriptions, with an estimated total drug spending of $8.7 billion, excluding
United HealthCare network pharmacy claims of 62.6 million having an estimated
total drug spending of $2.4 billion. For the nine months ended September 30,
2000, we processed approximately 175.4 million network pharmacy claims and
approximately 11.1 million mail pharmacy prescriptions, with

1
<PAGE> 6

an estimated total drug spending of approximately $8.2 billion, excluding United
HealthCare network pharmacy claims of 56.2 million having an estimated total
drug spending of $2.6 billion.

RECENT DEVELOPMENTS

Financial Results for the Nine Months Ended September 30, 2000. On October
16, 2000, we reported revenues for the nine months ended September 30, 2000 of
$4.9 billion, a 63.3% increase over $3.0 billion for the same period of 1999.
Gross profit increased 23.3% to $402.7 million for the nine months ended
September 30, 2000 from $326.7 million for the comparable period of 1999.
Selling, general and administrative expenses, excluding depreciation and
amortization, were $201.6 million, a 22.8% increase over $164.1 million reported
for the comparable period of 1999. We reported a net loss of $28.9 million, or
$0.76 per basic share and $0.74 per diluted share, for the nine months ended
September 30, 2000 compared to net income of $31.0 million, or $0.88 per basic
share and $0.86 per diluted share for the nine months ended September 30, 1999.
Included in the reported loss for the nine months ended September 30, 2000 were
a $155.0 million ($97.0 million after tax) non-cash write-down of our
PlanetRx.com, Inc. investment, a $1.5 million ($0.9 million after tax) gain on
the restructuring of our interest rate swap agreements and a $0.9 million after
tax extraordinary loss on the early retirement of debt. Included in net income
for the nine months ended September 30, 1999 was a $9.4 million ($5.8 million
after tax) non-recurring operating charge relating to the consolidation of our
Minneapolis facilities and a $7.2 million after tax extraordinary loss on the
early retirement of debt. Excluding these items for the nine months ended
September 30, 2000 and 1999, net income would have been $68.1 million, or $1.78
per basic share and $1.75 per diluted share, and $43.9 million, or $1.24 per
basic share and $1.21 per diluted share, respectively.

Cash flow from operations for the nine months ended September 30, 2000 was
$157.2 million. During the third quarter of 2000, we repaid the remaining $35
million on our revolving credit facility and prepaid $100 million on our Term A
loans. The prepayments on the Term A loans eliminate the scheduled principal
payments for fiscal years 2001, 2002 and a portion of the scheduled principal
payment for fiscal year 2003.

Expansion in Canada. The shareholders of Centre d'autorisation et de
paiement des services de sante, a leading Quebec-based PBM commonly referred to
as CAPSS, accepted the offer made by our Canadian subsidiary, ESI Canada, Inc.,
to acquire all of the outstanding shares of CAPSS, subject to regulatory
approval and satisfaction of certain conditions, for approximately CDN$25
million (approximately US$16.5 million). The transaction, which is expected to
close by year-end, will add approximately 1.5 million lives to ESI Canada's
membership base. The transaction is not expected to be dilutive to earnings in
2001 and is expected to be slightly accretive in 2002.

INDUSTRY

Prescription drugs are the fastest growing component of health care costs
in the United States. Since 1990, pharmaceutical sales have grown at a compound
annual growth rate of approximately 12%, and the U.S. Health Care Financing
Administration projects a compound annual growth rate of approximately 11%
through 2008. This growth is principally driven by new drug introductions,
increases in drug utilization rates and changes in drug strength, therapeutic
mix and dosage. In response to these trends, health benefit providers have been
seeking ways to better understand and control drug costs. PBMs help health
benefit providers to provide a cost-effective drug benefit and better understand
the impact of prescription drug utilization on total health care expenditures.

STRATEGY

Our strategy is to increase our membership base and grow profitability by
focusing on generating sales to new clients and expanding the services we
provide to existing clients, developing new products and

2
<PAGE> 7

services for sale to existing clients and pharmaceutical manufacturers,
investing in information technologies to enhance our services and increase
efficiencies, and selectively identifying and pursuing acquisitions to increase
our membership base and enhance our product offerings.

- Generation of Sales to New Clients and Growth from Existing Clients. Our
primary growth strategy is to pursue sales to new clients and generate
growth in the membership base of existing clients. Our compound annual
growth rate in members, excluding our recent acquisitions, is 45% from
our initial public offering through 1997, and including the acquisitions
of ValueRx and DPS is 53% through 1999 (excluding United HealthCare
membership). We are experiencing solid growth in each of the managed care
(excluding the loss of United HealthCare), employer, insurance carrier
and third party administrator market segments. Recent large new clients
under contract with us include Ceres Health Care, Inc., a subsidiary of
Ceres Group, Inc., and the State of Georgia. Growth within the membership
base of existing clients is also important to our strategy. When our
clients, such as managed care organizations, third-party administrators
and other third-party payors, market their service offerings to potential
customers, they generally market our prescription drug program as part of
their offerings. As their client base grows, our membership base
typically grows as well. Since our acquisitions of ValueRx and DPS, we
have aggressively undertaken a program to sell formulary management
services, mail pharmacy services and/or network pharmacy services to
clients for whom ValueRx or DPS previously provided only one or two of
these services. Since the second quarter of 1999, we have successfully
sold additional services to approximately 8.5 million existing members.

- Development and Sale of New Products and Services to Existing Clients and
Pharmaceutical Manufacturers. We continue to emphasize the development
and sale of new products and services as part of our PBM offerings to our
existing clients, and we have begun marketing our products and services
to selected pharmaceutical manufacturers. We believe these products and
services are necessary to compete effectively in the current business
environment and to differentiate us from our competitors on a measure
other than price. We intend to continue to invest in these capabilities
in the future. Products and services developed by us in recent years
include advanced formulary compliance programs, proprietary clinical
services, disease management programs, drug outcomes research, drug
therapy management programs, medical information management and
sophisticated management reporting capabilities. We believe a particular
growth area in the PBM industry will be medical information management.
We believe our Practice Patterns Science subsidiary is an industry leader
in this area, having developed proprietary software to process and sort
medical claims, prescription drug claims and clinical laboratory data for
use by managed care organizations and other health care companies. The
clients most interested in these advanced capabilities are managed care
organizations, but we believe third-party administrators and large
employers present opportunities for the sale of these advanced
capabilities as well. Recent products and services being offered to
pharmaceutical manufacturers include therapy compliance, therapy
management and market research programs. We also believe opportunities
exist for us to grow our non-PBM specialty distribution operation, which
assists pharmaceutical manufacturers with the distribution of products
requiring special handling/packaging or products targeted to a specific
physician or patient population.

- Investment in Information Technologies to Enhance Services and Increase
Efficiencies. We continue to implement and refine our information
technologies. We are developing interfaces with our clients to reduce our
costs and give our clients the tools necessary to more effectively manage
their pharmacy benefits. Member interfaces are being developed to educate
consumers and help them better manage the pharmacy component of their
health care, and to provide a more efficient means of handling member
benefit/service inquiries. Through our alliances with physician
connectivity companies, we are promoting the use of hand-held prescribing
devices by physicians to improve the information available to the
prescriber and enhance patient care. Portals are also being planned to
improve efficiencies in our relationships with network pharmacies and
pharmaceutical manufacturers.

3
<PAGE> 8

- Growth Through Strategic Acquisitions. During the past several years we
have supplemented our strong internal growth with selected acquisitions
of other PBMs. Our objectives in pursuing acquisitions are to increase
the scale of our business, expand our client base, increase our
penetration of PBM markets and expand our product and service offerings.
Our acquisitions of ValueRx and DPS substantially increased our
membership base, expanded our client base, increased our presence in key
market segments and enhanced our clinical capabilities and technologies.
Our acquisition of ValueRx added approximately 10.0 million members and
our acquisition of DPS added approximately 13.0 million members excluding
approximately 9.5 million United HealthCare members. We intend to
continue to selectively identify and pursue potential acquisition targets
in the future.

OTHER INFORMATION

We were incorporated in Missouri in 1986 and reincorporated in Delaware in
1992. Our principal executive offices are located at 13900 Riverport Drive,
Maryland Heights, Missouri 63043, and our phone number is (314) 770-1666.

CONCURRENT OFFERING

4
<PAGE> 9

THE OFFERING

Class A common stock offered
by NYLIFE..................... 6,000,000 shares

Common stock to be outstanding
after this offering:
Class A common stock........ 38,496,359 shares

Class B common stock........ none
------------

Total common stock.......... 38,496,359 shares
------------------
------------------

Does not include as of September 1, 2000:

- stock options and similar equity rights
granted to employees and independent
directors to purchase 3,499,365 shares of our
Class A common stock, of which 1,162,245 were
exercisable

- 1,007,368 reserved shares of our Class A
common stock for issuance in connection with
strategic alliances with certain clients

- 269,419 reserved shares of our Class A common
stock for our Employee Stock Purchase Plan
and our Executive Deferred Compensation Plan

Relative rights of holders of
our Class A and Class B common
stock....................... Our Class B common stock has ten votes per
share and our Class A common stock has one vote
per share. A subsidiary of NYLIFE is currently
the holder of all our outstanding Class B
common stock. Our Class B common stock
automatically converts to our Class A common
stock on a share-for-share basis upon transfer
of such shares to any entity other than New
York Life Insurance Company or an affiliate of
New York Life and otherwise at the option of
the holder thereof. The NYLIFE subsidiary has
agreed to exchange each outstanding share of
Class B common stock for one share of our Class
A common stock immediately prior to the
completion of this offering and distribute such
shares to NYLIFE. There will be no shares of
Class B common stock outstanding after this
offering. After the stock offering and the
Trust offering, NYLIFE will have 23.4% of the
voting power of our Class A common stock,
including the right to vote 3,000,000 shares
which the Trust may deliver upon exchange of
the Trust Securities, unless such shares are
delivered pursuant to the terms of the Trust.
New York Life and its subsidiaries have agreed
to vote any shares of our Class A common stock
that may be delivered by the Trust in the same
proportion and to the same effect as the votes
cast by our other stockholders at any meeting
of stockholders, subject to two exceptions
relating to elections of directors and approval
of our 2000 Long-Term Incentive Plan.

Use of proceeds............... We will not receive any proceeds from this
offering.

Nasdaq National Market
symbol........................ ESRX

5
<PAGE> 10

SUMMARY HISTORICAL FINANCIAL AND OPERATING DATA

<TABLE>
<CAPTION>
(UNAUDITED)
SIX MONTHS ENDED
YEAR ENDED DECEMBER 31, JUNE 30,
----------------------------------------------- -----------------------
1996 1997 1998(2) 1999(3) 1999(4) 2000(5)
-------- ---------- ---------- ---------- ---------- ----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenues....................... $773,615 $1,230,634 $2,824,872 $4,288,104 $1,895,836 $3,128,876
Gross profit................... 88,733 111,467 239,875 461,199 202,200 269,849
Operating income............... 39,630 48,850 89,234 136,784 64,463 99,057
Other income (expense), net.... 3,450 5,856 (12,994) 128,682 (26,616) (179,457)
Extraordinary loss............. -- -- -- 7,150 6,597 --
Net income (loss).............. 26,148 33,429 42,674 150,218 13,964 (52,745)
Basic earnings per share before
extraordinary item(1)........ $ 0.81 $ 1.02 $ 1.29 $ 4.36 $ 0.61 $ (1.39)
Diluted earnings per share
before extraordinary
item(1)...................... $ 0.80 $ 1.01 $ 1.27 $ 4.25 $ 0.59 $ (1.36)
</TABLE>

<TABLE>
<CAPTION>
AS OF (UNAUDITED)
DECEMBER 31, 1999 AS OF JUNE 30, 2000
----------------- -------------------
(IN THOUSANDS)
<S> <C> <C>
BALANCE SHEET DATA:
Cash........................................................ $ 132,630 $ 99,835
Working capital............................................. (34,003) (101,143)
Total assets................................................ 2,487,311 2,336,880
Total debt.................................................. 635,873 560,658
Stockholders' equity........................................ 699,482 629,264
</TABLE>

<TABLE>
<CAPTION>
(UNAUDITED)
SIX MONTHS ENDED
YEAR ENDED DECEMBER 31, JUNE 30,
-------------------------------------------------- -----------------------
1996 1997 1998(2) 1999(3) 1999(4) 2000(5)
---------- ---------- ---------- ----------- ---------- ----------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
SELECTED DATA:
Pharmacy benefit covered
lives(6).................. 10,000 13,000 23,000 49,000 46,000 49,000
Drug spending(7)(8)......... $1,636,000 $2,486,000 $4,495,000 $11,160,000 $4,532,000 $7,464,000
Network pharmacy claims
processed(8).............. 57,838 73,164 113,177 273,909 112,514 159,224
Mail pharmacy prescriptions
filled.................... 2,770 3,899 7,426 10,608 4,583 7,216
EBITDA(9)................... $ 46,337 $ 59,320 $ 115,683 $ 208,651 $ 93,524 $ 141,532
Cash flows provided by
operating activities...... $ 29,863 $ 52,391 $ 126,574 $ 214,059 $ 52,416 $ 98,027
Cash flows used in investing
activities................ $ (64,808) $ (16,455) $ (426,052) $ (759,576) $ (734,064) $ (27,514)
Cash flows provided by (used
in) financing
activities................ $ 48,652 $ 3,033 $ 357,959 $ 555,450 $ 641,306 $ (103,217)
</TABLE>

6
<PAGE> 11

-------------------------
(1) Earnings per share and weighted average shares outstanding have been
restated to reflect our two-for-one stock split effective October 30, 1998.

(2) Includes our acquisition of ValueRx effective April 1, 1998. Also includes a
non-recurring operating charge of $1,651 ($1,002 after tax) relating to our
managed vision business. Excluding this non-recurring operating charge, our
basic and diluted earnings per share before extraordinary item would have
been $1.32 and $1.30, respectively.

(3) Includes the acquisition of DPS effective April 1, 1999. Also includes
non-recurring operating charges and a one-time non-operating gain of $30,221
($18,188 after tax) and $182,930 ($112,037 after tax), respectively.
Excluding these amounts, our basic and diluted earnings per share before
extraordinary item would have been $1.76 and $1.72, respectively.

(4) Includes the acquisition of DPS effective April 1, 1999. Also includes
non-recurring operating charges of $9,400 ($5,773 after tax) relating to our
Minneapolis facility consolidation. Excluding this non-recurring charge, our
basic and diluted earnings per share before extraordinary item would have
been $0.78 and $0.76, respectively.

(5) Includes the write-down of marketable securities of $155,500 ($97,032 after
tax). Excluding this amount, our basic and diluted earnings per share before
extraordinary item would have been $1.16 and $1.14, respectively.

(7) Drug spending is a measure of the gross aggregate dollar value of drug
expenditures of all programs managed by us. The difference between drug
spending and revenue reported by us is the combined effect of excluding from
reported revenues:

- the drug ingredient cost for those clients that have established their own
pharmacy networks

- the expenditures for drugs of those companies on formulary-only programs
managed by us

- the co-pay portion of drug expenditures that are the responsibility of
members of health plans serviced by us

Therefore, drug spending provides a common basis to compare the drug
expenditures managed by a company given differences in revenue recognition.

(8) Includes drug spending and network pharmacy claims processed for United
HealthCare. Drug spending and network pharmacy claims processed for United
HealthCare were $2,422,000 and 62,591 for the year ended December 31, 1999,
respectively, $779,000 and 20,554 for the six months ended June 30, 1999,
respectively, and $2,001,000 and 41,729 for the six months ended June 30,
2000, respectively.

(9) EBITDA is earnings before other income (expense), interest, taxes,
depreciation and amortization, or operating income plus depreciation and
amortization. EBITDA is presented because it is a widely accepted indicator
of a company's ability to incur and service indebtedness. EBITDA, however,
should not be considered as an alternative to net income as a measure of
operating performance or an alternative to cash flow as a measure of
liquidity. In addition, our calculation of EBITDA may not be identical to
that used by other companies.

7
<PAGE> 12

RISK FACTORS

In addition to the other information in this prospectus, the following
factors should be considered carefully in evaluating an investment in the shares
of Class A common stock offered by this prospectus.

FAILURE TO EXECUTE OUR UNITED HEALTHCARE TRANSITION PLAN COULD ADVERSELY AFFECT
US

The pharmacy benefit management contract between DPS, our subsidiary, and
United HealthCare expired on May 31, 2000. In our financial analysis of the DPS
acquisition, we assumed United HealthCare would not renew its contract. However,
as of July 1, 2000, United HealthCare represented our largest client, with
approximately 8.3 million members, which accounted for approximately 17% of our
membership base. We developed a migration plan to transition the United
HealthCare membership to their new provider throughout 2000. The migration plan
is now substantially complete, and we currently serve only approximately 500,000
United HealthCare members. However, if we are unable to reduce our costs on a
basis commensurate with our expectations, the termination of this contract may
materially adversely affect our business, results of operations and cash flows.

FAILURE TO MAINTAIN INTERNAL GROWTH COULD ADVERSELY AFFECT OUR BUSINESS

We have experienced rapid internal growth over the past several years. Our
ability to maintain this internal growth rate is dependent upon our ability to
attract new clients, achieve growth in the membership base of our existing
clients and cross-sell additional services to our existing clients. If we are
unable to continue our client and membership growth, our results of operations
and financial position could be materially adversely affected.

COMPETITION IN THE PBM INDUSTRY COULD REDUCE OUR CLIENT MEMBERSHIP AND OUR
PROFIT MARGINS

Pharmacy benefit management is a very competitive business. Our competitors
include large and well-established companies that may have greater financial,
marketing and technological resources than we do. One major competitor in the
PBM business, Merck-Medco Managed Care, L.L.C., is owned by Merck & Co., Inc., a
large pharmaceutical manufacturer, which may give Merck-Medco purchasing or
other advantages over us by virtue of this ownership structure, and enable them
to succeed in taking away some of our clients. Consolidation in the PBM
industry, such as the recently completed acquisition of PCS, Inc. by Advance
Paradigm, Inc., may also lead to increased competition among a smaller number of
large PBM companies. Competition may also come from other sources in the future
from Internet-based connectivity companies, such as WebMD Corporation. We cannot
predict what effect, if any, these new competitors may have on the marketplace
or on our business.

Over the last several years intense competition in the marketplace has
caused many PBMs, including us, to reduce the prices charged to clients for core
services and share a larger portion of the formulary fees and related revenues
received from pharmaceutical manufacturers with clients. This combination of
lower pricing and increased revenue sharing, as well as increased demand for
enhanced service offerings and higher service levels, has caused our operating
profits to decline. We expect to continue marketing our services to larger
clients, who typically have greater bargaining power than smaller clients. This
might create continuing pressure on our margins. We can give no assurance that
new services provided to these clients will fully compensate for these reduced
margins.

8
<PAGE> 13

CHANGES IN STATE AND FEDERAL REGULATIONS COULD RESTRICT OUR ABILITY TO CONDUCT
OUR BUSINESS

Numerous state and federal laws and regulations affect our business and
operations. The categories include, but are not necessarily limited to:

- health care fraud and abuse laws and regulations, which prohibit certain
types of referral and other payments

- the Employee Retirement Income Security Act and related regulations,
which regulate many health care plans

- proposed comprehensive state PBM legislation

- consumer protection laws and regulations

- network pharmacy access laws, including "any willing provider" and "due
process" legislation, that regulate aspects of our network pharmacy
contracts

- legislation imposing benefit plan design restrictions, which limit how
our clients can design their drug benefit plans

- various licensure laws, such as managed care and third party
administrator licensure laws

- drug pricing legislation, including "most favored nation" pricing and
"unitary pricing" legislation

- mail pharmacy laws and regulations

- privacy and confidentiality laws and regulations, including those
proposed under the Federal Health Insurance Portability and
Accountability Act of 1996 (generally known as "HIPAA")

- Medicare prescription drug coverage proposals

- other Medicare and Medicaid reimbursement regulations

- potential regulation of the PBM industry by the U.S. Food and Drug
Administration

- pending legislation regarding importation of drug products into the
United States

We believe we operate our business in substantial compliance with all
existing legal requirements material to the operation of our business. There
are, however, significant uncertainties regarding the application of many of
these legal requirements to our business, and we cannot provide any assurance
that a regulatory agency charged with enforcement of any of these laws or
regulations will not interpret them differently or, if there is an enforcement
action brought against us, that our interpretation would prevail. In addition,
there are numerous proposed health care laws and regulations at the federal and
state levels, many of which could materially affect our ability to conduct our
business or adversely affect our results of operations. We are unable to predict
what additional federal or state legislation or regulatory initiatives may be
enacted in the future relating to our business or the health care industry in
general, or what effect any such legislation or regulations might have on us.

We are aware through reports in the press and other sources that a U.S.
Assistant Attorney General in Philadelphia is conducting an investigation into
certain practices of PBMs. These reports have indicated that some of our PBM
competitors have received subpoenas in connection with this investigation during
1999. We have not received a subpoena or been requested to testify or produce
documents in connection with this investigation. Press reports indicate that a
possible subject of the investigation is contractual relationships between the
PBMs and pharmaceutical manufacturers. We cannot predict what effect, if any,
this investigation may ultimately have on us or on the PBM industry generally.

The U.S. Secretary of Health and Human Services has issued proposed rules
under HIPAA which, when adopted, will establish standards for the use and
disclosure of personally identifiable health care information and for the system
security necessary for the maintenance and transmission of such information. We
believe we will be subject to the final regulations when issued. We believe we
will be able to comply fully with the proposed regulations, but we will incur
expenses in making required changes to
9
<PAGE> 14

our information systems and in training our employees to comply with the new
regulations. We are retaining a consulting firm to assist in evaluating the
extent of the work that would be required to comply with HIPAA. We are unable to
estimate our HIPAA compliance costs accurately until the final regulations are
issued, and there can be no assurance that such costs would not be material.

The federal Medicare program provides a comprehensive medical benefit
program for individuals age 65 and over, but currently covers only a few
outpatient prescription drugs. Currently both the Republicans and Democrats have
proposed various amendments to the Medicare program that would result in at
least partial coverage for most prescription drugs. We believe that a Medicare
prescription drug benefit could provide us with substantial new business
opportunities, but at the same time any such program could adversely affect
other aspects of our business. For instance, some of our clients sell medical
policies to seniors that provide a prescription drug benefit that we administer.
Other clients provide a prescription drug benefit to their retirees. Depending
on the plan that is ultimately adopted, a Medicare prescription drug benefit
could make such policies or plans less valuable to seniors, adversely affecting
that segment of our business. While we believe that there would be opportunities
for new business under a Medicare plan that would more than offset any adverse
effects, we can give no assurance that this would be the case.

FAILURE TO RETAIN KEY CLIENTS AND NETWORK PHARMACIES COULD ADVERSELY AFFECT OUR
BUSINESS AND LIMIT OUR ACCESS TO RETAIL PHARMACIES

We currently provide PBM services to approximately 12,000 client groups.
Our acquisitions have diversified our client base and reduced our dependence on
any single client. Our top 10 clients, measured as of July 1, 2000, but
excluding United HealthCare, represented approximately 23% of our total
membership base, but no single client represented more than approximately 5% of
our membership base. Our contracts with clients generally do not have terms of
longer than three years and, in some cases, are terminable by either party on
relatively short notice. Our larger clients generally distribute requests for
proposals and seek bids from other PBM providers in advance of the expiration of
their contracts. If several of these large clients elect not to extend their
relationship with us, and we are not successful in generating sales to replace
the lost business, our future business and operating results could be materially
adversely affected. In addition, we believe the managed care industry is
undergoing substantial consolidation, and another party that is not our client
could acquire some of our managed care clients. In such case, the likelihood
such client would renew its PBM contract with us could be reduced.

More than 55,000 retail pharmacies, representing more than 99% of all U.S.
retail pharmacies, participate in one or more of our networks. However, the top
10 retail pharmacy chains represent approximately 45% of the 55,000 pharmacies,
with these pharmacy chains representing even higher concentrations in certain
areas of the United States. Our contracts with retail pharmacies, which are non-
exclusive, are generally terminable by either party on relatively short notice.
If one or more of the top pharmacy chains elects to terminate its relationship
with us, our members' access to retail pharmacies and our business could be
materially adversely affected. In addition, large pharmacy chains either own
PBMs today, or could attempt to acquire a PBM in the future. Ownership of PBMs
by retail pharmacy chains could have material adverse effects on our
relationships with such pharmacy chains and on our business and results of
operations.

LOSS OF RELATIONSHIPS WITH PHARMACEUTICAL MANUFACTURERS AND CHANGES IN THE
REGULATION OF DISCOUNTS AND FORMULARY FEES PROVIDED TO US BY PHARMACEUTICAL
MANUFACTURERS COULD DECREASE OUR PROFITS

We maintain contractual relationships with numerous pharmaceutical
manufacturers which provide us with:

- discounts at the time we purchase the drugs to be dispensed from our mail
pharmacies

- formulary fees based upon sales of drugs from our mail pharmacies and
through pharmacies in our retail networks

10
<PAGE> 15

- administrative fees based upon the development and maintenance of
formularies which include the particular manufacturer's products

These fees are all commonly referred to as formulary fees or formulary
management fees.

We also provide various services for, or services which are funded wholly
or partially by, pharmaceutical manufacturers. These services include:

- compliance programs, which involve instruction and counseling of patients
concerning the importance of compliance with the drug treatment regimen
prescribed by their physician

- therapy management programs, which involve education of patients having
specific diseases, such as asthma and diabetes, concerning the management
of their condition

- market research programs in which we provide information to manufacturers
concerning drug utilization patterns

These arrangements are generally terminable by either party on relatively
short notice. If several of these arrangements are terminated or materially
altered by the pharmaceutical manufacturers, our operating results could be
materially adversely affected. In addition, formulary fee programs, as well as
some of the services we provide to the pharmaceutical manufacturers, have been
the subject of debate in federal and state legislatures and various other public
forums. Changes in existing laws or regulations, changes in interpretations of
existing laws or regulations or the adoption of new laws or regulations relating
to any of these programs, may materially adversely affect our business.

PENDING AND FUTURE LITIGATION COULD MATERIALLY AFFECT OUR RELATIONSHIPS WITH
PHARMACEUTICAL MANUFACTURERS OR SUBJECT US TO SIGNIFICANT MONETARY DAMAGES

Since 1993, retail pharmacies have filed over 100 separate lawsuits against
pharmaceutical manufacturers, wholesalers and certain PBMs, challenging brand
name drug pricing practices under various state and federal antitrust laws. The
plaintiffs alleged, among other things, that the manufacturers had offered, and
certain PBMs had knowingly accepted, discounts and rebates on purchases of brand
name prescription drugs that violated the Federal Sherman Act and the Federal
Robinson-Patman Act. Some manufacturers settled certain of these actions,
including a Sherman Act case brought on behalf of a nationwide class of retail
pharmacies. The class action settlements generally provided for commitments by
the manufacturers in their discounting practices to retail pharmacies. The
defendants who did not settle won the Sherman Act class action on a directed
verdict. With respect to the cases filed by plaintiffs who opted out of the
class action, some drug manufacturers have settled certain of these actions, but
such settlements are not part of the public record. The Robinson-Patman Act
cases are still pending.

We are not currently a party to any of these proceedings. To date, we do
not believe any of these settlements have had a material adverse effect on our
business. However, we cannot provide any assurance that the terms of the
settlements will not materially adversely affect us in the future or that we
will not be made a party to any separate lawsuit. In addition, we cannot predict
the outcome or possible ramifications to our business of the Robinson-Patman Act
cases.

We are also subject to risks relating to litigation and liability for
damages in connection with our PBM operations, including the dispensing of
pharmaceutical products by our mail pharmacies, the services rendered in
connection with our formulary management and informed decision counseling
services, and our non-PBM operations, including the products and services
provided in connection with our infusion therapy programs (and the associated
nursing services). We believe our insurance protection is adequate for our
present operations. However, we cannot provide any assurance that we will be
able to maintain our professional and general liability insurance coverage in
the future or that such insurance coverage will be available on acceptable terms
to cover any or all potential product or professional liability claims. A
successful product or professional liability claim in excess of our insurance
coverage could have a material adverse effect on our business.

11
<PAGE> 16

OUR LEVERAGE AND DEBT SERVICE OBLIGATIONS COULD IMPEDE OUR OPERATIONS AND
FLEXIBILITY

As of June 30, 2000, our net debt to net capitalization ratio was 42.3%,
which means that the amount of our outstanding debt is significant compared to
the net book value of our assets, and we have substantial repayment obligations
and interest expense. As of June 30, 2000, we had total consolidated debt of
approximately $561 million ($426 million after our $135 million in prepayments
during the third quarter 2000). We may incur additional indebtedness in the
future.

Our level of debt and the limitations imposed on us by our debt agreements
could have important consequences, including the following:

- we will have to use a portion of our cash flow from operations for debt
service rather than for our operations

- we may from time to time incur indebtedness under our credit facility,
which is subject to a variable rate of interest, making us vulnerable to
increases in interest rates

- we could be less able to take advantage of significant business
opportunities, such as acquisition opportunities, and react to changes in
market or industry conditions

- we could be more vulnerable to general adverse economic and industry
conditions

- we may be disadvantaged compared to competitors with less leverage

Furthermore, our ability to satisfy our obligations, including our debt
service requirements, will be dependent upon our future performance. Factors
which could affect our future performance include, without limitation,
prevailing economic conditions and financial, business and other factors, many
of which are beyond our control and which affect our business and operations.

Our bank credit facility is secured by the capital stock of each of our
existing and subsequently acquired domestic subsidiaries, excluding Practice
Patterns Science, Inc., Great Plains Reinsurance Company, ValueRx of Michigan,
Inc., Diversified NY IPA, Inc. and Diversified Pharmaceutical Services (Puerto
Rico), Inc., and 65% of the stock of our foreign subsidiaries. If we are unable
to meet our obligations under this bank credit facility, these creditors could
exercise their rights as a secured party and take possession of the pledged
capital stock of these subsidiaries. This would materially adversely affect our
results of operations and financial condition.

FAILURE TO CONTINUE TO DEVELOP NEW PRODUCTS, SERVICES AND DELIVERY CHANNELS MAY
ADVERSELY AFFECT OUR BUSINESS

We operate in a highly competitive environment. We and our competitors
continually develop new products and services to assist our clients in managing
the pharmacy benefit. If we are unsuccessful in continuing to develop innovative
products and services, our ability to attract new clients and retain existing
clients may suffer.

Technology is also an important component of our business, as we continue
to utilize new and better channels, such as the Internet, to communicate and
interact with our clients, members and business partners. If our competitors are
more successful than us in employing this technology, our ability to attract new
clients, retain existing clients and operate efficiently may suffer.

EFFORTS TO REDUCE HEALTH CARE COSTS AND ALTER HEALTH CARE FINANCING PRACTICES
COULD ADVERSELY AFFECT OUR BUSINESS

Efforts are being made in the United States to control health care costs,
including prescription drug costs, in response to, among other things, increases
in prescription drug utilization rates and drug prices. If these efforts are
successful or if prescription drug utilization rates were to decrease
significantly, our business and results of operations could be materially
adversely affected.

12
<PAGE> 17

We have designed our business to compete within the current structure of
the U.S. health care system. Changing political, economic and regulatory
influences may affect health care financing and reimbursement practices. If the
current health care financing and reimbursement system changes significantly,
our business could be materially adversely affected. Congress is currently
considering proposals to reform the U.S. health care system. These proposals may
increase governmental involvement in health care and PBM services, and otherwise
change the way our clients do business. Health care organizations may react to
these proposals and the uncertainty surrounding them by reducing or delaying
purchases of cost control mechanisms and related services that we provide. We
cannot predict what effect, if any, these proposals may have on our business.
Other legislative or market-driven changes in the health care system that we
cannot anticipate could also materially adversely affect our business.

FUTURE SALES OR ISSUANCES OF SHARES COULD ADVERSELY AFFECT OUR SHARE PRICE

As of September 1, 2000, in addition to the 6,000,000 shares of Class A
common stock being sold by NYLIFE and the 3,000,000 shares of Class A common
stock that may be delivered by the Express Scripts Automatic Exchange Security
Trust (assuming the underwriters in the Trust offering do not exercise their
over-allotment option in whole or in part), 3,768,784 shares of our Class A
common stock are issuable upon exercise of outstanding stock options and rights
granted under our stock option plans, our Employee Stock Purchase Plan and our
Executive Deferred Compensation Plan. Our Class B common stock will
automatically convert into a like number of shares of our Class A common stock
upon transfer to any entity other than New York Life or an affiliate of New York
Life or otherwise at the option of the holder thereof. The NYLIFE subsidiary
that currently holds our Class B common stock has agreed to exchange each
outstanding share of Class B common stock for one share of our Class A common
stock immediately prior to the completion of this offering and distribute such
shares to NYLIFE. After completion of the offering of Class A common stock being
sold by NYLIFE (assuming that NYLIFE delivers 3,000,000 shares of Class A common
stock to the Express Scripts Automatic Exchange Security Trust upon exchange of
the Trust Issued Automatic Exchange Securities on the exchange date as defined
in the Trust prospectus), 6,020,000 shares of our Class A common stock will be
eligible for sale by NYLIFE pursuant to Rule 144 under the Securities Act,
subject to the volume and other limitations contained therein, and will be
subject to registration rights as described below under "Relationship with
NYLIFE -- Stockholder and Registration Rights Agreement." Under the terms of
various strategic alliances, we may also be obligated to issue up to 1,007,368
additional shares of our Class A common stock to our strategic partners upon the
achievement by them of various membership and claims targets or the exercise by
them of warrants.

Any issuance of additional shares of our Class A common stock, including
those issuable in connection with our existing obligations, will result in a
dilution of the interest of our existing stockholders and could result in a
decrease in the market price of our Class A common stock.

NYLIFE has agreed to certain restrictions on its ability to transfer its
remaining shares of our Class A common stock after this offering. Our directors
and certain officers have also entered into lock-up agreements in connection
with this offering.

THE OFFERING OF TRUST SECURITIES BY THE EXPRESS SCRIPTS AUTOMATIC EXCHANGE
SECURITY TRUST COULD CAUSE OUR STOCK PRICE TO DECLINE

The price of the shares of our Class A common stock could become more
volatile and could be depressed by investors in anticipation of the potential
distribution into the market of additional shares of Class A common stock as a
result of the possible delivery of shares of Class A common stock by the Express
Scripts Automatic Exchange Security Trust, by possible sales of shares of Class
A common stock by investors who view the Trust Securities as a more attractive
means of equity participation in us and by hedging or arbitrage trading activity
that may develop involving the Trust Securities and the Class A common stock.

13
<PAGE> 18

RELATIONSHIP WITH NYLIFE

A NYLIFE subsidiary currently owns all of our outstanding shares of Class B
common stock, which automatically convert into shares of our Class A common
stock upon transfer to any entity other than New York Life or an affiliate of
New York Life or otherwise at the option of such subsidiary. The NYLIFE
subsidiary has agreed to exchange each outstanding share of Class B common stock
for one share of our Class A common stock immediately prior to the completion of
this offering and distribute such shares to NYLIFE. Immediately following the
stock offering and the Trust offering, NYLIFE will own approximately 23.4% of
our outstanding Class A common stock (approximately 21.1% if the underwriters
fully exercise their right to purchase additional shares in the stock offering
pursuant to their over-allotment option). The number of shares of Class A common
stock owned by NYLIFE after the stock offering and the Trust offering includes
3,000,000 shares exchangeable for the Trust Issued Automatic Exchange Securities
issued by the Express Scripts Automatic Exchange Security Trust (3,450,000
shares of Class A common stock if the underwriters fully exercise their right to
purchase additional Trust Securities pursuant to their over-allotment option).
NYLIFE will retain beneficial ownership and the right to vote and to receive
dividends with respect to such shares unless such shares are delivered pursuant
to the terms of the Trust. New York Life and its subsidiaries have agreed to
vote any shares of our Class A common stock that may be delivered by the Trust
in the same proportion and to the same effect as the votes cast by our other
stockholders at any meeting of stockholders, subject to two exceptions described
below relating to elections of directors and approval of our 2000 Long-Term
Incentive Plan. Delivery of such shares is expected on or about November ,
2003, unless NYLIFE exercises its right to deliver cash in lieu of such shares
(in which case NYLIFE will retain beneficial ownership of such shares) or unless
the Trust is liquidated, and such shares are delivered on an earlier date.

STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT

New York Life, a New York mutual insurance company of which NYLIFE is a
subsidiary, and we are parties to a Stockholder and Registration Rights
Agreement dated as of October 6, 2000 (which will become effective
contemporaneously with the closing of the stock offering or the Trust offering)
entered into in connection with the stock offering and the Trust offering. The
principal terms of this agreement are described below.

Conversion of Class B Common Stock. New York Life has agreed (for itself
and on behalf of its subsidiaries), unless the exchange contemplated by the
Asset Acquisition Agreement described below is effected, to convert each issued
and outstanding share of Class B common stock into one share of Class A common
stock contemporaneously with the completion of this offering.

Rights Regarding Our Board of Directors. As long as New York Life and its
non-investment subsidiaries, in the aggregate, beneficially hold 1,500,000 or
more shares of our Class A common stock (as adjusted for stock splits and
similar events), and such shares constitute 5% or more of our outstanding voting
stock, New York Life has the right to designate for nomination a total of two
directors to our board of directors. We are required to use the same efforts to
cause the election of such designees to our board of directors as we use with
our other nominees for director. If at any time New York Life and its non-
investment subsidiaries, in the aggregate, beneficially hold 1,500,000 or more
shares of our Class A common stock (as adjusted for stock splits and similar
events), and such shares constitute less than 5% of our outstanding voting
stock, then the number of directors New York Life shall be permitted to
designate to our board of directors shall be reduced to one. If at any time New
York Life and its non-investment subsidiaries, in the aggregate, beneficially
hold less than 1,500,000 shares of our Class A common stock (as adjusted for
stock splits and similar events), the number of directors New York Life shall be
permitted to designate to our board of directors shall be reduced to zero. If a
vacancy occurs with respect to a director which New York Life had the right to
designate, and New York Life has the right at such time to designate a director
for nomination, New York Life is entitled to designate a director to fill the
vacancy. If we nominate for election those persons designated by New York Life,
New York Life and its non-investment subsidiaries that hold shares are required
to vote their shares of voting stock in favor of all

14
<PAGE> 19

directors nominated for such election. In addition, New York Life and its
non-investment subsidiaries are required to vote their shares to approve our
2000 Long-Term Incentive Plan, as approved by our board of directors. Finally,
so long as New York Life is entitled to nominate two directors, we have agreed
to appoint one of the New York Life directors to each standing committee of our
board of directors, except our audit committee. Upon the consummation of this
offering, all but two of the directors on our board of directors affiliated with
New York Life shall resign.

Registration Rights. So long as New York Life and its non-investment
subsidiaries, in the aggregate, beneficially hold in excess of 1,500,000 shares
of our Class A common stock (as adjusted for stock splits and similar events),
New York Life may request that we effect up to three registrations of all or
part of such shares under the Securities Act. One of these registrations may be
requested to be effected as a shelf registration pursuant to Rule 415 under the
Securities Act, and two of these registrations may be requested to be effected
as firm commitment underwritten offerings under the Securities Act. We are not
obligated to file a registration statement at the request of New York Life:

- within 180 days after the closing of the offering of Class A common stock
pursuant to this prospectus

- within a period of 90 days after the effective date of any other
registration statement of ours (other than a registration statement on
Form S-8 or its equivalent) or

- while a registration statement relating to a shelf registration filed at
the request of New York Life is effective under the Securities Act

In addition, so long as New York Life and its non-investment subsidiaries, in
the aggregate, beneficially hold in excess of 1,500,000 shares of our Class A
common stock (as adjusted for stock splits and similar events), if we propose to
register shares of our Class A common stock for our own account under the
Securities Act (other than a registration on Form S-8 or their equivalent), New
York Life shall have piggy-back rights with respect to such registration. The
underwriters of any such offering have the right to limit the number of shares
included by New York Life in any such registration if the managing underwriter
indicates that, in its opinion, the number of shares to be included by New York
Life would adversely affect the offering. We will bear the expenses of any
registration described in this paragraph.

Voting of Class A Common Stock Underlying the Trust Securities. New York
Life and its subsidiaries have agreed to vote any shares of our Class A common
stock that may be delivered by the Trust in the same proportion and to the same
effect as the votes cast by our other stockholders at any meeting of
stockholders, subject to two exceptions described above relating to elections of
directors and approval of our 2000 Long-Term Incentive Plan.

Term. The Stockholder and Registration Rights Agreement shall terminate on
the earlier of:

- eight years from the closing of the stock offering or the Trust offering
or

- at such time as New York Life and its non-investment subsidiaries, in the
aggregate, beneficially hold less than 1,500,000 shares of our Class A
common stock (as adjusted for stock splits and similar events)

This is a summary of some important provisions of the Stockholder and
Registration Rights Agreement. This summary is subject to, and qualified in its
entirety by reference to, all the provisions of the Stockholder and Registration
Rights Agreement which is attached as an exhibit to the registration statement
of which this prospectus is a part.

ASSET ACQUISITION AGREEMENT

New York Life, NYLIFE and NYLIFE's subsidiary that currently holds our
Class B common stock and we are parties to an Asset Acquisition Agreement, dated
as of October 17, 2000. Pursuant to this agreement, the NYLIFE subsidiary will
exchange 15,020,000 shares of our Class B common stock for 15,020,000 shares of
our Class A common stock immediately prior to the consummation of this offering.

15
<PAGE> 20

After this exchange and pursuant to a reorganization, the NYLIFE subsidiary will
be liquidated and shares of Class A common stock owned by that subsidiary will
be distributed to NYLIFE. A portion of these shares will be sold in the stock
offering and may be delivered in the Trust offering.

The Asset Acquisition Agreement will terminate upon the earlier to occur
of:

- December 31, 2000 or

- the date on which the NYLIFE subsidiary that currently owns our Class B
common stock delivers written notice of termination to us

unless the asset exchange occurs prior to such time. Termination of the Asset
Acquisition Agreement will not alter the terms of the Stockholder and
Registration Rights Agreement described above.

This is a summary of some important provisions of the Asset Acquisition
Agreement. This summary is subject to, and qualified in its entirety by
reference to, all the provisions of the Asset Acquisition Agreement which is
attached as an exhibit to the registration statement of which this prospectus is
a part.

16
<PAGE> 21

USE OF PROCEEDS

We will not receive any of the proceeds from the sale of shares being
offered by NYLIFE pursuant to this prospectus.

PRICE RANGE OF COMMON STOCK AND DIVIDEND POLICY

Our Class A common stock has been traded on The Nasdaq National Market
under the symbol "ESRX" since June 9, 1992. The high and low prices of our Class
A common stock, as reported by The Nasdaq National Market, are set forth below
for the periods indicated. These prices reflect the two-for-one split on October
30, 1998, in the form of a 100% stock dividend to holders of record on October
20, 1998.

<TABLE>
<CAPTION>
HIGH LOW
-------- -------
<S> <C> <C>
1998
First Quarter............................................... $ 42.750 $27.000
Second Quarter.............................................. $ 45.000 $35.500
Third Quarter............................................... $ 45.250 $31.625
Fourth Quarter.............................................. $ 69.000 $33.875
1999
First Quarter............................................... $105.500 $59.125
Second Quarter.............................................. $ 91.000 $55.000
Third Quarter............................................... $ 92.375 $61.500
Fourth Quarter.............................................. $ 88.688 $44.375
2000
First Quarter............................................... $ 67.000 $28.500
Second Quarter.............................................. $ 66.625 $34.625
Third Quarter............................................... $ 78.000 $56.250
Fourth Quarter (through October 16, 2000)................... $ 83.000 $71.000
</TABLE>

Our Class B common stock has no established public trading market, but
these shares will automatically convert, on a share for share basis, to our
Class A common stock upon transfer to any entity other than New York Life or an
affiliate of New York Life or otherwise at the option of the holder thereof. The
NYLIFE subsidiary that currently holds all of our Class B common stock has
agreed to exchange each outstanding share of Class B common stock for one share
of our Class A common stock immediately prior to the completion of this offering
and distribute such shares to NYLIFE.

Our board of directors has not declared any cash dividends since our
initial public offering in 1992. Our board of directors does not currently
intend to declare any cash dividends in the foreseeable future. The terms of our
credit facility and our senior notes restrict our ability to declare or pay cash
dividends.

17
<PAGE> 22

CAPITALIZATION

The following table sets forth our unaudited capitalization as of June 30,
2000 and as adjusted for the exchange by a NYLIFE subsidiary of all the Class B
common stock owned by that subsidiary for a like number of shares of Class A
common stock issued by us immediately prior to the completion of this offering.

<TABLE>
<CAPTION>
AS ADJUSTED
FOR THIS
ACTUAL OFFERING
---------- -----------
<S> <C> <C>
Cash........................................................ $ 99,835 $ 99,835
========== ==========
Total debt(1)............................................... $ 560,658 $ 560,658
========== ==========
Stockholders' equity:
Preferred stock, $0.01 per share, 5,000,000 shares
authorized, and no shares issued and outstanding....... $ -- $ --
Class A common stock, $0.01 par value, 150,000,000 shares
authorized, 24,002,000 shares issued and 22,800,000
shares outstanding, and 39,022,000 shares issued and
37,820,000 shares outstanding as adjusted,
respectively(2)........................................ 240 390
Class B common stock, $0.01 par value, 31,000,000 shares
authorized, 15,020,000 shares issued and outstanding
and no shares outstanding as adjusted.................. 150 --
Additional paid-in-capital................................ 421,507 421,507
Accumulated other comprehensive income.................... (57) (57)
Retained earnings(3)...................................... 243,795 243,034
---------- ----------
665,635 664,874
Class A common stock in treasury at cost, 1,202,000
shares................................................. (36,371) (36,371)
---------- ----------
Total stockholders' equity.................................. $ 629,264 $ 628,503
---------- ----------
Net capitalization(4)....................................... $1,090,087 $1,089,326
========== ==========
Net debt to net capitalization(4)........................... 42.3% 42.3%
========== ==========
</TABLE>

-------------------------
(1) During the quarter ended September 30, 2000, we prepaid $135 million on our
credit facility.

(2) Does not include as of September 1, 2000:

- stock options and similar equity rights granted to employees and
independent directors to purchase 3,499,365 shares of our Class A common
stock, of which 1,162,245 were exercisable

- 1,007,368 reserved shares of our Class A common stock for issuance in
connection with strategic alliances with certain clients

- 269,419 reserved shares of our Class A common stock for our Employee Stock
Purchase Plan and our Executive Deferred Compensation Plan

(3) The expenses in connection with the issuance and distribution of the shares
being registered, other than underwriting discounts and commissions, are
being paid by us.

(4) Net capitalization is calculated as net debt plus stockholders' equity. Net
debt reflects total debt less cash.

18
<PAGE> 23

SELECTED FINANCIAL AND OPERATING DATA

The following table sets forth our selected financial and operating data
for the five years ended December 31, 1999 and six months ended June 30, 1999
and 2000. The financial data, excluding the selected data, for the fiscal years
ended December 31, 1997, 1998 and 1999 have been derived from our consolidated
financial statements included in this prospectus which have been audited by
PricewaterhouseCoopers LLP, independent accountants. The financial data,
excluding the selected data, for the fiscal years ended December 31, 1995 and
1996 have been derived from our consolidated financial statements not included
in this prospectus which have been audited by PricewaterhouseCoopers LLP. The
financial data, excluding the selected data, for the six months ended June 30,
1999 and 2000 have been derived from our unaudited consolidated financial
statements included in this prospectus.

The data set forth below should be read in conjunction with the report of
PricewaterhouseCoopers LLP, our consolidated financial statements and related
notes and "Management's Discussion and Analysis of Financial Condition and
Results of Operations" included elsewhere in this prospectus.

<TABLE>
<CAPTION>
(UNAUDITED)
SIX MONTHS ENDED
YEAR ENDED DECEMBER 31, JUNE 30,
--------------------------------------------------------------- -----------------------
1995 1996 1997 1998(2) 1999(3) 1999(4) 2000(5)
---------- ---------- ---------- ---------- ----------- ---------- ----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenues:
Revenues............................ $ 544,460 $ 773,615 $1,230,634 $2,824,872 $ 4,285,104 $1,895,836 $3,122,791
Other revenues...................... -- -- -- -- 3,000 -- 6,085
---------- ---------- ---------- ---------- ----------- ---------- ----------
544,460 773,615 1,230,634 2,824,872 4,288,104 1,895,836 3,128,876
---------- ---------- ---------- ---------- ----------- ---------- ----------
Cost and expenses:
Cost of revenues.................... 478,283 684,882 1,119,167 2,584,997 3,826,905 1,693,636 2,859,027
Selling, general and
administrative.................... 37,300 49,103 62,617 148,990 294,194 128,337 170,792
Non-recurring charges............... -- -- -- 1,651 30,221 9,400 --
---------- ---------- ---------- ---------- ----------- ---------- ----------
515,583 733,985 1,181,784 2,735,638 4,151,320 1,831,373 3,029,819
---------- ---------- ---------- ---------- ----------- ---------- ----------
Operating income...................... 28,877 39,630 48,850 89,234 136,784 64,463 99,057
Other income (expense), net........... 757 3,450 5,856 (12,994) 128,682 (26,616) (179,457)
---------- ---------- ---------- ---------- ----------- ---------- ----------
Income (loss) before income taxes..... 29,634 43,080 54,706 76,240 265,466 37,847 (80,400)
Provision for (benefit from) income
taxes............................... 11,307 16,932 21,277 33,566 108,098 17,286 (27,655)
---------- ---------- ---------- ---------- ----------- ---------- ----------
Income (loss) before extraordinary
items............................... 18,327 26,148 33,429 42,674 157,368 20,561 (52,745)
Extraordinary loss on early retirement
of debt............................. -- -- -- -- 7,150 6,597 --
---------- ---------- ---------- ---------- ----------- ---------- ----------
Net income (loss)..................... $ 18,327 $ 26,148 $ 33,429 $ 42,674 $ 150,218 $ 13,964 $ (52,745)
========== ========== ========== ========== =========== ========== ==========
Basic earnings (loss) per share(1)
Before extraordinary item........... $ 0.62 $ 0.81 $ 1.02 $ 1.29 $ 4.36 $ 0.61 $ (1.39)
Extraordinary loss on early
retirement of debt................ -- -- -- -- 0.20 0.19 --
---------- ---------- ---------- ---------- ----------- ---------- ----------
Net income (loss)................... $ 0.62 $ 0.81 $ 1.02 $ 1.29 $ 4.16 $ 0.42 $ (1.39)
========== ========== ========== ========== =========== ========== ==========
Diluted earnings (loss) per share(1)
Before extraordinary item........... $ 0.60 $ 0.80 $ 1.01 $ 1.27 $ 4.25 $ 0.59 $ (1.36)
Extraordinary loss on early
retirement of debt................ -- -- -- -- 0.19 0.19 --
---------- ---------- ---------- ---------- ----------- ---------- ----------
Net income (loss)................... $ 0.60 $ 0.80 $ 1.01 $ 1.27 $ 4.06 $ 0.40 $ (1.36)
========== ========== ========== ========== =========== ========== ==========
Weighted average shares outstanding(1)
Basic............................... 29,560 32,160 32,713 33,105 36,095 33,633 38,068
Diluted............................. 30,545 32,700 33,122 33,698 37,033 34,553 38,751
</TABLE>

19
<PAGE> 24

-------------------------
(1) Earnings per share and weighted average shares outstanding have been
restated to reflect the two-for-one stock split effective October 30, 1998.

(2) Includes our acquisition of ValueRx effective April 1, 1998. Also includes a
non-recurring operating charge of $1,651 ($1,002 after tax) relating to our
managed vision business. Excluding this restructuring charge, our basic and
diluted earnings per share before extraordinary item would have been $1.32
and $1.30, respectively.

(4) Includes the acquisition of DPS effective April 1, 1999. Also includes
non-recurring operating charges of $9,400 ($5,773 after tax). Excluding this
amount, our basic and diluted earnings per share before extraordinary item
would have been $0.78 and $0.76, respectively.

(6) Includes pharmacy benefit covered lives under the United HealthCare
contract, which were approximately 9.5 million at December 31, 1999, 9.5
million as of June 30, 1999 and 8.3 million as of June 30, 2000. In
computing the number of lives we serve, certain estimates and adjustments
are made and we believe that different PBMs use different factors in making
these estimates and adjustments. We believe, however, that these numbers are
a reasonable approximation of the actual number of lives served by us.

- the drug ingredient cost for those clients that have established their own
pharmacy networks

- the expenditures for drugs of those companies on formulary-only programs
managed by us

- the co-pay portion of drug expenditures that are the responsibility of
members of health plans serviced by us

Therefore, drug spending provides a common basis to quantify the drug
expenditures managed by a company irrespective of our revenue recognition
policy.

20
<PAGE> 25

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

During the first six months of 2000 we continued to execute our growth
strategy by increasing our membership to approximately 40.5 million members as
of July 1, 2000 compared with 36.0 million members as of July 1, 1999 (excluding
approximately 8.3 million and 9.5 million members, respectively, served under
the United HealthCare contract that expired in May 2000, for which we have
implemented a transition plan to transfer these members to the new provider). We
also continue to develop new products and services for sale to existing clients
and pharmaceutical manufacturers and expand the services provided to existing
clients. During the first six months of 2000, approximately 2.3 million members
began utilizing expanded services that provide for more advanced formulary
management and the addition of mail or network services where only one of these
services had been previously utilized. We have one of the largest managed care
membership bases of any PBM company. Although our membership counts are based on
eligibility data provided by our clients, they necessarily involve some
estimates, extrapolations and approximations. For example, some plan designs
allow for family coverage under a single identification number, and we make
assumptions about the average number of persons per family in calculating the
membership covered by such plans. Because these assumptions may vary between
PBMs, membership counts may not be comparable between our competitors and us.
However, we believe our membership count provides a reasonable estimation of the
population we serve, and can be used as one measure of our growth.

As previously disclosed, on April 1, 1999, we acquired Diversified
Pharmaceutical Services, Inc. and Diversified Pharmaceutical Services (Puerto
Rico) Inc., from SmithKline Beecham Corporation and SmithKline Beecham
InterCredit BV for approximately $715 million, which included a purchase price
adjustment for closing working capital and transaction costs. Consequently, our
operating results include those of DPS from April 1, 1999. The net assets
acquired from DPS have been recorded at their estimated fair value, resulting in
$754,236,000 of goodwill that is being amortized over 30 years. This acquisition
has been accounted for under the purchase method of accounting.

We derive our revenues primarily from the sale of PBM services in the
United States and Canada. Our PBM revenues generally include administrative
fees, dispensing fees and ingredient costs of pharmaceuticals dispensed from
retail pharmacies included in one of our networks or from one of our mail
pharmacies, and the associated costs are recorded in cost of revenues (the
"Gross Basis"). Where we only administer the contracts between our clients and
the clients' network pharmacies, as is the case for most of the customer
contracts with DPS, we record as revenues only the administrative fee we receive
from our activities (the "Net Basis"). We also derive PBM revenues from the sale
of informed decision counseling services through our Express Health LineSM
division, and the sale of medical information management services (which include
the development of data warehouses to combine medical claims and prescription
drug claims), disease management support services and quality and outcomes
assessments through our Health Management Services division and Practice
Patterns Science, Inc. subsidiary.

Non-PBM revenues are derived from:

- the sale of pharmaceuticals for and the provision of infusion therapy
services through our subsidiary IVTx, Inc., doing business as Express
Scripts Infusion Services

- administrative fees received from pharmaceutical manufacturers for the
dispensing or distribution of their pharmaceuticals requiring special
handling or packaging through our Express Scripts Specialty Distribution
Services subsidiary

21
<PAGE> 26

RESULTS OF OPERATIONS

SIX MONTHS AND THREE MONTHS ENDED JUNE 30, 2000 COMPARED TO 1999

REVENUES

<TABLE>
<CAPTION>
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
---------------------------------- ------------------------------------
% INCREASE % INCREASE
2000 OVER 2000 OVER
1999 2000 1999 1999 2000 1999
-------- ---------- ---------- ---------- ---------- ----------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
PBM Gross Basis revenues........ $914,082 $1,562,322 70.9% $1,792,336 $2,949,049 64.5%
PBM Net Basis revenues.......... 67,396 65,081 (3.4)% 73,578 129,626 76.2%
Other revenues.................. -- 3,116 nm -- 6,085 nm
-------- ---------- ---- ---------- ---------- ----
Total PBM revenues............ $981,478 $1,630,519 66.1% $1,865,914 $3,084,760 65.3%
Non-PBM revenues.............. 15,271 22,848 49.6% 29,922 44,116 47.4%
-------- ---------- ---- ---------- ---------- ----
Total revenues............. $996,749 $1,653,367 65.9% $1,895,836 $3,128,876 65.0%
======== ========== ==== ========== ========== ====
</TABLE>

-------------------------
nm = not meaningful

Our growth in PBM Gross Basis revenues during the second quarter of 2000
and the six months ended June 30, 2000 over 1999 is primarily due to a
combination of the following factors: the conversion of historical Express
Scripts and DPS clients to our retail pharmacy networks and hence to the Gross
Basis of recording revenues; higher drug ingredient costs resulting from price
increases for existing drugs and new drugs introduced into the marketplace;
increased membership; higher utilization; and the conversion of certain clients
to a manufacturer program in which we derive an administrative fee for our
services, which is recorded in revenue, from a formulary management program
whereby amounts received from pharmaceutical manufacturers are recorded as a
reduction of cost of revenues. The increase in revenues for the six months ended
June 30, 2000 is also due to DPS revenues being reported for all of 2000
compared to only one quarter in 1999.

Network pharmacy claims revenue and network pharmacy claims processed
increased $464,804,000, or 63.9%, and 2,719,000, or 3.6%, respectively, during
the second quarter of 2000 over 1999 and $869,357,000, or 63.4%, and 46,709,000,
or 41.5%, respectively, for the six months ended June 30, 2000 over 1999. The
average revenue per network pharmacy claim increased 58.2% over the second
quarter of 1999 primarily as a result of the increased rate of historical
Express Scripts and DPS clients moving from retail pharmacy networks contracted
by the clients to one contracted by us and higher drug ingredient costs. As
previously discussed under "-- Overview", we record the associated revenues for
clients utilizing our retail pharmacy networks on the Gross Basis, therefore
this shift to our retail pharmacy network results in increased Gross Basis
revenues. The average revenue per network pharmacy claim increased 15.5% for the
first six months of 2000 over 1999 also as a result of additional clients moving
to one of our retail pharmacy networks, but the percentage change impact is
diluted compared to the second quarter due to the three additional months of DPS
claims in the first six months of 2000 over 1999.

Mail pharmacy services revenues and mail pharmacy claims processed
increased $179,958,000, or 74.4%, and 1,396,000, or 60.6%, respectively, for the
second quarter of 2000 over 1999, and $340,351,000, or 71.7%, and 2,633,000, or
57.4%, respectively, for the six months ended June 30, 2000 over 1999. These
increases are primarily due to the addition of new members with high mail
utilization rates as well as increased utilization by existing members. For the
three months and six months ended June 30, 2000 the average revenue per mail
pharmacy claim increased 8.5% and 9.1% over the three months and six months,
respectively, ended June 30, 1999 primarily due to higher drug ingredient costs,
as discussed above.

Other revenue increased $3,116,000 and $6,085,000, respectively, for the
second quarter and the six months ended June 30, 2000 over 1999 due to fees
received under our agreement with PlanetRx.com, Inc.

22
<PAGE> 27

Effective July 5, 2000 we restructured our agreement with PlanetRx in exchange
for a one-time cash payment of $8,000,000. Approximately $3,700,000 of the
payment represents amounts earned through the second quarter of 2000, the
remainder represents a fee for the termination of the prior contract. No
additional cash payments will be paid to us under the restructured agreement.
Additionally, we retain our ownership of approximately 10.3 million common
shares, or 19.8%, of PlanetRx.

The increase in revenue for non-PBM services during 2000 compared to 1999
is primarily due to additional volume within Specialty Distribution Services
resulting from a new contract that took effect during the fourth quarter of
1999.

COST AND EXPENSES

<TABLE>
<CAPTION>
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
------------------------------------------------ --------------------------------------------------
% OF % INCREASE % OF % INCREASE
REVENUES 2000 OVER REVENUES 2000 OVER
1999 2000 1999 2000 1999 1999 2000 1999 2000 1999
-------- ---------- ---- ---- ---------- ---------- ---------- ---- ---- ----------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
PBM(1).................... $857,941 $1,501,446 87.4% 92.1% 75.0% $1,670,033 $2,830,310 89.5% 91.8% 69.5%
Non-PBM(2)................ 12,048 14,518 78.9% 63.5% 20.5% 23,603 28,717 78.9% 65.1% 21.7%
-------- ---------- ---- ---- ---- ---------- ---------- ---- ---- ----
Cost of revenues.......... 869,989 1,515,964 87.3% 91.7% 74.3% 1,693,636 2,859,027 89.3% 91.4% 68.8%
Selling, general and
administrative.......... 63,539 69,015 6.4% 4.2% 8.6% 103,757 133,396 5.5% 4.3% 28.6%
Depreciation and
amortization(3)......... 18,358 18,406 1.8% 1.1% 0.3% 24,580 37,396 1.3% 1.2% 52.1%
Non-recurring expenses.... 9,400 -- 0.9% 0.0% nm 9,400 -- 0.5% 0.0% nm
-------- ---------- ---- ---- ---- ---------- ---------- ---- ---- ----
Total cost and expenses... $961,286 $1,603,385 96.4% 97.0% 66.8% $1,831,373 $3,029,819 96.6% 96.8% 65.4%
======== ========== ==== ==== ==== ========== ========== ==== ==== ====
</TABLE>

-------------------------
(1) % of revenues data is percentage against PBM revenues

(2) % of revenues data is percentage against non-PBM revenues

(3) Represents depreciation and amortization expense included in selling,
general and administrative expenses on our Statement of Operations. Cost of
revenues, above, also includes depreciation and amortization expense on
property and equipment of $2,216 and $2,502 for the three months ended June
30, 1999 and 2000, respectively, and $4,481 and $5,079 for the six months
ended June 30, 1999 and 2000, respectively.

nm = not meaningful

Cost of revenues for PBM services as a percentage of total PBM revenues has
increased for the second quarter and the six months ended June 30, 2000 over
1999. This increase is primarily due to converting both historical Express
Scripts and DPS clients from pharmacy networks contracted by the client to one
contracted by us, for which we record the drug ingredient cost in cost of
revenue (see further discussion under "-- Overview"), and the establishment of a
contract reserve due to pricing issues with a particular client agreement. These
increases in cost of revenues were partially offset by increases in amounts
received from pharmaceutical manufacturers for our formulary management programs
during the first half of 2000.

Cost of revenues for non-PBM services decreased as a percentage of non-PBM
revenues in 2000 from 1999 primarily due to additional volume of business within
Specialty Distribution Services, where we record as revenue only our
administrative fee for distributing pharmaceutical manufacturers' products.
Specialty Distribution Services was also able to derive operating cost
efficiencies as a result of the increase in volume serviced under the contract
that took effect in the fourth quarter of 1999, as discussed above.

Selling, general and administrative expenses, excluding depreciation and
amortization, increased $5,476,000, or 8.6%, in the second quarter of 2000 over
1999 and $29,639,000, or 28.6%, for the first six months of 2000 over 1999. The
increase in 2000 is primarily due to costs incurred in funding our Internet
initiatives and expenditures required to expand the operational and
administrative support functions to enhance management of the pharmacy benefit.
The fees received under our agreement with PlanetRx enabled us to accelerate our
Internet initiatives in the first half of the year. The elimination of such fees
is not expected to materially impact net income for 2000 or 2001. However, as a
percentage of total revenue,

23
<PAGE> 28

selling, general and administrative expenses decreased to 4.2% and 4.3%,
respectively, for the three and six months ended June 30, 2000 from 6.4% and
5.5%, respectively, for the three and six months ended June 30, 1999.

Depreciation and amortization substantially increased for the six months
ended June 30, 2000 over 1999 due to the acquisition of DPS, as 1999 only
included amortization of the DPS goodwill and other intangible assets for three
months. During the first six months of 2000, we have recorded amortization
expense for goodwill and other intangible assets of $30,988,000 compared to
$20,585,000 for the six months ended June 30, 1999. The remaining increases in
2000 were primarily due to expansion of our operations and enhancement of our
information systems to better serve our clients.

During the second quarter of 1999, we recorded a pre-tax restructuring
charge of $9,400,000 associated with the consolidation of our Plymouth,
Minnesota facility into our Bloomington, Minnesota facility. In December 1999,
the associated accrual was reduced by $2,301,000, primarily as a result of
subleasing a portion of the unoccupied space. The consolidation plan includes
the relocation of all employees at the Plymouth facility to the Bloomington
facility that began in August 1999 and will end in the third quarter of 2000.
Included in the restructuring charge are anticipated cash expenditures of
approximately $4,823,000 for lease termination fees and rent on unoccupied space
(which payments will continue through April 2001, when the lease expires) and
anticipated non-cash charges of approximately $2,276,000 for the write-down of
leasehold improvements and furniture and fixtures. The restructuring charge does
not include any costs associated with the physical relocation of the employees.

OTHER INCOME (EXPENSE), NET

Our interest expense, net has decreased by $10,650,000 and $2,659,000, to
$11,137,000 and $23,957,000, respectively, for the quarter ended and the six
months ended June 30, 2000 compared to 1999. The decrease is a result of
utilizing the $299,381,000 proceeds from our June 1999 common stock offering to
repay a portion of our credit facility, as well as utilizing $179,131,000 of our
internally generated cash to pay-down our credit facility from June 1999 through
June 30, 2000. Additionally, we have repurchased $10,115,000 of our Senior Notes
as of June of 2000 (see "-- Liquidity and Capital Resources").

As previously announced, we recorded a $155,500,000 ($97,032,000 after tax)
non-cash impairment charge related to our investment in PlanetRx common stock
during the second quarter of 2000 as the loss in value was deemed to be other
than temporary. Therefore, any unrealized loss associated with recording our
investment in PlanetRx at current market value that we had recorded in
stockholders' equity was written off to the current period earnings, in addition
to any additional charges necessary to write-down the value of our investment in
accordance with Financial Accounting Standards Board Statement No. 115,
"Accounting for Certain Investments in Debt and Equity Securities."

PROVISION FOR INCOME TAXES

For the second quarter and six months ended June 30, 2000, we had a tax
benefit of $42,478,000 and $27,655,000 due to the marketable securities
impairment write-down discussed under "-- Other income (expense), net."
Excluding the $9,400,000 restructuring charge in 1999 and $58,468,000 tax
benefit from the write-down in 2000, our effective tax rate would have been
44.6% and 41.2% for the quarter ended June 30, 1999 and 2000, respectively, and
44.3% and 41.0% for the six months ended June 30, 1999 and 2000, respectively.
Our effective tax rate for continuing operations decreased from 1999 primarily
due to the reduction in the non-deductible goodwill and customer contract
amortization expense associated with the ValueRx acquisition as a percentage of
income before income taxes. The goodwill and customer contract amortization for
the DPS acquisition is deductible for income tax purposes due to the filing of
an Internal Revenue Code sec.338(h)(10) election.

24
<PAGE> 29

NET INCOME AND EARNINGS PER SHARE

Our net income decreased $74,598,000 to a net loss of $74,177,000 for the
second quarter of 2000 from 1999 and $66,709,000 to a net loss of $52,745,000
for the first six months of 2000 from 1999. The following items impacted
earnings:

- a non-cash impairment charge during the second quarter of 2000 in the
amount of $155,500,000 ($97,032,000 net of tax) relating to our PlanetRx
investment (see "-- Other income (expense), net")

- a restructuring charge during the second quarter of 1999 in the amount of
$9,400,000 ($5,773,000 net of tax) for the Minneapolis facility
consolidation (see "-- Cost and expenses")

- an extraordinary loss on the early retirement of debt during the second
quarter of 1999 in the amount of $6,597,000, net of tax

- assuming our equity and debt offerings in 1999 occurred on April 1, 1999,
we would have realized a reduction in interest expense of approximately
$3,807,000, net of tax

Excluding these effects on net income for 1999 and 2000 net income per
diluted share would have been $0.42 and $0.59 for the second quarter of 1999 and
2000, respectively, and $0.82 and $1.14 for the six months ended June 30, 1999
and 2000, respectively.

FISCAL YEAR 1999 COMPARED TO 1998 AND FISCAL YEAR 1998 COMPARED TO 1997

NET REVENUES

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, % INCREASE % INCREASE
------------------------------------ 1998 OVER 1999 OVER
1997 1998 1999 1997 1998
---------- ---------- ---------- ---------- ----------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
PBM Gross Basis revenues.............. $1,168,922 $2,742,485 $4,007,077 134.6% 46.1%
PBM Net Basis revenues................ 22,251 22,626 212,217 1.7% 837.9%
Other revenues........................ -- -- 3,000 nm nm
---------- ---------- ---------- ----- -----
Total PBM revenues.................. $1,191,173 $2,765,111 $4,222,294 132.1% 52.7%
Non-PBM revenues.................... 39,461 59,761 65,810 51.4% 10.1%
---------- ---------- ---------- ----- -----
Total revenues................... $1,230,634 $2,824,872 $4,288,104 129.5% 51.8%
========== ========== ========== ===== =====
</TABLE>

-------------------------
nm = not meaningful

Our growth in PBM revenues during 1999 over 1998 is primarily due to the
inclusion of ValueRx for the full twelve months of 1999 compared to only nine
months of 1998, the inclusion of DPS for nine months of 1999, increased member
utilization and higher drug ingredient costs resulting from price increases for
existing drugs, new drugs introduced into the marketplace and changes in
therapeutic mix and dosage. Our growth in PBM revenues during 1998 over 1997 is
primarily due to the inclusion of ValueRx, higher drug ingredient costs and mail
utilization.

Revenues for network pharmacy claims increased $1,039,588,000, or 51.8%, in
1999 over 1998 and $1,175,659,000, or 141.7%, in 1998 over 1997. Network
pharmacy claims processed increased 142.0% to 273,909,000 in 1999 over 1998. The
average revenue per network pharmacy claim decreased 37.2% from 1998 primarily
due to the acquisition of DPS, as DPS records revenue on the Net Basis which
substantially reduces the average revenue per network pharmacy claim. Excluding
DPS, the average revenue per network pharmacy claim increased 8.2% over 1998.
During 1998, network pharmacy claims processed increased 54.7% to 113,177,000
over 1997. The average revenue per network pharmacy claim

25
<PAGE> 30

increased 56.3% in 1998 from 1997 primarily due to a higher percentage of
clients' revenue being reported on the Gross Basis compared to the Net Basis.

Revenues for mail pharmacy services increased $389,244,000, or 52.8%, in
1999 over 1998 and $385,149,000, or 109.6%, in 1998 over 1997. These increases
are the result of the growth in mail pharmacy claims processed of 42.8% to
10,608,000 in 1999 over 1998 and 90.5% to 7,426,000 in 1998 over 1997. These
increases are primarily due to the acquisitions of ValueRx and DPS, increased
utilization by existing members as well as the addition of new members. The
average revenue per mail pharmacy claim increased 7.0% in 1999 over 1998 and
10.0% in 1998 over 1997 primarily due to higher drug ingredient costs as stated
above.

The increase in revenue for non-PBM services in 1999 and 1998 is primarily
due to additional business within Specialty Distribution Services and continued
changes in the product mix sold in our Infusion Services business that resulted
in higher drug ingredient costs. These increases were partially offset by the
reduction in revenues from our managed vision business due to the restructuring
of this operation during 1998.

COST AND EXPENSES

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------------------------------------- % INCREASE
% OF REVENUES 1998 1999
1997 1998 1999 1997 1998 1999 OVER 1997 OVER 1998
---------- ---------- ---------- ---- ---- ---- --------- ---------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
PBM(1)........................... $1,088,225 $2,540,360 $3,774,618 91.4% 91.9% 89.4% 133.4% 48.6%
Non-PBM(2)....................... 30,942 44,637 52,287 78.4% 74.7% 79.5% 44.3% 17.1%
---------- ---------- ---------- ---- ---- ---- ----- -------
Cost of revenues................. 1,119,167 2,584,997 3,826,905 90.9% 91.5% 89.2% 131.0% 48.0%
Selling, general and
administrative................. 57,257 130,116 231,543 4.7% 4.6% 5.4% 127.2% 78.0%
Depreciation and
amortization(3)................ 5,360 18,874 62,651 0.4% 0.7% 1.5% 252.1% 231.9%
Non-recurring expenses........... -- 1,651 30,221 0.0% 0.0% 0.7% nm 1,730.5%
---------- ---------- ---------- ---- ---- ---- ----- -------
Total cost and expenses.......... $1,181,784 $2,735,638 $4,151,320 96.0% 96.8% 96.8% 131.5% 51.7%
========== ========== ========== ==== ==== ==== ===== =======
</TABLE>

-------------------------
(1) % of revenues data is percentage against PBM revenues

(2) % of revenues data is percentage against non-PBM revenues

(3) Represents depreciation and amortization expense included in selling,
general and administrative expenses on our Statement of Operations. Cost of
revenues, above, also includes depreciation and amortization expense on
property and equipment of $4,998, $7,575 and $9,216 for the years ended
December 31, 1997, 1998 and 1999, respectively.

nm = not meaningful

Our cost of revenues for PBM services as a percentage of total PBM revenues
decreased in 1999 from 1998 primarily due to the acquisition of DPS, as DPS
records revenues under the Net Basis. In future periods, we expect the gross
margin percentage will be somewhat higher than in prior periods until we convert
DPS clients to our pharmacy networks. As this conversion occurs, we will record
revenues for converted clients on the Gross Basis and we anticipate that the
gross margin percentage will then begin to decline, although profitability is
not expected to be adversely affected by these changes. Excluding DPS, the gross
margin percentage for the year ended December 31, 1999 decreased to 7.4% from
8.1% for the year ended December 31, 1998. The decrease is primarily due to
lower drug ingredient margins resulting from changes in therapeutic mix, lower
pricing offered to clients and increased revenue sharing offset by improving
margins from our Health Management Service business. The gross margin percentage
in 1998 decreased from 1997 primarily due to a shift toward our established
pharmacy networks, lower pricing offered to clients and increased revenue
sharing. Prior to 1998, we had been experiencing this trend and the acquisition
of ValueRx continued the trend as ValueRx clients primarily used ValueRx
established retail pharmacy networks. Partially offsetting the gross margin
decrease were operating efficiencies

26
<PAGE> 31

achieved in our mail pharmacies during 1998 and revenues generated from
integrated PBM services, such as medical drug analysis, that provide higher
gross margins.

Cost of revenues for non-PBM services increased as a percentage of non-PBM
revenues over 1998 primarily due to the continued change in product mix sold,
resulting in additional costs of approximately $2,141,000. In addition, cost of
revenues from Specialty Distribution Services increased 88.9% over 1998 as a
result of establishing a new facility to support a larger operation. Cost of
revenue as a percentage of revenue in 1998 decreased from 1997 primarily due to
the inclusion of Specialty Distribution Services, which provides higher gross
margins, as well as improved gross margins from the restructuring of Vision
Services.

Selling, general and administrative expenses, excluding depreciation and
amortization, increased $101,427,000, or 78.0%, in 1999 over 1998 and
$72,859,000, or 127.2%, in 1998 over 1997. The increase in 1999 is primarily due
to our acquisition of DPS, costs incurred during the integration of DPS and
ValueRx ($8,833,000 in 1999), costs incurred in funding our Internet operations,
costs required to expand the operational and administrative support functions to
enhance management of the pharmacy benefit, and the inclusion of ValueRx for a
full twelve months. The increase during 1998 was the result of our acquisition
of ValueRx, costs incurred during the integration of ValueRx ($8,331,000 in
1998) and costs required to expand the operational and administrative support
functions to enhance management of the pharmacy benefit. During 1997, 1998 and
1999, we capitalized $1,982,000, $10,244,000 ($5,209,000 of which related to
integration) and $15,997,000 ($8,349,000 of which related to integration),
respectively, in new systems development costs. As a percentage of total
revenues, selling, general and administrative expenses, excluding depreciation
and amortization, for 1999 increased to 5.4% from 4.6% in 1998 and 4.7% in 1997.
The increase in the percentage of revenues in 1999 is primarily attributed to
DPS recording revenue on the Net Basis.

Depreciation and amortization substantially increased during 1999 over 1998
and 1998 over 1997 due to the acquisitions of DPS and ValueRx. During 1999, we
recorded amortization expense for goodwill and other intangible assets of
$53,297,000 compared to $12,183,000 in 1998. The remaining increases in 1999
were primarily due to integration, expanding our operations and enhancing our
information systems to better serve our clients.

During 1999 and 1998, we incurred the following non-recurring charges:

- During the second quarter of 1999, we incurred a $9,400,000 charge for
the consolidation of our Plymouth, Minneapolis facility into our
Bloomington, Minnesota facility. The consolidation plan includes the
relocation of all employees at the Plymouth facility to the Bloomington
facility, expected to be completed in the third quarter of 2000. We
obtained the two facilities through acquisitions of ValueRx and DPS.
Included within the charge were anticipated cash expenditures of
approximately $5,700,000 ($4,318,000 paid in 1999) for lease termination
fees and rent on unoccupied space to be paid through April 2001 and
anticipated non-cash charges of approximately $3,700,000 ($2,248,000
written-off in 1999) for the write-off of leasehold improvements and
furniture and fixtures. The charge does not include any costs associated
with the physical relocation of the employees. During the fourth quarter
of 1999, we reduced the original estimates of non-cash charges by
$1,424,000 and of the anticipated cash expenditures attributable to rent
on the unoccupied space by $877,000 due to the landlord renting the space
sooner than we had anticipated.

- As a result of the integration of our acquisitions, we entered into a
contract during the fourth quarter of 1999 to consolidate the operation
of our computer systems with a single vendor. As a result, 51 employees
were notified that their employment was being transitioned to the
outsourcer, requiring $332,000 in severance payments to the employees. In
addition, we will incur $1,816,000 in cash expenditures associated with
the termination of an existing outsourcing contract and additional
transition payments to the outsourcer. We incurred non-cash charges of
$485,000 related to the impairment of certain software projects abandoned
due to the outsourcing. These projects were

27
<PAGE> 32

written off during the fourth quarter of 1999. Completion of this plan is
expected to occur during the first quarter of 2000 when all cash
expenditures will be made.

- To coordinate our PBM service offerings, we restructured the operations
of our Practice Patterns Science subsidiary by transferring the
management responsibility to Health Management Services during the fourth
quarter of 1999. As a result, we incurred $133,000 in severance payments
in December 1999 to one employee and have paid the remaining $277,000 in
severance costs to eight employees during January 2000. In addition, we
incurred a $559,000 charge related to our purchase of the common stock
held by the management of Practice Patterns Science.

- In conjunction with the sale of the assets of YourPharmacy.com, Inc. to
PlanetRx, we recorded a $19,520,000 stock compensation charge relating to
former YourPharmacy.com employees. The amount of the charge was
determined using the initial public offering price of $16 per share for
PlanetRx common stock.

- During the second quarter of 1998, we incurred a $1,651,000 charge for
the restructuring of our managed vision business due to us reaching an
agreement with Cole Managed Vision, a subsidiary of Cole National
Corporation, to provide certain vision care services for our clients and
their members. The charge consisted of a $1,235,000 write-down in fixed
assets and $416,000 for the transition of 61 employees and was completed
during the third quarter of 1999.

OTHER INCOME (EXPENSE), NET

During 1999, we recognized a one-time gain of $182,930,000 related to the
sale of the assets of YourPharmacy.com, Inc. in exchange for a 19.9% ownership
interest in PlanetRx. This one-time gain was partially offset by a $39,780,000,
or 196.6%, increase in interest expense resulting from the debt incurred to
purchase DPS (see "-- Liquidity and Capital Resources"). Interest expense was
significantly higher in 1998 over 1997 due to the financing of the ValueRx
acquisition with $360 million of borrowed funds (see "-- Liquidity and Capital
Resources").

Interest income in 1999 decreased from 1998 due to using our available cash
to purchase DPS and for repayment of debt. The increase in interest income in
1998 over 1997 is due to investing larger cash balances.

PROVISION FOR INCOME TAXES

Our effective tax rate for continuing operations decreased to 40.7% in 1999
from 44.0% in 1998 primarily due to a higher income before income taxes to
offset the non-deductible goodwill and customer contract amortization expense
associated with the ValueRx acquisition. The goodwill and customer contract
amortization for the DPS acquisition is deductible for income tax purposes due
to the filing of an Internal Revenue Code sec.338(h)(10) election. The effective
tax rate increased to 44.0% in 1998 from 38.9% in 1997 primarily due to
non-deductible goodwill and customer contracts amortization expense resulting
from the ValueRx acquisition.

NET INCOME AND EARNINGS PER SHARE

Our net income increased $107,544,000 or 252.0% in 1999 over 1998, and
$9,245,000 or 27.7% in 1998 over 1997. Net income for 1999 was affected due to
the following one-time items:

- non-recurring charges discussed in "-- Cost and expenses" totaling
$30,221,000 ($18,188,000, net of tax)

- one-time gain of $182,930,000 ($112,037,000, net of tax) discussed in
"-- Other income (expense), net"

- an extraordinary loss on the early retirement of debt of $7,150,000, net
of tax. The extraordinary loss is associated with refinancing the debt
incurred in connection with our acquisition of ValueRx, refinancing the
debt incurred in connection with our acquisition of DPS from the proceeds
of our

28
<PAGE> 33

equity and debt offerings, and repayment of the debt from our own cash,
as discussed in "-- Liquidity and Capital Resources" below.

Excluding these one-time items, net income for 1999 would have been
$63,519,000, or $1.76 per basic share and $1.72 per diluted share compared to
$1.32 per basic share and $1.30 per diluted share for 1998, excluding a
non-recurring charge for the managed vision business of $1,651,000 ($1,002,000,
net of tax). Had our equity offering and Senior Notes offering been completed by
April 1, 1999 our net income, excluding the one-time items above, would have
been $67,326,000 or $1.81 per basic share and $1.77 per diluted share.

Basic and diluted weighted average shares outstanding for 1999 increased
9.0% and 9.9%, respectively, over 1998. The increase for both basic and diluted
shares outstanding is primarily related to our offering of 5,175,000 shares of
our Class A common stock in June 1999. The net proceeds of the offering were
used to retire a portion of our long term debt, as discussed in "-- Liquidity
and Capital Resources".

LIQUIDITY AND CAPITAL RESOURCES

During the first six months of 2000, net cash provided by operations
increased $45,611,000 to $98,027,000 from $52,416,000 in 1999. This increase is
primarily due to bringing our inventory levels back down to our normal operating
levels after increasing our inventory during the fourth quarter of 1999 by
approximately $30,000,000 for our mail pharmacies' anticipation of potentially
higher demand due to our members' Year 2000 concerns. Net cash provided by
operations increased $87,485,000 from December 31, 1998 to 1999. Included in the
increase is a one-time increase in cash balances of $113,732,000 relating to the
reclassification of negative cash balances to claims and rebates payable due to
the establishment of new banking relations during 1999, which resulted in moving
certain cash disbursement accounts to banks not holding our cash concentration
accounts. This increase was offset by the previously discussed increase in
inventory for our mail pharmacies' anticipation of potentially higher demand due
to our members' Year 2000 concerns.

The inclusion of DPS reduced our days sales outstanding to 31.0 days at
June 30, 2000 from 36.9 days at December 31, 1998 and 35.9 days at December 31,
1997. Gross revenues must be used to calculate the days sales outstanding due to
the impact of the Gross Basis versus the Net Basis of recording revenues, as
discussed in "-- Overview" and "-- Revenues." The accounts receivable balance
includes the cost of the pharmaceutical dispensed, which may not be included in
revenues, as required by generally accepted accounting principles, based on the
contractual terms embedded in client and pharmacy contracts. The following table
presents our days sales outstanding for the years ended:

<TABLE>
<CAPTION>
SIX MONTHS ENDED
YEAR ENDED DECEMBER 31, JUNE 30,
------------------------------------ -----------------------
1997 1998 1999 1999 2000
---------- ---------- ---------- ---------- ----------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
Total revenues....................... $1,230,634 $2,824,872 $4,288,104 $1,895,836 $3,128,876
Client/pharmacy pass through......... 764,367 726,960 3,570,108 1,324,929 1,680,688
---------- ---------- ---------- ---------- ----------
Gross revenues....................... $1,995,001 $3,551,832 $7,858,212 $3,220,765 $4,809,564
========== ========== ========== ========== ==========
Average monthly gross receivables.... $ 196,213 $ 359,423 $ 597,160 $ 525,057 $ 819,207
========== ========== ========== ========== ==========
Days sales outstanding............... 35.9 36.9 27.7 29.5 31.0
========== ========== ========== ========== ==========
</TABLE>

Our allowance for doubtful accounts has increased $4,485,000 or 26.0% to
$21,766,000 at June 30, 2000 from $17,281,000 at December 31, 1999. As a
percentage of at risk receivables (receivables for which we have a corresponding
contractual obligation to pay the applicable retail pharmacy), the allowance for
doubtful accounts is 3.1% at June 30, 2000 compared to 2.2%, 3.9% and 2.6% at
December 31, 1997, 1998 and 1999, respectively.

29
<PAGE> 34

We previously announced that we anticipated our cash flow from operations
would be temporarily reduced by approximately $20,000,000 due to the termination
of the United HealthCare contract during the third quarter of 2000. We
subsequently negotiated with United HealthCare a revision to the previously
announced transition plan which will extend the transition period and cause the
temporary cash reduction to occur primarily during the fourth quarter of 2000
and the first quarter of 2001. The effect of this extension will reduce the
maximum amount of the reduction and spread the effect over a longer period of
time, thereby reducing the effect in any one quarter. We expect to fund the
termination of the United HealthCare contract in 2000 and 2001 primarily with
operating cash flow. We will continue to utilize our operating cash flows for
future debt prepayments, stock repurchases, integration costs, technology
initiatives and other normal operating cash needs as we deem appropriate.

Our capital expenditures for the six months ended June 30, 2000 increased
$10,336,000, or 63.9%, over 1999 primarily due to integration related activities
as a result of our acquisitions, our concerted effort to invest in our
information technology to enhance the services provided to our clients and the
continued renovation of our Maryland Heights, Missouri operations facility. Our
capital expenditures in 1999 increased $13,105,000 or 54.9% over 1998 primarily
due to integration related activities as a result of our acquisitions, our
concerted effort to invest in our information technology to enhance the services
provided to our clients and the completion of our corporate headquarters. The
$10,948,000 increase in 1998 capital expenditures over 1997 is primarily due to
our integration of the ValueRx operations and our concerted effort to invest in
information technology to enhance the services provided to our clients. In
addition, we invested in equipment to improve efficiency and manage growth at
our mail pharmacy facilities. We expect to continue investing in technology that
will provide efficiencies in operations, manage growth and enhance the service
provided to our clients. We expect to fund future anticipated capital
expenditures primarily with operating cash flow or, to the extent necessary,
with working capital borrowings under our $300 million revolving credit
facility, discussed below.

On April 1, 1999, we executed a $1.05 billion credit facility with a bank
syndicate led by Credit Suisse First Boston and Bankers Trust Company consisting
of $750 million in term loans, including $285 million of Term A loans and $465
million of Term B loans, and a $300 million revolving credit facility. As of
July 1999, the Term B loans had been paid off through net proceeds from our
equity and senior notes offerings and $74,131,000 of our internally generated
cash. As a result, we recorded an extraordinary loss as discussed in "-- Net
income and earnings per share" above under "-- Fiscal Year 1999 Compared to 1998
and Fiscal Year 1998 Compared to 1997". As of June 30, 2000, we had outstanding
balances on our revolving credit facility and our Term A loans of $35 million
and $285 million, respectively. During the third quarter 2000, we repaid the
remaining $35 million on our revolving credit facility and prepaid $100 million
on our Term A loans which were applied against our March 2001, 2002 and 2003
scheduled payments. The Term A loans and the revolving credit facility mature on
March 31, 2005. The credit facility is secured by the capital stock of each of
our existing and subsequently acquired domestic subsidiaries, excluding Practice
Patterns Science, Inc., Great Plains Reinsurance Company, ValueRx of Michigan,
Inc., Diversified NY IPA, Inc. and Diversified Pharmaceutical Services (Puerto
Rico), Inc., and is also secured by 65% of the stock of our foreign
subsidiaries.

The credit facility requires us to pay interest quarterly on an interest
rate spread based on several LIBOR or base rate options. Using a LIBOR spread,
the Term A loans and the revolving loan had an interest rate of 8.77% on June
30, 2000. Effective July 2000, the LIBOR interest rate spread has been reduced
from 2% to 1.5% based upon calculations set forth in our credit facility. To
alleviate interest rate volatility, we have entered into two separate swap
arrangements, which are discussed in "-- Market Risk" below. Beginning in March
2003, we are required to make annual principal payments on the Term A loans of
$56,750,000 in 2003, $62,700,000 in 2004 and $65,550,000 in 2005. The credit
facility contains covenants that limit the indebtedness we may incur, dividends
paid and the amount of annual capital expenditures. The covenants also establish
a minimum interest coverage ratio, a maximum leverage ratio, and a minimum fixed
charge coverage ratio. In addition, we are required to pay an annual fee of
0.5%, payable in quarterly installments, on the unused portion of the revolving
credit facility ($265 million at

30
<PAGE> 35

June 30, 2000). At June 30, 2000, we are in compliance with all covenants
associated with the credit facility.

Additionally, on April 1, 1999, we executed a $150 million senior
subordinated bridge credit facility from Credit Suisse First Boston Corporation
and Bankers Trust Company. The proceeds from the bridge credit facility and $890
million in borrowings from the credit facility were used to consummate the DPS
acquisition, refinance our $440 million credit facility, of which $360 million
was outstanding, and other indebtedness and pay related fees and expenses.

In June 1999, we completed our equity offering of 5,175,000 shares of our
Class A common stock at an offering price of $61 per share, and also completed
our offering of $250 million 9 5/8% Senior Notes due 2009. The net proceeds from
the equity and debt offerings of $299,378,000 and $243,503,000, respectively,
were used to retire the $150 million senior subordinated bridge credit facility
plus accrued interest and repay a portion of the Term B portion of the credit
facility plus accrued interest. The Senior Notes require interest to be paid
semi-annually on June 15 and December 15. The Senior Notes are callable at
specified rates beginning in June 2004. The Senior Notes are unconditionally and
joint and severally guaranteed by our wholly-owned domestic subsidiaries other
than Practice Patterns Science, Inc., Great Plains Reinsurance Company, ValueRx
of Michigan, Inc., Diversified NY IPA, Inc., and Diversified Pharmaceutical
Services (Puerto Rico), Inc. During the second quarter of 2000, we repurchased
$10,115,000 of our Senior Notes on the open market for $10,150,000, which
includes $385,000 of accrued interest. As of June 30, 2000, the outstanding
balance on our Senior Notes was $239,885,000.

During the first half of 2000, we repurchased 790,000 shares of our Class A
common stock for $30,247,000. As of June 30, 2000, we have repurchased a total
of 1,265,000 shares of our Class A common stock under the stock repurchase
program that we announced on October 25, 1996. Our board of directors approved
the repurchase of up to 2,500,000 shares, and placed no limit on the duration of
the program. Additional common stock repurchases, if any, will be made in such
amounts and at such times as we deem appropriate based upon prevailing market
and business conditions, subject to restrictions on stock repurchases contained
in our bank credit facility and the Indenture which governs our Senior Notes.

We regularly review potential acquisitions and affiliation opportunities.
We believe that available cash resources, bank financing or the issuance of
additional common stock could be used to finance future acquisitions or
affiliations. However, there can be no assurance we will make new acquisitions
or affiliations in 2000 or thereafter.

OTHER MATTERS

In June 1998, Financial Accounting Standards Board Statement 133,
Accounting for Derivative Instruments and Hedging Activities was issued. FAS 133
requires all derivatives to be recognized as either assets or liabilities in the
statement of financial position and measured at fair value. In addition, FAS 133
specifies the accounting for changes in the fair value of a derivative based on
the intended use of the derivative and the resulting designation. The effective
date for FAS 133 was originally effective for all fiscal quarters of fiscal
years beginning after June 15, 1999. However, the Financial Accounting Standards
Board has deferred the effective date so that it will begin for all fiscal
quarters of fiscal years beginning after June 15, 2000, and will be applicable
to our first quarter of fiscal year 2001. Our present interest rate swaps will
be considered cash flow hedges. Accordingly, the change in the fair value of the
swaps will be reported on the balance sheet as an asset or liability. The
corresponding unrealized gain or loss and any changes in unrealized gain or loss
from the initial measurement date representing the effective portion of these
hedges will be initially recognized in stockholders' equity and other
comprehensive income. If we had adopted FAS 133 as of June 30, 2000, we would
have recorded the unrealized gain of $7,645,000 as an asset and increase in
stockholders' equity and other comprehensive income.

IMPACT OF INFLATION

Changes in prices charged by manufacturers and wholesalers for
pharmaceuticals affect our revenues and cost of revenues. To date, we have been
able to recover price increases from our clients under the

31
<PAGE> 36

terms of our agreements, although under selected arrangements in which we have
performance measurements on drug costs with our clients we could be adversely
affected by inflation in drug costs if the result is an overall increase in the
cost of the drug plan to the client. To date, changes in pharmaceutical prices
have not had a significant adverse affect on us.

MARKET RISK

We have entered into two interest rate swaps that have fixed the interest
rate as of June 30, 2000 for $285 million, or 89.1%, of our variable rate debt
under our credit facility. As of June 30, 2000, both swaps are effective, one
with a notional principal amount of $270 million and a fixed rate of interest of
5.88% per annum, plus the interest rate spread of 2.0%, which has been reduced
to 1.5% effective July 2000. This swap began amortizing in April 1999 in
semi-annual installments that increased to $36 million in April 2000, reducing
the principal notional amount of the swap to $270 million. Our second swap
became effective with an initial notional principal amount of $15 million and a
fixed rate of interest of 6.25% per annum, plus the interest rate spread of
2.0%, which has been reduced to 1.5% effective July 2000. Therefore, we have, in
effect, converted $270 million of our variable rate debt under our credit
facility to fixed rate debt at 5.88% per annum, plus the interest rate spread of
2.0%, and $15 million of our variable rate debt under our credit facility to
fixed rate debt at 6.25% per annum, plus the interest rate spread of 2.0%. The
fair value of our swaps at June 30, 2000 is $7,645,000. In conjunction with our
$100 million prepayment on our Term A loan during the third quarter of 2000, we
restructured our two interest rate swaps reducing the notional amounts of the
swaps to a combined $185 million.

Interest rate risk is monitored on the basis of changes in the fair value
and a sensitivity analysis is used to determine the impact interest rate changes
will have on the fair value of the interest rate swaps, measuring the change in
the net present value arising from the change in the interest rate. The fair
value of the swaps are then determined by calculating the present value of all
cash flows expected to arise thereunder, with future interest rate levels
implied from prevailing mid-market yields for money-market instruments, interest
rate futures and/or prevailing mid-market swap rates. Anticipated cash flows are
then discounted on the assumption of a continuously compounding zero-coupon
yield curve. A 10 basis point decline in interest rates at June 30, 2000 would
have caused the fair value of the swaps to decrease by $2,274,000, resulting in
a fair value of $5,371,000.

32
<PAGE> 37

BUSINESS

INDUSTRY OVERVIEW

Prescription drug costs are the fastest growing component of health care
costs in the United States. The U.S. Health Care Financing Administration
estimates that prescription drugs accounted for approximately 8% of U.S. health
care expenditures in 1998, and are expected to increase to 11% by 2008. U.S.
prescription drug sales for 1998 were approximately $90.6 billion, and the
Health Care Financing Administration projects continued sales increases at an
average annual growth rate of approximately 11% through 2008, compared to an
average annual growth rate of approximately 6% for total health care costs
during this period. Factors underlying this trend include:

- increases in research and development expenditures by pharmaceutical
manufacturers, resulting in many new drug introductions

- a shorter U.S. Food and Drug Administration approval cycle for new
pharmaceuticals

- high prices for new "blockbuster" drugs

- an aging population

- increased demand for prescription drugs due to increased disease
awareness by patients, effective direct-to-consumer advertising by
pharmaceutical manufacturers and a growing reliance on medication in lieu
of lifestyle changes

This trend creates a significant challenge to HMOs, health insurers,
employers and unions that want to provide a drug benefit as part of the health
plans they offer to members of their respective organizations. These health
benefit providers, or "payors", engage the services of PBMs to help them provide
a cost-effective drug benefit as part of their health plan and to better
understand the impact of prescription drug utilization on their overall health
care expenditures.

In general, PBMs coordinate the distribution of outpatient pharmaceuticals
through a combination of benefit management services, including retail drug card
programs, mail pharmacy services and formulary management programs. PBMs emerged
during the late 1980s by combining traditional pharmacy claims processing and
mail pharmacy services to create an integrated product offering that could help
manage the prescription drug benefit for payors. During the early 1990s,
numerous PBMs were formed, with some providers offering a comprehensive,
integrated package of services. Currently, there are an estimated 100 PBMs
serving a population of approximately 190.0 million members and processing
approximately 2 billion prescriptions annually. The PBM industry processed
approximately $83 billion worth of prescriptions in 1999. The three largest PBMs
account for approximately 80% of prescription volume or member lives.

The services offered by the larger PBMs have broadened to include disease
management programs, compliance programs, outcomes research, drug therapy
management programs and sophisticated data analysis. Because these advanced
capabilities require resources that may not be available to all PBMs,
consolidation in the industry has occurred in recent years as PBMs seek to
increase scale and capability by merging with or purchasing other PBMs.

THE COMPANY

We are the third largest PBM in North America. We are independent from
pharmaceutical manufacturer ownership, and believe our independence is important
to our clients as it allows us to make unbiased formulary recommendations to our
clients, balancing both clinical efficacy and cost.

We provide a combination of benefit management services, including retail
drug card programs, mail pharmacy services, drug formulary management programs
and other clinical management programs for approximately 12,000 client groups
that include HMOs, health insurers, third-party administrators, employers and
union-sponsored benefit plans. Some of our largest clients include Aetna U.S.
Healthcare,

33
<PAGE> 38

Oxford Health Plans, Blue Cross Blue Shield of Massachusetts, the State of
Georgia, Blue Shield of California and the State of New York Empire Plan
Prescription Drug Program.

As of October 1, 2000, our PBM services were provided to approximately 41.5
million members in the United States and Canada who were enrolled in health
plans sponsored by our clients, excluding approximately 500,000 members
associated with United HealthCare health plans. The United HealthCare membership
began transitioning to another provider on June 1, 2000 and the transition is
now substantially complete. Although membership counts are based on eligibility
data, they necessarily involve some estimates, extrapolations and
approximations. For example, some plan designs allow for family coverage under
one identification number, and we make assumptions about the average number of
persons per family in calculating our total membership. Because these
assumptions may vary among PBMs, membership counts may not be comparable between
our competitors and us. However, we believe our membership count provides a
reasonable estimation of the population we serve, and can be used as one measure
of our growth.

Our PBM offerings include:

- network pharmacy claims processing, mail pharmacy services, benefit
design consultation, drug utilization review, formulary management
programs, disease management and medical and drug data analysis services,
and compliance and therapy management programs for our clients

- market research programs for pharmaceutical manufacturers

- medical information management services, which include outcome
assessments, the development of data warehouses combining medical claims
and prescription drug claims, and sophisticated decision support tools to
evaluate disease specific interventions on cost and quality, through our
wholly owned subsidiary Practice Patterns Science, Inc.

- informed decision counseling services through our Express Health LineSM
division

Our non-PBM offerings include:

- infusion therapy services through our wholly owned subsidiary, Express
Scripts Infusion Services

- distribution of pharmaceuticals requiring special handling or packaging
through our Express Scripts Specialty Distribution Services subsidiary

Our revenues are generated primarily from the delivery of prescription
drugs through our contractual network of retail pharmacies, mail pharmacy
services and infusion therapy services. In 1997, 1998 and 1999, revenues from
the delivery of prescription drugs to our members represented 97.3%, 98.2% and
93.4%, respectively, of our total revenues. Revenues from services, such as the
administration of contracts between our clients and the clients' retail pharmacy
networks (the "Net Basis"), market research programs, the sale of medical
information management services, the sale of informed decision counseling
services and our Specialty Distribution Services comprised the remainder of our
revenues.

STRATEGY

- Development and Sale of New Products and Services to Existing Clients and
Pharmaceutical Manufacturers. We continue to emphasize the development
and sale of new products and services as part of our PBM offerings to our
existing clients, and we have begun marketing our products and services
to selected pharmaceutical manufacturers. We believe these products and
services are necessary to compete effectively in the current business
environment and to differentiate us from our competitors on measures
other than price. We intend to continue to invest in these capabilities
in the future. Products and services developed by us in recent years
include advanced formulary compliance programs, proprietary clinical
services, disease management programs, drug outcomes research, drug
therapy management programs, medical information management and
sophisticated management reporting capabilities. We believe a particular
growth area in the PBM industry will be medical information management.
We believe our Practice Patterns Science subsidiary is an industry leader
in this area, having developed proprietary software to process and sort
medical claims, prescription drug claims and clinical laboratory data for
use by managed care organizations and other health care companies. The
clients most interested in these advanced capabilities are managed care
organizations, but we believe third-party administrators and large
employers present opportunities for the sale of these advanced
capabilities as well. Recent products and services being offered to
pharmaceutical manufacturers include the implementation of therapy
compliance, therapy management and market research programs. We also
believe opportunities exist for us to grow our non-PBM specialty
distribution operation, which assists pharmaceutical manufacturers with
the distribution of products requiring special handling/packaging or
products targeted to a specific physician or patient population.

35
<PAGE> 40

PRODUCTS AND SERVICES

PHARMACY BENEFIT MANAGEMENT

Overview. Our PBM services involve the management of outpatient
prescription drug usage to foster high quality, cost-effective pharmaceutical
care through the application of managed care principles and advanced information
technologies. We offer our PBM services to our clients in the United States and
Canada. Our PBM offerings include:

- retail pharmacy network administration

- mail pharmacy services

- benefit plan design consultation

- formulary administration

- electronic point-of-sale claims processing

- drug utilization review

- the development of advanced formulary compliance and therapeutic
intervention programs

- therapy management services such as prior authorization, therapy
guidelines, step therapy protocols and formulary management interventions

- sophisticated management information reporting and analytic services

- outcomes assessments, the development of data warehouses combining
medical claims and prescription drug claims, and sophisticated decision
support tools to evaluate disease specific interventions on cost and
quality

- informed decision counseling

- drug information through our DrugDigest.org and express-scripts.com
websites

During 1999, 98.5% of our revenues were derived from PBM services, compared
to 96.8% and 97.9% during 1997 and 1998, respectively. The number of network
pharmacy claims processed and mail pharmacy claims processed, including United
HealthCare, has increased to 273.9 million and 10.6 million claims,
respectively, in 1999, from 42.9 million and 2.1 million claims, respectively,
in 1995. During 1997 and 1998, we processed 73.2 million and 113.2 million
network pharmacy claims, respectively, and 3.9 million and 7.4 million mail
pharmacy claims, respectively. For the first nine months of 2000, 98.7% of our
revenues were derived from PBM services. The number of network pharmacy claims
processed and mail pharmacy claims processed, including United HealthCare, is
231.6 million and 11.1 million, respectively.

Retail Pharmacy Network Administration. We contract with retail pharmacies
to provide prescription drugs to members of the pharmacy benefit plans managed
by us. In the United States, these pharmacies typically discount the price at
which they will provide drugs to members in return for designation as a network
pharmacy. We manage three nationwide networks in the United States and one
nationwide network in Canada that are responsive to client preferences related
to cost containment and

36
<PAGE> 41

convenience of access for members. We also manage over 350 networks of
pharmacies that we have designed to meet the specific needs of some of our
larger clients or that are under direct contract with our managed care clients.

All retail pharmacies in our pharmacy networks communicate with us on-line
and in real time to process prescription drug claims. When a member of a plan
presents his or her identification card at a network pharmacy, the network
pharmacist sends the specified claim data in an industry-standard format through
our systems, which process the claim and respond to the pharmacy, typically
within one or two seconds. The electronic processing of the claim involves:

- confirming the member's eligibility for benefits under the applicable
health benefit plan and the conditions to or limitations of coverage,
such as the amount of copayments or deductibles the member must pay

- performing a concurrent drug utilization review analysis and alerting the
pharmacist to possible drug interactions and reactions or other
indications of inappropriate prescription drug usage

- updating the member's prescription drug claim record

- if the claim is accepted, confirming to the pharmacy that it will receive
payment for the drug dispensed

Mail Pharmacy. We integrate our retail pharmacy services with our mail
pharmacy services. We operate five mail pharmacies, located in Maryland Heights,
Missouri; Tempe, Arizona; Albuquerque, New Mexico; Bensalem, Pennsylvania; and
Troy, New York. These pharmacies provide members with convenient access to
maintenance medications and enable our clients and us to control drug costs
through operating efficiencies and economies of scale. In addition, through our
mail service pharmacies, we are directly involved with the prescriber and
member, and are generally able to achieve a higher level of generic
substitutions and therapeutic interventions than can be achieved through the
retail pharmacy networks. This further reduces our clients' costs.

Benefit Plan Design and Consultation. We offer consultation and financial
modeling to assist the client in selecting a benefit plan design that meets its
needs for member satisfaction and cost control. The most common benefit design
options we offer to our clients are:

- financial incentives and reimbursement limitations on the drugs covered
by the plan, including drug formularies, flat dollar or percentage of
prescription cost copayments, deductibles or annual benefit maximum

- generic drug substitution incentives

- incentives or requirements to use only network pharmacies or to order
certain drugs only by mail

- reimbursement limitations on the number of days' supply of a drug that
can be obtained

The selected benefit design is entered into our electronic claims processing
system, which applies the plan design parameters as claims are submitted and
enables our clients and us to monitor the financial performance of the plan.

Formulary Development, Compliance and Therapy Management. Formularies are
lists of drugs for which coverage is provided under the applicable plan. They
are widely used in managed health care plans and, increasingly, by other health
plan managers. We have over 10 years of formulary development expertise and an
extensive clinical pharmacy department.

Our foremost consideration in the formulary development process is the
clinical appropriateness of the drug, not the cost of the drug. In developing
formularies, we first undertake a rigorous therapeutic assessment of the drug's
clinical effectiveness. After the clinical recommendation is made, it is
evaluated on an economic basis. No drug is added to the formulary until our
National Pharmacy & Therapeutics Committee, a panel of 17 independent physicians
and 4 of our pharmacists, approves it. This panel does not consider any
information regarding the discount or formulary fee arrangement that might be
negotiated

37
<PAGE> 42

with the manufacturer in making its clinical recommendation. This ensures that
the clinical result is not affected by the purchasing arrangement.

We administer a number of different formularies for our clients that often
identify preferred drugs whose use is encouraged or required through various
benefit design features. Historically, many clients have selected a plan design
that includes an open formulary in which substantially all drugs are covered by
the plan and preferred drugs, if any, are merely recommended. Additional options
include restricted formularies, in which various financial or other incentives
exist for the selection of preferred drugs over their non-preferred
counterparts, or closed formularies, in which benefits are available only for
drugs listed on the formulary. Formulary preferences can be encouraged:

- by restricting the formulary through plan design features, such as tiered
copayments, which require the member to pay a higher amount for a
non-preferred drug

- through prescriber education programs, in which we or the managed care
client actively seek to educate the prescribers about the formulary
preferences

- through our drug choice management program, which actively promotes
therapeutic and generic interchanges to reduce drug costs

We also provide formulary compliance services to our clients. For example,
if the doctor has not prescribed the preferred drug on a client formulary, we
notify the pharmacist through our claims processing system. The pharmacist or we
can then contact the doctor to attempt to obtain the doctor's consent to switch
the prescription to the preferred product. The doctor retains final
decision-making authority in prescribing the medication. The doctor will
consider the substitution in light of the patient's medical history, and either
writes a new prescription or denies the substitution.

We also offer innovative proprietary drug utilization review and clinical
intervention programs, to assist clients in managing compliance with the
prescribed drug therapy in identifying potential and inappropriate prescribing
practices.

Although we derive substantial revenue from pharmaceutical manufacturers,
we recognize our primary responsibility is to the plan sponsors, and we believe
our contracts with the pharmaceutical manufacturers provide us the flexibility
to utilize the most efficacious products.

Information Reporting and Analysis and Disease Management
Programs. Through the use of increasingly sophisticated information and
reporting systems, we are better able to manage the prescription drug benefit.
We have developed various services to offer our clients. One service enables a
client to analyze prescription drug data to identify cost trends and budget for
expected drug costs, to assess the financial impact of plan design changes and
to identify costly utilization patterns through an on-line prescription drug
decision support tool called ProActSM. This service permits our clients'
medically sophisticated personnel, such as a clinical pharmacist employed by an
HMO, to analyze prescription drug data on-line.

In addition, our Practice Patterns Science subsidiary builds sophisticated
data warehouses combining medical claims, prescription drug claims and clinical
laboratory data to provide decision support to the health care industry.
Proprietary Practice Patterns Science applications enable users to quickly
evaluate shifts in medical conditions afflicting membership and the
effectiveness of interventions from a cost and quality of care perspective.
Practice Patterns Science users can evaluate the impact of new prescription
drugs on the cost and results of treating specific medical conditions. Working
with leading health care organizations, Practice Patterns Science continues to
push the sophistication of data warehouses and the applications to provide
insight into the subtleties of health care delivery.

We offer additional disease management and education programs to assist
health benefit plans and our members in managing the total health care costs
associated with certain diseases, such as asthma, diabetes and cardiovascular
disease. These programs are based upon the premise that patient and provider
behavior can positively influence medical outcomes and reduce overall medical
costs. Patient identification can be accomplished through claims data analysis
or self-enrollment. Risk stratification surveys are conducted to

38
<PAGE> 43

establish a plan of care for individual program participants. Patient education
is primarily effected through a series of telephone and written communications
with nurses and pharmacists, and both providers and patients receive progress
reports on a regular basis. Outcome surveys are conducted and results are
compiled to analyze the clinical, personal and economic impact of the program.

Electronic Claims Processing System. Our electronic claims processing
system enables us to implement sophisticated intervention programs to assist in
managing prescription drug utilization. The system can be used to alert the
pharmacist to generic substitution and therapeutic intervention opportunities
and formulary compliance issues, or to administer prior authorization and
step-therapy protocol programs at the time a claim is submitted for processing.
Our claims processing system also creates a database of drug utilization
information that can be accessed both at the time the prescription is dispensed
and also on a retrospective basis to analyze utilization trends and prescribing
patterns for more intensive management of the drug benefit.

Informed Decision Counseling. We offer health care decision counseling
services through our Express Health LineSM division. This service allows a
member to call a toll-free telephone number and discuss a health care matter
with a care counselor who utilizes on-line decision support protocols and other
guidelines to provide information to assist the member in making an informed
decision in seeking appropriate treatment. Records of each call are maintained
on-line for future reference. The service is available 24 hours a day. Some
multilingual capabilities and service for the hearing impaired are also
available. The counselors provide follow-up service to members to determine if
their situation was resolved or if the counselor may provide additional
assistance. Member satisfaction and outcomes assessments are tracked through a
combination of member surveys, a quality assurance plan and system reports.

Consumer Health and Medical Information. In July 1999, we launched an
Internet site, DrugDigest.org, to provide a comprehensive source of
non-commercial health and medical information. DrugDigest.org enables a consumer
to stay informed about the wide variety of medicines on the market today,
understand their treatment options and take an active role in their healthcare.
These services are offered through reference material on drugs, vitamins,
medical research and disease management, discussion groups, "Ask the Pharmacist"
feature, and an e-Letter program enabling consumers to register and receive news
and research on medical conditions most important to them. Drug information is
also available through our express-scripts.com website.

NON-PBM

In addition to PBM services, we also provide non-PBM services, including
outpatient infusion therapy and specialty distribution services to our clients.
During 1999, 1.5% of our revenues were derived from non-PBM services, compared
to 3.2% and 2.1% during 1997 and 1998, respectively. This decline is partially
due to the acquisitions of ValueRx and DPS, which significantly increased our
PBM service revenues. For the nine months ended September 30, 2000, 1.3% of our
revenues were derived from non-PBM services.

Express Scripts Infusion Services. We provide infusion therapy services
which involve the administration of prescription drugs and other products to a
patient by catheter, feeding tube or intravenously, through our wholly owned
subsidiary, IVTx, Inc., operating under the name Express Scripts Infusion
Services. Our clients, which include managed care organizations, third-party
administrators, insurance companies, case management companies, unions and
self-insured employers, benefit from outpatient infusion therapy services
because the length of hospital stays can be reduced. Rather than receiving
infusion therapy in a hospital, we provide infusion therapy services to patients
at home, in a physician's office or in a free-standing center operated by a
managed care organization or other entity. We provide antimicrobial,
cardiovascular, hematologic, nutritional, analgesic, chemotherapeutic,
hydration, endocrine, respiratory and AIDS management treatments to patients.
Infusion Services generally prepares the treatments in one of its infusion
therapy pharmacies, which are licensed independently of our mail pharmacies. The
treatments are either administered under the supervision of a staff of
registered nurses or licensed vocational nurses who are employed at one of our
sites or, in areas where we do not have a

39
<PAGE> 44

facility, through contracted registered nurses employed or otherwise retained by
nursing agencies. We may also contract for pharmacy services for patients who
live in outlying areas.

We have facilities supporting our infusion services operations in Houston,
Texas; Dallas, Texas; Columbia, Maryland; Maryland Heights, Missouri; Columbia,
Missouri; Springfield, New Jersey; and West Chester, Pennsylvania. Infusion
Services' information system maintains patient profiles and documents doses and
supplies dispensed, and its drug utilization review component accesses our
prescription records for members receiving both infusion and oral drug therapies
to screen for drug interactions, incompatibilities and allergies.

Express Scripts Specialty Distribution Services. We provide specialty
distribution services by assisting pharmaceutical manufacturers with the
distribution of, and creation of a database of information for, products
requiring special handling/packaging or products targeted to a specific
physician or patient population or to indigent patients. These services are
provided in our Tempe, Arizona facility and new facilities located next to our
Corporate Headquarters in Maryland Heights, Missouri.

SUPPLIERS

We maintain an extensive inventory in our mail pharmacies of brand name and
generic pharmaceuticals. If a drug is not in our inventory, we can generally
obtain it from a supplier within one or two business days. We purchase our
pharmaceuticals either directly from manufacturers or through wholesalers.
During 1999, approximately 78.7% of our pharmaceutical purchases were through
one wholesaler, most of which were brand name pharmaceuticals. Generic
pharmaceuticals are generally purchased directly from manufacturers. We believe
that alternative sources of supply for most generic and brand name
pharmaceuticals are readily available.

CLIENTS

We are a major provider of PBM services to the managed care industry,
including several large HMOs, and the employer industry, both directly and
through third-party administrators. Some of our largest managed care clients are
Aetna U.S. Healthcare, Inc., Oxford Health Plans, Blue Cross Blue Shield of
Massachusetts and Blue Shield of California. Some of our largest employer groups
include the State of New York Empire Plan Prescription Drug Program (through a
subcontracting relationship with CIGNA HealthCare), the State of Georgia and the
State of Ohio Bureau of Workers' Compensation Fund. We also market our PBM
services through preferred provider organizations, group purchasing
organizations, health insurers, third-party administrators of health plans and
union-sponsored benefit plans.

With the completion of the DPS acquisition, United HealthCare was our
largest client, with approximately 9.5 million members. Our contract with United
HealthCare expired on May 31, 2000, and United HealthCare is moving to another
provider at this time. We developed a migration plan to transition the United
HealthCare membership to their new provider throughout 2000. The migration plan
is now substantially complete, and we currently serve only approximately 500,000
United HealthCare members. In our financial analysis of the DPS acquisition, we
assumed United HealthCare would not renew its contract. However, if we are
unable to reduce our costs on a basis commensurate with our expectations and
manage the transition of this large client to another provider both efficiently
and effectively, the termination of this contract may materially adversely
affect our business, results of operations and cash flows.

MEDICARE PRESCRIPTION DRUG COVERAGE

The federal Medicare program provides a comprehensive medical benefit
program for individuals age 65 and over. Today Medicare covers only a few
outpatient prescription drugs. Both the Republicans and Democrats have proposed
amendments to the Medicare program that would result in at least partial
coverage for most outpatient prescription drugs. The Medicare population is
large, and prescription drug utilization among seniors is substantially higher
on average than that of other age groups.

40
<PAGE> 45

Many of the Medicare prescription drug proposals generally outline the
program but lack important details regarding the administration of the plan. We
believe that a Medicare prescription drug benefit could provide us with
substantial new business opportunities, but at the same time any such program
could adversely affect other aspects of our business. For instance, some of our
clients sell medical policies to seniors that provide a prescription drug
benefit that we administer. Other clients provide a prescription drug benefit to
their retirees. Depending on the plan that is ultimately adopted, a Medicare
prescription drug benefit could make such policies or plans less valuable to
seniors, adversely affecting that segment of our business. While we believe that
there would be opportunities for new business under a Medicare plan that would
more than offset any adverse effects, we can give no assurance that this would
be the case.

ACQUISITIONS

On April 1, 1999, we acquired DPS from SmithKline Beecham Corporation and
one of its affiliates for $715 million in cash, which reflects a purchase price
adjustment for closing working capital and transaction costs. The acquisition
positioned us as the third largest PBM in North America in terms of total
members and provided us with one of the largest managed care membership bases of
any PBM. In addition, the acquisition provided us with enhanced clinical
capabilities and technologies.

On April 1, 1998, we acquired the PBM business known as "ValueRx" from
HCA -- The HealthCare Corporation (formerly Columbia/HCA HealthCare) for
approximately $460 million in cash. Historically, while ValueRx, like us, served
all segments of the PBM market, we primarily focused on managed care and smaller
self-funded plan sponsors, and ValueRx concentrated on health insurance carriers
and large employer and union groups. We believe the ValueRx acquisition has
provided and will continue to provide us with additional resources and
expertise, which will allow us to better serve our clients and competitively
pursue new business in all segments of the PBM market.

COMPANY OPERATIONS

General. In our various facilities in the United States, we own and
operate five mail pharmacies and eight member service/pharmacy help desk call
centers. Electronic pharmacy claims processing is principally directed through
our Maryland Heights, Missouri facility then routed to the appropriate computer
platform at our Maryland Heights, Missouri or Tempe, Arizona facility, which are
maintained, managed and operated by Electronic Data Systems, or at facilities
owned by EDS which maintains certain of our computer hardware. At our Canadian
facility, we have sales and marketing, client services, pharmacy help desk,
clinical, provider relations and certain management information systems
capabilities.

Sales and Marketing. We market and sell our PBM services in the United
States primarily through an internal staff of sales directors and sales managers
located in various cities throughout the United States. The sales
representatives are supported by a staff of client service representatives,
clinical pharmacy managers and business analyst consultants who focus on
assisting our clients in managing the rising trend in pharmacy costs. Marketing
and sales in Canada are conducted by representatives located in Mississauga,
Ontario. Although we cross-sell our infusion services to our PBM clients,
Infusion Services and Specialty Distribution Services also employ personnel to
sell these specific products.

Member Services. Although we sell our services to clients, the ultimate
recipient of many of our services are the members of health plans sponsored by
our clients. We believe, therefore, that client satisfaction is dependent upon
member satisfaction. Members can call us toll-free, 24 hours a day, 7 days a
week, to obtain information about their prescription drug plan. We employ member
service representatives who are trained to respond to member inquiries.

Provider Relations. Our Provider Relations department is responsible for
contracting and administering our pharmacy networks. To participate in our
retail pharmacy networks, pharmacists must meet certain qualifications and are
periodically required to represent to us that their applicable state licensing
requirements are being maintained and that they are in good standing. Pharmacies
can contact our various pharmacy help desks toll-free, 24 hours a day, 7 days a
week, for information and assistance in filling

41
<PAGE> 46

prescriptions for members. In addition, our Provider Relations group audits
selected pharmacies in the retail pharmacy networks to determine compliance with
the terms of the contract with our clients or us.

Clinical Support. Our Health Management Services division employs clinical
pharmacists, data analysts and outcomes researchers who provide technical
support for our PBM services. These staff members assist in providing high level
clinical pharmacy services such as formulary development, drug information
programs, clinical interventions with physicians, development of drug therapy
guidelines and the evaluation of drugs for inclusion in clinically sound
therapeutic intervention programs. The Health Management Services division also
analyzes and prepares reports on clinical pharmacy data for our clients and
conducts specific data analyses to evaluate the cost-effectiveness of certain
drug therapies.

Information Systems. Our Information Systems department supports our
pharmacy claims processing systems and other management information systems that
are essential to our operations. Uninterrupted point-of-sale electronic network
pharmacy claims processing is a significant operational requirement for us. We
are in the process of integrating the traditional Express Scripts system with
the systems acquired through the ValueRx and DPS acquisitions into an enhanced
version of the system used by DPS. All claims are presently processed through
systems which are maintained, managed and operated by EDS at our Maryland
Heights, Missouri facility and Tempe, Arizona facility, or at facilities owned
by EDS, which maintains certain computer hardware for us at its facility in
Plano, Texas. Disaster recovery services for all systems are provided through
our EDS services agreement. We have substantial capacity for growth in our
claims processing facilities.

COMPETITION

We believe the primary competitive factors in our business are price,
quality of service and breadth of available services. We believe our principal
competitive advantages are our size, our independence from pharmaceutical
manufacturer ownership, our strong managed care and employer group customer base
which supports the development of more sophisticated PBM services and our
commitment to provide flexible and distinctive service to our clients.

There are a large number of companies offering PBM services in the United
States. Most of these companies are smaller than us and offer their services on
a local or regional basis. We do, however, compete with a number of large,
national companies, including Merck-Medco Managed Care, L.L.C. (a subsidiary of
Merck & Co., Inc.), AdvancePCS and CaremarkRx, Inc., as well as numerous
insurance and Blue Cross and Blue Shield plans and certain HMOs which have their
own PBM capabilities. Several of these other companies may have greater
financial, marketing or technological resources than us. In addition, a
competitor that is owned by a pharmaceutical manufacturer may have pricing
advantages that are unavailable to us and other independent PBMs. However, we
believe our independence from pharmaceutical manufacturer ownership allows us to
make unbiased formulary recommendations to our clients, balancing both clinical
efficacy and cost. Some clients have indicated that our independence has been an
important factor in their decision-making process. Consequently, we believe our
independence provides us an advantage in marketing to these clients.

Consolidation has been, and may continue to be, an important factor in the
pharmaceutical industry, and particularly so in the PBM segment, due to the
scale required to economically provide the full range of PBM services. We
believe the size of our membership base provides us with the scale necessary to
compete effectively in this marketplace.

Some of our PBM services, such as disease management services, informed
decision counseling services and medical information management services,
compete with those being offered by pharmaceutical manufacturers, other PBMs,
large national companies, specialized disease management companies and
information service providers. Our non-PBM services compete with a number of
large national companies as well as with local providers.

42
<PAGE> 47

SERVICE MARKS AND TRADEMARKS

We, and our subsidiaries, have registered the service marks "Express
Scripts(R)", "PERx(R)", "ExpressTherapeutics(R)", "IVTx(R)", "PERxCare(R)",
"RxWizard(R)", "RxWorkbench(R)", "PTE(R)", "InformRX(R)", "M.U.S.I.C.(R)"
"ValueRx(R)", "Value Health, Inc.(R)" and "Diversified(R)", among others, with
the United States Patent and Trademark Office. Our rights to these marks will
continue so long as we comply with the usage, renewal filing and other legal
requirements relating to the renewal of service marks. We are in the process of
applying for registration of several other trademarks and service marks. If we
are unable to obtain any additional registrations, we believe there would be no
material adverse effect on our business.

INSURANCE

Our PBM operations, including the dispensing of pharmaceutical products by
our mail service pharmacies, and the services rendered in connection with our
disease management and informed decision counseling services, and our non-PBM
operations, such as the products and services provided in connection with our
infusion therapy programs (including the associated nursing services), may
subject us to litigation and liability for damages. We believe that our
insurance protection is adequate for our present business operations, but there
can be no assurance that we will be able to maintain our professional and
general liability insurance coverage in the future or that such insurance
coverage will be available on acceptable terms or adequate to cover any or all
potential product or professional liability claims. A successful product or
professional liability claim in excess of our insurance coverage, or one for
which an exclusion from coverage applies, could have a material adverse effect
upon our financial position or results of operations.

FACILITIES AND EMPLOYEES

We operate our PBM and non-PBM businesses out of leased facilities
throughout the United States and Canada.

<TABLE>
<CAPTION>
PBM FACILITIES NON-PBM FACILITIES
-------------- ------------------
<S> <C>
Maryland Heights, Missouri Maryland Heights, Missouri
Earth City, Missouri Columbia, Missouri
Tempe, Arizona Dallas, Texas
Bloomington, Minnesota Houston, Texas
Plymouth, Minnesota Columbia, Maryland
Bensalem, Pennsylvania Tempe, Arizona
Troy, New York Springfield, New Jersey
Farmington Hills, Michigan West Chester, Pennsylvania
Albuquerque, New Mexico
Horsham, Pennsylvania
Mississauga, Ontario
</TABLE>

Our Maryland Heights, Missouri facility houses our corporate offices.
Express Scripts Infusion Services' and Specialty Distribution Services'
corporate offices are also located at our Maryland Heights, Missouri facility.
Specialty Distribution Services is operated out of our facility in Tempe,
Arizona and a separate facility in Maryland Heights, Missouri. We believe our
facilities have been generally well maintained and are in good operating
condition. Our existing facilities contain approximately 1,200,000 square feet
in area, in the aggregate.

We own and lease computer systems at all processing centers. In late 1999,
we entered into a five year agreement with EDS to outsource our information
systems operations. Under the terms of the agreement, EDS has responsibility for
operating and maintaining the computer systems. Our software for drug
utilization review and other products has been developed internally by us or
purchased under perpetual, nonexclusive license agreements with third parties.
Our computer systems at each site are extensively integrated and share common
files through local and wide area networks. An uninterruptible

43
<PAGE> 48

power supply and diesel generator allow our computers, telephone systems and
mail pharmacy at each major site to continue to function during a power outage.
To protect against loss of data and extended downtime, we store software and
redundant files at both on-site and off-site facilities on a regular basis and
have contingency operation plans in place. We cannot, however, provide any
assurance that our contingency or disaster recovery plans would adequately
address all relevant issues.

As of September 1, 2000, we employed a total of 5,110 employees in the
United States and 83 employees in Canada. Approximately 625 of the U.S.
employees are members of collective bargaining units. Specifically, we employ
members of the Service Employees International Union at our Bensalem,
Pennsylvania facility, members of the United Auto Workers Union at our
Farmington Hills, Michigan facility, and members of the United Food and
Commercial Workers Union at our Albuquerque, New Mexico facility. We believe our
relationships with our employees and our unions are good.

LEGAL PROCEEDINGS

We acquired all of the outstanding capital stock of Value Health, Inc., a
Delaware corporation, and Managed Prescription Network, a Delaware corporation,
HCA -- The HealthCare Corporation (formerly Columbia/HCA HealthCare) and its
affiliates on April 1, 1998 as part of our acquisition of ValueRx. VHI, MPN
and/or their subsidiaries were party to various legal proceedings,
investigations or claims at the time of the ValueRx acquisition. The effect of
these actions on our future financial results is not subject to reasonable
estimation because considerable uncertainty exists about the outcomes.
Nevertheless, in the opinion of management, the ultimate liabilities resulting
from any of these lawsuits, investigations or claims now pending will not
materially affect our consolidated financial position, results of operations or
cash flows.

ValueRx and several of its subsidiaries are party to two securities
litigation matters, Bash, et al. v. Value Health, Inc., et al., No. 3:97 cv 2711
(JCH) (D. Conn.) and Freedman, et al. v. Value Health, Inc., et al., No. 3:95 cv
2038 (JCH) (D. Conn.). The two lawsuits, each filed in 1995, allege that VHI and
other defendants made false or misleading statements to the public in connection
with VHI's acquisition of Diagnostek in 1995. Neither complaint specifies the
amount of damages sought. On February 18, 1999, the court granted plaintiffs'
motions for class certification and certified a class consisting of:

- all persons who purchased or otherwise acquired shares of VHI during the
period from April 3, 1995, through and including November 7, 1995,
including those who acquired shares issued in connection with the
Diagnostek merger

- all persons who purchased or otherwise acquired shares of Diagostek
during the period from March 27, 1995, through and including July 28,
1995

Fact discovery in the consolidated lawsuit is complete and expert discovery
will be completed and dispositive motions will be filed over the course of the
next several months. No trial date has been set. In connection with the ValueRx
acquisition, HCA -- The HealthCare Company agreed to defend and hold us and our
affiliates, including VHI, harmless from and against any liability that may
arise in connection with either of these proceedings. Consequently, we do not
believe we will incur any material liability in connection with these matters.

In addition, in the ordinary course of our business there have arisen
various legal proceedings, investigations or claims now pending against us and
our subsidiaries unrelated to the ValueRx acquisition. The effect of these
actions on future financial results is not subject to reasonable estimation
because considerable uncertainty exists about the outcomes. Nevertheless, in the
opinion of management, the ultimate liabilities resulting from any of these
lawsuits, investigations or claims now pending will not materially affect our
consolidated financial position, results of operations or cash flows.

offered, and certain PBMs had knowingly accepted, discounts and rebates on
purchases of brand name prescription drugs that violated the federal
Robinson-Patman Act. Retail pharmacies also filed claims against the
pharmaceutical manufacturers and drug wholesalers alleging a conspiracy not to
discount pharmaceutical drugs in violation of Section 1 of the Sherman Act. Many
of the cases were consolidated and were certified as a class action. Some of the
pharmaceutical manufacturers settled both the Sherman Act and the
Robinson-Patman claims against them. The class action Sherman Act settlements
generally provide that the manufacturers will not refuse to pay discounts or
rebates to retail pharmacies based on their status as such. Settlements with
plaintiffs who opted out of the class are not part of the public record. The
pharmaceutical manufacturer and wholesaler defendants in the class action who
did not settle went to trial and were dismissed by the court on a motion for
directed verdict. That dismissal was affirmed by the Court of Appeals for the
Seventh Circuit, except for one claim which was remanded to the trial court and
has now been dismissed. Many of the plaintiffs who opted out of the class action
still have pending their Robinson-Patman and Sherman Act claims. The class
action did not involve the Robinson-Patman claims, so many of those matters are
still pending, as well. We are not a party to any of these proceedings. To date,
we do not believe any settlements have had a material adverse effect on our
business. However, we cannot provide any assurance that the terms of the
settlements will not materially adversely affect us in the future. In addition,
we cannot predict the outcome or possible ramifications to our business of the
cases in which the plaintiffs are trying their claims separately, and we cannot
provide any assurance that we will not be made a party to any such separate
lawsuits in the future.

45
<PAGE> 50

MANAGEMENT

EXECUTIVE OFFICERS AND DIRECTORS

Our executive officers and directors are as follows:

<TABLE>
<CAPTION>
NAME AGE POSITION
---- --- --------
<S> <C> <C>
Howard L. Waltman......................... 68 Chairman of the Board
Barrett A. Toan........................... 53 President, Chief Executive Officer and Director
David A. Lowenberg........................ 50 Chief Operating Officer
Terrence D. Arndt......................... 57 Senior Vice President of Marketing
Stuart L. Bascomb......................... 59 Executive Vice President -- Sales and Provider
Relations and Director
Thomas M. Boudreau........................ 48 Senior Vice President, General Counsel and
Secretary
Mabel F. Chen............................. 57 Senior Vice President and Director of Site
Operations
Robert W. (Joe) Davis..................... 54 Senior Vice President and Chief Information
Systems Officer
Mark O. Johnson........................... 47 Senior Vice President of Administration
Linda L. Logsdon.......................... 53 Executive Vice President of Health Management
Services
George Paz................................ 45 Senior Vice President and Chief Financial Officer
Joseph W. Plum............................ 53 Vice President and Chief Accounting Officer
Howard I. Atkins.......................... 49 Director
Gary G. Benanav........................... 54 Director
Frank J. Borelli.......................... 65 Director*
Judith E. Campbell........................ 52 Director
Barbara B. Hill........................... 48 Director
Richard M. Kernan, Jr. ................... 59 Director
Richard A. Norling........................ 54 Director*
Frederick J. Sievert...................... 52 Director
Stephen N. Steinig........................ 55 Director*
Seymour Sternberg......................... 57 Director
Gary E. Wendlandt......................... 50 Director
Norman Zachary............................ 74 Director*
</TABLE>

-------------------------
* Audit Committee member

Mr. Waltman was elected Chairman of the Board in March 1992. Mr. Waltman
has been a director since our inception in September 1986. Mr. Waltman also
serves as an advisor to Galen Group, a venture capital fund, and is a director
of Computer Outsourcing Services Inc.

Mr. Toan was elected Chief Executive Officer in March 1992 and President
and a director in October 1990. Mr. Toan has been an executive employee of ours
since May 1989.

Mr. Lowenberg was elected our Chief Operating Officer in September 1999,
and also served as Director of Site Operations from October 1994 until September
1999 and Vice President in November 1993. Mr. Lowenberg was General Manager of
the Tempe facility from March 1993 until January 1995.

Mr. Arndt joined us and was elected Senior Vice President of Marketing in
April 1999. Prior to joining us, Mr. Arndt was President and Chief Operating
Officer of EDI USA from July 1997 to April 1999. Mr. Arndt served as Vice
President of Business Development for Card Establishment Services,

46
<PAGE> 51

a former division of CitiBank owned by the firm of Welsh, Carson, Anderson and
Stowe, from July 1994 to July 1997. Mr. Arndt is also a director of
PlanetRx.com, Inc.

Mr. Bascomb was elected Executive Vice President in March 1989 and a
director in January 2000, and also served as Chief Financial Officer and
Treasurer from March 1992 until May 1996. Since May 1996, Mr. Bascomb has served
as Executive Vice President -- Sales and Provider Relations.

Mr. Boudreau was elected Senior Vice President, General Counsel and
Secretary in October 1994. He has served as General Counsel since June 1994.

Ms. Chen was elected Senior Vice President and Director of Site Operations
in November 1999. From March 1996 until November 1999, Ms. Chen served as Vice
President and General Manager of our Tempe facility. From January 1995 until
joining Express Scripts, Ms. Chen served as the Director of Medicaid for the
State of Arizona.

Mr. Davis was elected Senior Vice President and Chief Information Systems
Officer in September 1997. Mr. Davis served as Director of Technical Services
and Computer Operations from July 1993 until July 1995, and as Vice President
and General Manager of our St. Louis Operations from July 1995 until September
1997.

Mr. Johnson was elected Senior Vice President of Integration in May 1999,
and has served as Senior Vice President of Administration since February 2000.
Prior to joining us, Mr. Johnson served as President of DPS from May 1998 to
April 1999 and Senior Vice President, Client Service and Sales of DPS from May
1997 to May 1998. From August 1996 to May 1997, Mr. Johnson was President and
Chief Executive Officer of American Day Treatment Center, Inc. and also served
as Executive Vice President, Operations and Chief Operating Officer from March
1992 to August 1996.

Ms. Logsdon was elected Executive Vice President of Health Management
Services in May 1999, and served as Senior Vice President of Health Management
Services from May 1997 until May 1999. Ms. Logsdon served as Vice President of
Demand and Disease Management from November 1996 until May 1997. Prior to
joining us in November 1996, Ms. Logsdon served as Vice President of Corporate
Services and Chief Operating Officer of United HealthCare's Midwest
Companies-GenCare/Physicians Health Plan/MetraHealth, a St. Louis-based health
maintenance organization, from February 1995 to October 1996.

Mr. Paz joined us and was elected Senior Vice President and Chief Financial
Officer in January 1998. Prior to joining us, Mr. Paz was a partner in the
Chicago office of Coopers & Lybrand from December 1995 to December 1997.

Mr. Plum was elected Vice President in October 1994 and has served as Chief
Accounting Officer since March 1992 and Corporate Controller since March 1989.

Mr. Atkins was elected a director in January 1997. Mr. Atkins has been an
Executive Vice President and the Chief Financial Officer of New York Life since
April 1996. From September 1991 until joining New York Life, Mr. Atkins was the
Executive Vice President and Chief Financial Officer of Midlantic Bank
Corporation. Mr. Atkins is a manager of NYLIFE and is also a director (or
manager) and officer of other subsidiaries of New York Life and a director of
Life Assurance Holding Corporation Limited.

Mr. Benanav was elected a director in January 2000. Mr. Benanav has been
Chairman and Chief Executive Officer of New York Life International, Inc. since
December 1997, and a Vice Chairman of New York Life since November 1999. He was
Executive Vice President of New York Life from December 1997 until November
1999. Prior to joining New York Life, Mr. Benanav served as the President and
CEO of Aeris Ventures, a venture capital firm, from January 1997 until November
1997 and as the Chief Operating Officer of ProHealth Physicians, Inc., a
physicians' management services organization, from October 1996 until November
1997. From July 1972 until May 1996, Mr. Benanav served in various capacities
with Aetna Life and Casualty Company, including Executive Vice President from
and after December 1993. He is a director of New York Life and Barnes Group,
Inc. Mr. Benanav is a manager of NYLIFE and is also a director and officer of
other subsidiaries of New York Life.
47
<PAGE> 52

Mr. Borelli was elected a director in January 2000. Mr. Borelli has been
Senior Vice President of Marsh & McLennan Companies, a global professional
services firm, since January 2000. From October 1984 until January 2000, Mr.
Borelli was Senior Vice President and Chief Financial Officer of Marsh &
McLennan. Mr. Borelli is also a director of Marsh & McLennan and The Interpublic
Group of Companies Inc.

Ms. Campbell was elected a director in November 1997. Ms. Campbell has been
a Senior Vice President and the Chief Information Officer of New York Life since
June 1997. From October 1995 until joining New York Life, Ms. Campbell was
Senior Vice President of Consumer Banking, Manager of Deposit Products, Consumer
Payments and Direct Banking of PNCBank. Ms. Campbell is also a manager of NYLIFE
and an officer of another subsidiary of New York Life.

Ms. Hill was elected a director in January 2000. Ms. Hill served as the
President and Chief Executive Officer of Rush Prudential Health Plans from
January 1996 until June 2000. Ms. Hill served as an executive officer of Aetna
Health Plans of the Midwest from October 1994 until joining Rush Prudential. Ms.
Hill is also a director of Vision Twenty One, Inc., a managed vision care
company.

Mr. Kernan was elected a director in March 1992. He has been an Executive
Vice President of New York Life since March 1991 and the Chief Investment
Officer of New York Life since June 1997. Mr. Kernan is also Chairman of the
Board of Trustees of The MainStay Funds, the Chairman and CEO of MainStay VP
Series Fund, Inc., both companies affiliated with New York Life, a director of
New York Life, a manager and the Chairman of NYLIFE, and a director (or manager)
and officer of other subsidiaries of New York Life.

Mr. Norling was elected a director in March 1992. Mr. Norling has been the
Chief Executive Officer of Premier, Inc., the largest voluntary healthcare
alliance in the U.S., since September 1998. From September 1997 until September
1998, Mr. Norling was the Chief Operating Officer of Premier. From July 1989
until joining Premier, Mr. Norling was the President and Chief Executive Officer
of Fairview Hospital and HealthCare Services, a regional integrated network of
hospitals, ambulatory care services and health care management enterprises. Mr.
Norling is also a director of Premier.

Mr. Sievert was elected a director in July 1995. Since January 1997, Mr.
Sievert has been a Vice Chairman of New York Life. From February 1995 to
December 1996, Mr. Sievert was an Executive Vice President of New York Life. Mr.
Sievert is also a director of New York Life, a manager of NYLIFE, and a director
and officer of other subsidiaries of New York Life.

Mr. Steinig was elected a director in January 1994. Since 1989, Mr. Steinig
has been Senior Vice President and Chief Actuary of New York Life. Mr. Steinig
is also an officer of certain subsidiaries of New York Life.

Mr. Sternberg was elected a director in March 1992. Mr. Sternberg is the
Chairman, President and Chief Executive Officer of New York Life. He has been
with New York Life since February 1989, serving as the President and Chief
Operating Officer from October 1995 to April 1997 and the Vice Chairman from
February to September 1995. Mr. Sternberg is also a manager and President of
NYLIFE, and a director (or manager) and officer of other subsidiaries of New
York Life.

Mr. Wendlandt was elected a director in January 2000. Mr. Wendlandt has
been an Executive Vice President of New York Life since May 1999. Mr. Wendlandt
is also a member of the Board of Trustees of The MainStay Funds, a company
affiliated with New York Life, is the Chairman and CEO of New York Life
Investment Management LLC, is a manager of NYLIFE and is a director (or manager)
and officer of certain other subsidiaries of New York Life. From June 1972 until
joining New York Life, Mr. Wendlandt held various positions with Mass Mutual
Life Insurance Company, including the position of Executive Vice President and
Chief Investment Officer from June 1993 until May 1999.

Mr. Zachary was elected a director in March 1992. Mr. Zachary has been
retired since 1991. Prior to his retirement, Mr. Zachary held various positions
at Logica Data Architects, Inc.

48
<PAGE> 53

EMPLOYMENT AGREEMENT WITH MR. TOAN

Contemporaneously with the completion of this offering, an amendment to our
employment agreement with Mr. Toan will become effective. The amendment:

- extends the term of the employment agreement to March 31, 2005

- provides an additional grant of 90,000 options to purchase shares of our
Class A common stock to Mr. Toan under our 2000 Long-Term Incentive Plan

- provides an award of 50,000 shares of restricted stock to Mr. Toan under
our 2000 Long-Term Incentive Plan

- provides a contribution of $3.5 million to Mr. Toan's retirement account
under our Executive Deferred Compensation Plan

The amendment also provides that any options or restricted stock held by Mr.
Toan will vest in full not later than March 31, 2005, if he is still employed by
us at that time.

49
<PAGE> 54

PRINCIPAL STOCKHOLDERS

The following table sets forth information regarding the beneficial
ownership of our Class A and Class B common stock as of September 1, 2000
(unless otherwise noted) by:

- each person known by us to own beneficially more than five percent of the
outstanding shares of Class A or Class B common stock prior to and after
the stock offering and the Trust offering

- each of our five most highly compensated executive officers and each of
our directors

- all of our executive officers and directors as a group

Included are amounts of shares which may be acquired on September 1, 2000
or within 60 days of September 1, 2000 pursuant to the exercise of stock options
by executive officers or outside directors. Unless otherwise indicated, each of
the persons or entities listed below exercises sole voting and investment power
over the shares that each of them beneficially owns. All beneficial stockholders
other than New York Life, the parent of NYLIFE, own shares of Class A common
stock. New York Life, as beneficial owner, owns all of the outstanding shares of
Class B common stock prior to the stock offering and the Trust offering. After
the offerings, there will be no shares of Class B common stock outstanding.

<TABLE>
<CAPTION>
AMOUNT AND NATURE PERCENT OF CLASS
OF BENEFICIAL ----------------------
OWNERSHIP AS OF PRIOR TO AFTER
NAME AND ADDRESS SEPTEMBER 1, 2000 OFFERINGS OFFERINGS
---------------- ----------------- --------- ---------
<S> <C> <C> <C>
CLASS A COMMON STOCK:
Howard Atkins..................................... 1,500 * *
Stuart L. Bascomb(1).............................. 85,800 * *
Gary G. Benanav................................... 1,000 * *
Frank J. Borelli.................................. 0 * *
Judith E. Campbell................................ 0 * *
Barbara B. Hill................................... 0 * *
Richard M. Kernan, Jr............................. 0 * *
Richard A. Norling(2)............................. 52,559 * *
Frederick J. Sievert.............................. 0 * *
Stephen N. Steinig................................ 0 * *
Seymour Sternberg(3).............................. 7,000 * *
Barrett A. Toan(4)................................ 389,000 1.6% 1.0%
Howard L. Waltman(5).............................. 40,234 * *
Gary E. Wendlandt................................. 1,000 * *
Norman Zachary(6)................................. 35,834 * *
Linda Logsdon(7).................................. 80,640 * *
David A. Lowenberg(8)............................. 66,240 * *
George Paz(9)..................................... 13,840 * *
Directors and Executive Officers as a Group (24
persons)(10)................................... 916,425 3.8% 2.4%
FMR Corp.(11)..................................... 2,087,500 8.7% 5.4%
82 Devonshire Street Boston, Massachusetts
02109
AMVESCAP PLC(12).................................. 2,049,800 8.5% 5.3%
1 Devonshire Square London, England EC2M4YR
Pilgrim Baxter & Associates, Ltd.(13)............. 1,927,500 8.0% 5.0%
825 Duportail Road Wayne, Pennsylvania 19087
NYLIFE LLC(14)(15)(16)............................ 0 0% 23.4%
51 Madison Avenue New York, New York 10010
</TABLE>

50
<PAGE> 55

-------------------------
* Indicates less than 1%

(1) Consists of options for 68,320 shares granted under the Amended and
Restated 1992 Stock Option Plan and the Amended and Restated 1994 Stock
Option Plan (the "Employee Plans"), 10,800 shares owned by Mr. Bascomb, of
which 3,300 shares are held as co-trustee, with shared voting and
dispositive power, of a trust for the benefit of his mother, and 6,680
restricted shares granted pursuant to Express Scripts, Inc. 2000 Long-Term
Incentive Plan (the "2000 LTIP"). Excluded are 1,279 phantom shares
invested in the Company Stock Fund under the Executive Deferred
Compensation Plan, calculated as of December 31, 1999.

(2) Consists of options for 48,834 shares granted under the Amended and
Restated 1992 Stock Option Plan for Outside Directors (the "Outside
Directors Plan") and 3,725 shares owned by Mr. Norling.

(3) Excludes 360 shares held by Mr. Sternberg's son, as to which shares Mr.
Sternberg disclaims beneficial ownership.

(4) Consists of options for 348,000 shares granted under our Amended and
Restated 1992 Employee Stock Option Plan and our Amended and Restated 1994
Employee Stock Option Plan, 21,500 shares owned by Mr. Toan, and 19,500
restricted shares granted pursuant to the 2000 LTIP. The shares subject to
the options are restricted from transfer with the transfer restriction
lapsing as to 20% of the original number thereof on each anniversary date
of the date of grant. Under the terms of Mr. Toan's employment agreement,
the transfer restriction is subject to complete lapse in the event of a
"Change of Control" (as defined in the agreement) or termination of Mr.
Toan's employment by us without "Cause" (as defined in the agreement), by
Mr. Toan for "Good Reason" (as defined in the agreement) or by reason of
death, disability or retirement. Pursuant to his employment agreement, Mr.
Toan may also have the right to require us to purchase a portion of his
shares within 12 months after his termination of employment without Cause,
for Good Reason or upon death or disability. Upon termination of Mr. Toan's
employment, we will purchase any shares issued upon the exercise of the
options that remain subject to the transfer restriction at the lesser of
the option exercise price or the then current market value of the Class A
common stock. Pursuant to the amendment to Mr. Toan's employment agreement
discussed above that will take effect contemporaneously with the completion
of this offering, any options or restricted shares held by Mr. Toan will
vest in full not later than March 31, 2005 if he is still employed by us at
that time. Excluded are 448 phantom shares invested in the Company Stock
Fund under the Executive Deferred Compensation Plan, calculated as of
December 31, 1999.

(5) Consists of options for 39,234 shares granted under the Outside Directors
Plan, and 1,000 shares owned by Mr. Waltman.

(6) Consists of options for 34,834 shares granted under the Outside Directors
Plan, and 1,000 shares owned by Mr. Zachary.

(7) Consists of options for 68,460 shares granted under the Employee Plans,
5,500 shares owned by Ms. Logsdon, and 6,680 restricted shares granted
pursuant to the 2000 LTIP. Excluded are 43 phantom shares invested in the
Company Stock Fund under the Executive Deferred Compensation Plan,
calculated as of December 31, 1999.

(8) Consists of options for 57,040 shares granted under the Employee Plans, 400
shares owned by Mr. Lowenberg, of which 100 shares are held jointly with
his minor son, with shared voting and dispositive power, and 8,800
restricted shares granted pursuant to the 2000 LTIP. Excluded are 122
phantom shares invested in the Company Stock Fund under the Executive
Deferred Compensation Plan, calculated as of December 31, 1999.

(9) Consists of options for 6,960 shares granted under the Employee Plans, 200
shares owned by Mr. Paz, and 6,680 restricted shares granted pursuant to
the 2000 LTIP. Excluded are 28 phantom shares invested in the Company Stock
Fund under the Executive Deferred Compensation Plan, calculated as of
December 31, 1999.

(10) Consists of options for 776,035 shares granted under the Outside Directors
Plan and the Employee Plans, 56,625 owned by the officers and directors as
a group, and 83,765 restricted shares granted pursuant to the 2000 LTIP.
Excluded are 2,087 phantom shares invested in the Company Stock Fund under
the Executive Deferred Compensation Plan, calculated as of December 31,
1999.

(11) The information with respect to the beneficial ownership of these shares is
as of December 31, 1999 and has been obtained from Amendment No. 1 to
Schedule 13G dated February 14, 2000. The schedule reports that the

51
<PAGE> 56

beneficial owner is a registered investment advisor and shares voting power
with respect to all of the shares reported but has sole dispositive power
as to all of the shares reported.

(12) The information with respect to the beneficial ownership of these shares is
as of December 31, 1999 and has been obtained from Amendment No. 3 to
Schedule 13G dated February 3, 2000. The schedule reports that the
beneficial owner is a parent holding company and shares voting power and
dispositive power as to all of the shares reported.

(13) The information with respect to the beneficial ownership of these shares is
as of December 31, 1999 and has been obtained from Amendment No. 12 to
Schedule 13G dated January 7, 2000. The schedule reports that the
beneficial owner is a registered investment advisor and shares voting power
with respect to all of the shares reported but has sole dispositive power
as to all of the shares reported.

(14) Messrs. Atkins, Benanav, Kernan, Sievert, Steinig, Sternberg, and
Wendlandt, and Ms. Campbell, our directors, are also directors and/or hold
various executive positions with New York Life and/or NYLIFE HealthCare.
All of these directors disclaim beneficial ownership of our Class B common
stock owned by NYLIFE HealthCare.

(15) NYLIFE LLC is a wholly owned subsidiary of New York Life. NYLIFE HealthCare
Management, Inc., a wholly owned subsidiary of NYLIFE LLC, holds 15,020,000
shares of Class B common stock, which automatically convert upon transfer
by NYLIFE HealthCare to any entity other than New York Life or an affiliate
of New York Life at any time into shares of Class A common stock on a
share-for-share basis and otherwise at the option of NYLIFE HealthCare.
Neither NYLIFE LLC nor any of its subsidiaries currently owns shares of our
Class A common stock. NYLIFE HealthCare has agreed to exchange each share
of Class B common stock into one share of our Class A common stock
immediately prior to the completion of this offering and distribute such
shares to NYLIFE LLC. NYLIFE LLC will retain the right to vote 3,000,000
shares of Class A common stock which the Trust may deliver upon exchange of
the Trust Securities offered in the Trust offering, unless such shares are
delivered pursuant to the terms of the Trust. New York Life and its
subsidiaries have agreed to vote any shares of our Class A common stock
that may be delivered by the Trust in the same proportion and to the same
effect as the votes cast by our other stockholders at any meeting of
stockholders, subject to two exceptions relating to elections of directors
and approval of our 2000 Long-Term Incentive Plan.

(16) Assumes that the underwriters' over-allotment option is not exercised.

52
<PAGE> 57

DESCRIPTION OF CAPITAL STOCK

Our authorized capital stock consists of 150,000,000 shares of Class A
common stock, par value $0.01 per share, 31,000,000 shares of Class B common
stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par
value $0.01 per share.

COMMON STOCK

As of September 1, 2000, 24,235,121 shares of Class A common stock were
issued and 23,476,359 shares were outstanding, and 15,020,000 shares of Class B
common stock were issued and outstanding. The outstanding Class A common stock
is, and the Class A common stock offered by this prospectus when issued and paid
for will be, fully paid and non-assessable. A NYLIFE subsidiary, the only holder
of our Class B common stock, has agreed to exchange each outstanding share of
Class B common stock for one share of our Class A common stock immediately prior
to the completion of this offering and distribute such shares to NYLIFE.

Dividends. Dividends on the common stock will be paid if, when and as
determined by our board of directors out of funds legally available for this
purpose. Holders of Class A and Class B common stock have the same rights
regarding dividends.

Voting Rights. Holders of Class A common stock are entitled to one vote
for each share held by them on all matters presented to stockholders. Pursuant
to our certificate of incorporation, the holders of Class B common stock have
ten votes per share. A NYLIFE subsidiary, the only holder of our Class B common
stock, has agreed to exchange each outstanding share of Class B common stock for
one share of our Class A common stock immediately prior to the completion of
this offering and distribute such shares to NYLIFE. After this offering, there
will be no shares of Class B common stock outstanding. The affirmative vote of
the holders of a majority of the outstanding Class A common stock is required
for an amendment of the by-laws that would alter the requirement that a majority
of the directors on the audit committee be persons who are not directors of New
York Life or its subsidiaries, other than us, or officers or employees of New
York Life or its subsidiaries, other than us. Our stockholders do not have
cumulative voting rights with respect to the election of directors. Our by-laws
provide for notice requirements for stockholder nominations and proposals at
annual meetings and preclude stockholders holding less than 50% of all
outstanding voting shares from bringing business before any special meeting. No
action required or permitted to be taken at an annual or special meeting of our
stockholders may be taken by written consent without a meeting. We have elected
not to be subject to Section 203 of the General Corporation Law of the State of
Delaware, which prohibits some publicly held Delaware corporations from engaging
in a business combination with an interested stockholder. An interested
stockholder is any person or entity who, together with affiliates and
associates, owns, or within the three immediately preceding years did own, 15%
or more of a corporation's voting stock.

Liquidation Rights. After satisfaction of the preferential liquidation
rights of any preferred stock, the holders of the Class A and Class B common
stock are entitled to share, ratably, in the distribution of all remaining net
assets.

Preemptive and Other Rights. The holders of common stock do not have
preemptive rights as to additional issues of common stock or, other than the
Class B common stock, conversion rights. The shares of common stock are not
subject to redemption or to any further calls or assessments and are not
entitled to the benefit of any sinking fund provisions. Our Class B common stock
automatically converts to our Class A common stock on a share-for-share basis
upon transfer to any entity other than New York Life or an affiliate of New York
Life and otherwise at the option of the holder thereof. A subsidiary of NYLIFE,
the only holder of our Class B common stock, has agreed to exchange each
outstanding share of Class B common stock for one share of our Class A common
stock immediately prior to the completion of this offering and distribute such
shares to NYLIFE. After this offering, there will be no shares of Class B common
stock outstanding.

53
<PAGE> 58

PREFERRED STOCK

Our certificate of incorporation authorizes our board of directors to issue
from time to time, in one or more series, shares of preferred stock with the
designations and preferences, relative voting rights -- except that voting
rights, if any, in respect of the election of directors shall be limited to
voting with the holders of Class A and Class B common stock, as a single class,
with no more than one vote per share of preferred stock -- redemption,
conversion, participation and other rights and qualifications, limitations and
restrictions permitted by law. No shares of preferred stock have been issued.

54
<PAGE> 59

SELLING STOCKHOLDER

The following table sets forth information about NYLIFE's beneficial
ownership of our Class A common stock before and after the stock offering and
the Trust offering. Beneficial ownership is determined in accordance with SEC
rules. NYLIFE will retain beneficial ownership and the right to vote and to
receive dividends with respect to the shares of the Class A common stock that
may be delivered by the Express Scripts Automatic Exchange Security Trust upon
exchange of the Trust Securities on the exchange date, as defined in the Trust
prospectus, unless such shares are delivered pursuant to the terms of the Trust.
New York Life and its subsidiaries have agreed to vote any shares of our Class A
common stock that may be delivered by the Trust in the same proportion and to
the same effect as the votes cast by our other stockholders at any meeting of
stockholders, subject to two exceptions relating to elections of directors and
approval of our 2000 Long-Term Incentive Plan. Delivery of such shares is
expected on or about November , 2003, unless NYLIFE exercises its right to
deliver cash in lieu of such shares (in which case NYLIFE will retain beneficial
ownership of such shares) or unless the Trust is liquidated and such shares are
delivered on an earlier date. The information in the table assumes that the
underwriters will not exercise their right to purchase additional shares of
Class A common stock in the stock offering or additional Trust Securities in the
Trust offering pursuant to their over-allotment options.

<TABLE>
<CAPTION>
PERCENTAGE PERCENTAGE OF
SHARES SHARES OF SHARES SHARES SHARES
BENEFICIALLY BENEFICIALLY BENEFICIALLY BENEFICIALLY BENEFICIALLY
OWNED OWNED OWNED OWNED AFTER OWNED AFTER
PRIOR TO AFTER AFTER DELIVERY OF DELIVERY OF
THE THE STOCK THE STOCK SHARES BY THE SHARES BY THE
OFFERINGS(1) OFFERING(1) OFFERING(2) TRUST(1)(3) TRUST(2)(3)
------------ ------------ ------------ --------------- --------------
<S> <C> <C> <C> <C> <C>
NYLIFE LLC 15,020,000 9,020,000 23.4% 6,020,000 15.6%
51 Madison Avenue
New York, New York 10010
</TABLE>

-------------------------

(1) As of the date of this prospectus, NYLIFE LLC does not directly own any
shares of our common stock. NYLIFE HealthCare Management, Inc., a wholly
owned subsidiary of NYLIFE LLC, owns 15,020,000 shares of Class B common
stock, which automatically convert upon transfer by NYLIFE HealthCare to any
entity other than New York Life or an affiliate of New York Life at any time
into shares of our Class A common stock on a share-for-share basis and
otherwise at the option of NYLIFE HealthCare. NYLIFE HealthCare currently
owns no shares of our Class A common stock. NYLIFE HealthCare has agreed to
exchange each share of Class B common stock into one share of our Class A
common stock immediately prior to the completion of this offering and
distribute such shares to NYLIFE LLC.

(2) Based on 38,496,359 total shares outstanding.

(3) Assumes that NYLIFE LLC will deliver 3,000,000 shares of Class A common
stock upon maturity of the Trust on or about November , 2003. NYLIFE LLC
may deliver fewer shares or may choose to settle its obligations under the
Trust in cash. See the Trust prospectus for a description of the obligations
of NYLIFE LLC in the Trust offering.

55
<PAGE> 60

UNDERWRITING

Under the terms and subject to the conditions contained in an underwriting
agreement dated November , 2000, NYLIFE has agreed to sell to the underwriters
named below, for whom Credit Suisse First Boston Corporation, Goldman, Sachs &
Co., Banc of America Securities LLC, Salomon Smith Barney Inc. and CIBC World
Markets Corp. are acting as representatives, the following respective numbers of
shares of Class A common stock:

<TABLE>
<CAPTION>
NUMBER
UNDERWRITER OF SHARES
----------- ---------
<S> <C>
Credit Suisse First Boston Corporation......................
Goldman, Sachs & Co.........................................
Banc of America Securities LLC..............................
Salomon Smith Barney Inc. ..................................
CIBC World Markets Corp. ...................................
--------
Total.....................................................
========
</TABLE>

The underwriting agreement provides that the underwriters are obligated to
purchase all the shares of Class A common stock in the offering if any are
purchased, other than those shares covered by the over-allotment option
described below. The underwriting agreement also provides that if an underwriter
defaults, the purchase commitments of non-defaulting underwriters may be
increased or the offering may be terminated.

NYLIFE and the Express Scripts Automatic Exchange Security Trust have
entered into a separate underwriting agreement for the offer and sale by the
Trust to Credit Suisse First Boston Corporation and Goldman, Sachs & Co. of
3,000,000 Trust Securities, plus up to an additional 450,000 Trust Securities
(less the number of Trust Securities purchased in connection with the formation
of the Trust) solely to cover over-allotments. On or about November , 2003, or
upon earlier liquidation of the Trust in certain circumstances, the Trust will
distribute shares of our Class A common stock (or, at NYLIFE's option, the cash
equivalent value and/or such other consideration as is delivered by NYLIFE to
the Trust pursuant to a forward purchase contract between NYLIFE and the Trust)
to the holders of the Trust Securities at the rate specified in the Trust
prospectus.

NYLIFE has granted to the underwriters a 30-day option to purchase on a pro
rata basis up to 900,000 additional outstanding shares of Class A common stock
at the initial public offering price less the underwriting discounts and
commissions. The option may be exercised only to cover any over-allotments of
our Class A common stock.

The underwriters propose to offer the shares of Class A common stock
initially at the public offering price on the cover page of this prospectus and
to selling group members at that price less a selling concession of $ per
share. The underwriters and selling group members may allow a discount of $ per
share on sales to other broker/dealers. After the initial public offering, the
public offering price and concession and discount to broker/dealers may be
changed by the representatives.

The following table summarizes the compensation and estimated expenses we
and NYLIFE will pay:

<TABLE>
<CAPTION>
PER SHARE TOTAL
------------------------------- -------------------------------
WITHOUT WITH WITHOUT WITH
OVER-ALLOTMENT OVER-ALLOTMENT OVER-ALLOTMENT OVER-ALLOTMENT
-------------- -------------- -------------- --------------
<S> <C> <C> <C> <C>
Underwriting Discounts and Commissions
paid by NYLIFE...................... $ $ $ $
Expenses payable by NYLIFE............ $ $ $ $
Expenses payable by us................ $ $ $ $
</TABLE>

56
<PAGE> 61

We have agreed that we will not offer, sell, contract to sell, pledge or
otherwise dispose of, directly or indirectly, or file with the Securities and
Exchange Commission a registration statement under the Securities Act relating
to, any shares of our Class A common stock or securities convertible into or
exchangeable or exercisable for any shares of our Class A common stock, or
publicly disclose the intention to make any offer, sale, pledge, disposition or
filing, subject to certain exceptions set forth in the underwriting agreement,
without the prior written consent of Credit Suisse First Boston Corporation and
Goldman, Sachs & Co. for a period of 90 days after the date of this prospectus.

Our officers, directors and NYLIFE have agreed that they will not offer,
sell, contract to sell, pledge or otherwise dispose of, directly or indirectly,
any shares of our Class A common stock or securities convertible into or
exchangeable or exercisable for any shares of our Class A common stock, enter
into a transaction which would have the same effect, or enter into any swap,
hedge or other arrangement that transfers, in whole or in part, any of the
economic consequences of ownership of our Class A common stock, whether any of
these transactions are to be settled by delivery of our Class A common stock or
other securities, in cash or otherwise, or publicly disclose the intention to
make any offer, sale, pledge or disposition, or to enter into any transaction,
swap, hedge or other arrangement, without, in each case, the prior written
consent of Credit Suisse First Boston Corporation and Goldman, Sachs & Co. for a
period of 90 days after the date of this prospectus, except that certain of our
directors will not be so restricted with respect to up to an aggregate of 32,500
shares of Class A common stock, and except as otherwise set forth in the
underwriting agreement.

We and, if we fail to do so, NYLIFE have agreed to indemnify the
underwriters against liabilities under the Securities Act, or contribute to
payments which the underwriters may be required to make in that respect.

Credit Suisse First Boston, an affiliate of Credit Suisse First Boston
Corporation, is an agent and a lender under our credit facility. Some affiliates
of the other underwriters were, or may currently or in the future be, lenders
under our credit facility. Some of the underwriters and their affiliates have in
the past provided investment banking, commercial lending and financial advisory
services for us, New York Life and affiliates of New York Life for which they
received customary compensation, and they may from time to time do so in the
future.

We will apply to list the shares of Class A common stock being offered by
this prospectus on The Nasdaq National Market.

In connection with the offering, the underwriters may engage in stabilizing
transactions, over-allotment transactions, syndicate covering transactions,
penalty bids and passive market making in accordance with Regulation M under the
Exchange Act.

- Stabilizing transactions permit bids to purchase the underlying security
so long as the stabilizing bids do not exceed a specified maximum.

- Over-allotment involves sales by the underwriters of shares in excess of
the number of shares the underwriters are obligated to purchase, which
creates a syndicate short position. The short position may be either a
covered short position or a naked short position. In a covered short
position, the number of shares over-allotted by the underwriters is not
greater than the number of shares that they may purchase in the
over-allotment option. In a naked short position, the number of shares
involved is greater than the number of shares in the over-allotment
option. The underwriters may close out any short position by either
exercising their over-allotment option and/or purchasing shares in the
open market.

- Syndicate covering transactions involve purchases of the Class A common
stock in the open market after the distribution has been completed in
order to cover syndicate short positions. In determining the source of
shares to close out the short position, the underwriters will consider,
among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares
through the over-allotment option. If the underwriters sell more shares
than could be covered by the over-allotment option -- a naked short
position -- the position
57
<PAGE> 62

can only be closed out by buying shares to the open market. A naked short
position is more likely to be created if the underwriters are concerned
that there could be downward pressure on the price of the shares in the
open market after pricing that could adversely affect investors who
purchase in the offering.

- Penalty bids permit the representatives to reclaim a selling concession
from a syndicate member when the Class A common stock originally sold by
the syndicate member is purchased in a stabilizing or syndicate covering
transaction to cover syndicate short positions.

- In passive market making, market makers in the Class A common stock who
are underwriters or prospective underwriters may, subject to limitations,
make bids for or purchases of the Class A common stock until the time, if
any, at which a stabilizing bid is made.

These stabilizing transactions, syndicate covering transactions and penalty bids
may have the effect of raising or maintaining the market price of the Class A
common stock or preventing or retarding a decline in the market price of the
Class A common stock. As a result, the price of the Class A common stock may be
higher than the price that might otherwise exist in the open market. These
transactions may be effected on The Nasdaq Stock Market's National Market or
otherwise and, if commenced, may be discontinued at any time.

A prospectus in electronic format may be made available on the web sites
maintained by one or more of the underwriters participating in this offering.
The representatives may agree to allocate a number of shares to underwriters for
sale to their online brokerage account holders. Internet distributions will be
allocated by the underwriters that will make internet distributions on the same
basis as other allocations.

58
<PAGE> 63

NOTICE TO CANADIAN RESIDENTS

RESALE RESTRICTIONS

The distribution of the Class A common stock in Canada is being made only
on a private placement basis exempt from the requirement that we and NYLIFE
prepare and file a prospectus with the securities regulatory authorities in each
province where trades of Class A common stock are made. Any resale of the Class
A common stock in Canada must be made under applicable securities laws which
will vary depending on the relevant jurisdiction, and which may require resales
to be made under available statutory exemptions or under a discretionary
exemption granted by the applicable Canadian securities regulatory authority.
Purchasers are advised to seek legal advice prior to any resale of the Class A
common stock.

REPRESENTATIONS OF PURCHASERS

By purchasing Class A common stock in Canada and accepting a purchase
confirmation, a purchaser is representing to us, NYLIFE and the dealer from whom
the purchase confirmation is received that:

- the purchaser is entitled under applicable provincial securities laws to
purchase the Class A common stock without the benefit of a prospectus
qualified under those securities laws,

- where required by law, the purchaser is purchasing as principal and not
as agent, and

- the purchaser has reviewed the text above under Resale Restrictions.

RIGHTS OF ACTION (ONTARIO PURCHASERS)

The securities being offered are those of a foreign issuer and Ontario
purchasers will not receive the contractual right of action prescribed by
Ontario securities laws. As a result, Ontario purchasers must rely on other
remedies that may be available, including common law rights of action for
damages or rescission or rights of action under the civil liability provisions
of the United States federal securities laws.

ENFORCEMENT OF LEGAL RIGHTS

All of the issuer's directors and officers as well as the experts named
herein and NYLIFE may be located outside of Canada and, as a result, it may not
be possible for Canadian purchasers to effect service of process within Canada
upon the issuer or such persons. All or a substantial portion of the assets of
the issuer and such persons may be located outside of Canada and, as a result,
it may not be possible to satisfy a judgment against the issuer or such persons
in Canada or to enforce a judgment obtained in Canadian courts against such
issuer or persons outside of Canada.

NOTICE TO BRITISH COLUMBIA RESIDENTS

A purchaser of Class A common stock to whom the Securities Act (British
Columbia) applies is advised that such purchaser is required to file with the
British Columbia Securities Commission a report within ten days of the sale of
any Class A common stock acquired by the purchaser pursuant to this offering.
The report must be in the form attached to British Columbia Securities
Commission Blanket Order BOR #95/17, a copy of which may be obtained from us.
Only one report must be filed for Class A common stock acquired on the same date
and under the same prospectus exemption.

TAXATION AND ELIGIBILITY FOR INVESTMENT

Canadian purchasers of Class A common stock should consult their own legal
and tax advisors with respect to the tax consequences of an investment in the
Class A common stock in their particular circumstances and about the eligibility
of the Class A common stock for investment by the purchaser under relevant
Canadian legislation.

59
<PAGE> 64

FORWARD-LOOKING STATEMENTS

This prospectus and the documents incorporated in this prospectus by
reference include forward-looking statements under the Securities Act. In
addition, from time to time, we or our representatives have made or may make
forward-looking statements orally or in writing. The words "may," "will,"
"expect," "anticipate," "believe," "estimate," "plan," "intend" and similar
expressions have been used in this prospectus and the documents incorporated in
this prospectus by reference to identify forward-looking statements. We have
based these forward-looking statements on our current views with respect to
future events and financial performance. Actual results could differ materially
from those projected in the forward-looking statements. These forward-looking
statements are subject to risks, uncertainties and assumptions, including, among
other things:

- risks associated with managing the termination of the United HealthCare
contract

- risks associated with our ability to maintain internal growth rates

- continued pressure on margins resulting from client demands for enhanced
service offerings and higher service levels

- competition, including price competition, competition in the bidding and
proposal process and our ability to consummate contract negotiations with
prospective clients

- adverse results in regulatory matters, the adoption of adverse
legislation or regulations, more aggressive enforcement of existing
legislation or regulations, or a change in the interpretation of existing
legislation or regulations

- the possible termination of contracts with key clients or providers

- the possible loss of relationships with pharmaceutical manufacturers, or
changes in pricing, discount or other practices of pharmaceutical
manufacturers

- adverse results in litigation

- risks associated with our leverage and debt service obligations

- risks associated with our ability to continue to develop new products,
services and delivery channels

- developments in the health care industry, including the impact of
increases in health care costs, changes in drug utilization patterns and
introductions of new drugs

- other risks described from time to time in our filings with the SEC

We are not obligated to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. All
subsequent written and oral forward-looking statements attributable to us or
persons acting on our behalf are expressly qualified in their entirety by the
cautionary statements contained throughout this prospectus and the documents
incorporated in this prospectus by reference. Because of these risks,
uncertainties and assumptions, you should not place undue reliance on these
forward-looking statements.

60
<PAGE> 65

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and special reports, proxy statements and other
information with the SEC under the Exchange Act. The Exchange Act file number
for our SEC filings is 000-20199. You may read and copy any document we file at
the following SEC public reference rooms:

<TABLE>
<S> <C> <C>
Judiciary Plaza 500 West Madison Street 7 World Trade Center
450 Fifth Street, N.W. 14th Floor Suite 1300
Room 1024 Chicago, Illinois 60661 New York, New York 10048
Washington, D.C. 20549
</TABLE>

You may obtain information on the operation of the public reference room in
Washington, D.C. by calling the SEC at 1-800-SEC-0330.

We file information electronically with the SEC. Our SEC filings also are
available from the SEC's Internet site at http://www.sec.gov, which contains
reports, proxy and information statements and other information regarding
issuers that file electronically. Our Class A common stock is listed on The
Nasdaq National Market.

You may also read and copy our SEC filings and other information at the
offices of Nasdaq Operations, 1735 K Street, N.W., Washington, D.C. 20006.

This prospectus is part of a registration statement we filed with the SEC.
The SEC allows us to "incorporate by reference" selected documents we file with
it, which means that we can disclose important information to you by referring
you to those documents. The information in the documents incorporated by
reference is considered to be part of this prospectus, and information in
documents that we file later with the SEC will automatically update and
supersede this information. We incorporate by reference the documents listed
below and any future filings we will make with the SEC under Section 13(a),
13(c), 14 or 15(d) of the Exchange Act:

- Annual Report on Form 10-K dated March 29, 2000, for the fiscal year
ended December 31, 1999

- Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31,
2000, and June 30, 2000

- Current Reports on Form 8-K dated February 10, 2000 (2), March 3, 2000,
April 24, 2000, June 23, 2000, July 21, 2000, and October 17, 2000

- Description of Common Stock contained in the Registration Statement on
Form 8-A dated May 12, 1992

We will provide a copy of the documents we incorporate by reference, at no
cost, to any person who receives this prospectus, including any beneficial owner
of our common stock. To request a copy of any or all of these documents, you
should write or telephone us at the following address and telephone number:

General Counsel
Express Scripts, Inc.
13900 Riverport Drive
Maryland Heights, Missouri 63043
Telephone: (314) 770-1666

61
<PAGE> 66

LEGAL MATTERS

Certain legal matters with respect to the Class A common stock being
offered by this prospectus are being passed upon for us by Thomas M. Boudreau,
our Senior Vice President, General Counsel and Secretary, and by Simpson Thacher
& Bartlett, New York, New York, and for the underwriters by Cahill Gordon &
Reindel, New York, New York.

EXPERTS

The financial statements as of December 31, 1999 and 1998 and for each of
the three years in the period ended December 31, 1999 included in this
prospectus and incorporated by reference to the Annual Report on Form 10-K for
the year ended December 31, 1999 have been so included/incorporated in reliance
on the reports of PricewaterhouseCoopers LLP, independent accountants, given on
the authority of said firm as experts in auditing and accounting.

62
<PAGE> 67

INDEX TO FINANCIAL STATEMENTS

EXPRESS SCRIPTS, INC.
UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

<TABLE>
<S> <C>
Unaudited Consolidated Balance Sheet........................ F-3
Unaudited Consolidated Statement of Operations.............. F-4
Unaudited Consolidated Statement of Changes in Stockholders'
Equity.................................................... F-5
Unaudited Consolidated Statement of Cash Flows.............. F-6
Notes to Unaudited Consolidated Financial Statements........ F-7
</TABLE>

EXPRESS SCRIPTS, INC.
CONSOLIDATED FINANCIAL STATEMENTS

<TABLE>
<S> <C>
Report of Independent Accountants........................... F-15
Consolidated Balance Sheet.................................. F-16
Consolidated Statement of Operations........................ F-17
Consolidated Statement of Changes in Stockholders' Equity... F-18
Consolidated Statement of Cash Flows........................ F-19
Notes to Consolidated Financial Statements.................. F-20
</TABLE>

F-1
<PAGE> 68

EXPRESS SCRIPTS, INC.

UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2000 AND
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 1999 AND 2000

F-2
<PAGE> 69

EXPRESS SCRIPTS, INC.

UNAUDITED CONSOLIDATED BALANCE SHEET

<TABLE>
<CAPTION>
DECEMBER 31, JUNE 30,
1999 2000
------------ --------
(IN THOUSANDS)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents................................. $ 132,630 $ 99,835
Receivables, net.......................................... 783,086 845,699
Inventories............................................... 113,248 75,984
Other current assets...................................... 37,391 34,224
---------- ----------
Total current assets................................... 1,066,355 1,055,742
Investment in marketable securities......................... 150,365 10,270
Property and equipment, net................................. 97,573 112,319
Goodwill, net............................................... 982,496 984,785
Other intangible assets, net................................ 183,420 163,538
Other assets................................................ 7,102 10,226
---------- ----------
Total assets........................................... $2,487,311 $2,336,880
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Claims and rebates payable................................ $ 850,630 $ 855,839
Current portion of long-term debt......................... -- 42,750
Other current liabilities................................. 249,728 258,296
---------- ----------
Total current liabilities.............................. 1,100,358 1,156,885
Long-term debt.............................................. 635,873 517,908
Other liabilities........................................... 51,598 32,823
---------- ----------
Total liabilities...................................... 1,787,829 1,707,616
---------- ----------
STOCKHOLDERS' EQUITY:
Preferred stock, $0.01 par value, 5,000,000 shares
authorized, and no shares issued and outstanding
Class A Common Stock, $0.01 par value, 150,000,000 shares
authorized, 23,981,000 and 24,002,000 shares issued and
outstanding, respectively.............................. 240 240
Class B Common Stock, $0.01 par value, 31,000,000 shares
authorized, 15,020,000 shares issued and outstanding... 150 150
Additional paid-in capital................................ 418,921 421,507
Accumulated other comprehensive income.................... (9,521) (57)
Retained earnings......................................... 296,540 243,795
---------- ----------
706,330 665,635
Class A Common Stock in treasury at cost, 465,000 and
1,202,000 shares, respectively......................... (6,848) (36,371)
---------- ----------
Total stockholders' equity........................... 699,482 629,264
---------- ----------
Total liabilities and stockholders' equity........... $2,487,311 $2,336,880
========== ==========
</TABLE>

See accompanying notes to consolidated financial statements.

F-3
<PAGE> 70

EXPRESS SCRIPTS, INC.

UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS

<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
--------------------- ------------------------
1999 2000 1999 2000
-------- ---------- ---------- ----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C>
Revenues:
Revenues................................... $996,749 $1,650,251 $1,895,836 $3,122,791
Other revenues............................. -- 3,116 -- 6,085
-------- ---------- ---------- ----------
996,749 1,653,367 1,895,836 3,128,876
-------- ---------- ---------- ----------
Cost and expenses:
Cost of revenues........................... 869,989 1,515,964 1,693,636 2,859,027
Selling, general and administrative........ 81,897 87,421 128,337 170,792
Non-recurring.............................. 9,400 -- 9,400 --
-------- ---------- ---------- ----------
961,286 1,603,385 1,831,373 3,029,819
-------- ---------- ---------- ----------
Operating income............................. 35,463 49,982 64,463 99,057
-------- ---------- ---------- ----------
Other income (expense):
Write-down of marketable securities........ -- (155,500) -- (155,500)
Interest income............................ 1,444 2,046 2,837 3,427
Interest expense........................... (23,231) (13,183) (29,453) (27,384)
-------- ---------- ---------- ----------
(21,787) (166,637) (26,616) (179,457)
-------- ---------- ---------- ----------
Income (loss) before income taxes............ 13,676 (116,655) 37,847 (80,400)
Provision for (benefit from) income taxes.... 6,658 (42,478) 17,286 (27,655)
-------- ---------- ---------- ----------
Income (loss) before extraordinary item...... 7,018 (74,177) 20,561 (52,745)
Extraordinary item, net of taxes of $4,144... (6,597) -- (6,597) --
-------- ---------- ---------- ----------
Net income (loss)............................ $ 421 $ (74,177) $ 13,964 $ (52,745)
======== ========== ========== ==========
Basic earnings (loss) per share:
Before extraordinary item.................. $ 0.20 $ (1.96) $ 0.61 $ (1.39)
Extraordinary item......................... (0.19) -- (0.19) --
-------- ---------- ---------- ----------
Net income (loss).......................... $ 0.01 $ (1.96) $ 0.42 $ (1.39)
======== ========== ========== ==========
Weighted average number of common shares
outstanding during the period -- Basic
EPS........................................ 34,055 37,812 33,633 38,068
======== ========== ========== ==========
Diluted earnings (loss) per share
Before extraordinary item.................. $ 0.20 $ (1.93) $ 0.59 $ (1.36)
Extraordinary item......................... (0.19) -- (0.19) --
-------- ---------- ---------- ----------
Net income (loss).......................... $ 0.01 $ (1.93) $ 0.40 $ (1.36)
======== ========== ========== ==========
Weighted average number of common shares
outstanding during the period -- Diluted
EPS........................................ 34,952 38,507 34,553 38,751
======== ========== ========== ==========
</TABLE>

See accompanying notes to consolidated financial statements.

F-4
<PAGE> 71

EXPRESS SCRIPTS, INC.

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

<TABLE>
<CAPTION>
NUMBER OF SHARES AMOUNT
----------------- --------------------------------------------------------------------------------
ACCUMULATED
CLASS A CLASS B CLASS A CLASS B ADDITIONAL OTHER
COMMON COMMON COMMON COMMON PAID-IN COMPREHENSIVE RETAINED TREASURY
STOCK STOCK STOCK STOCK CAPITAL INCOME EARNINGS STOCK TOTAL
------- ------- ------- ------- ---------- -------------- -------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31,
1999..................... 23,981 15,020 $240 $150 $418,921 $(9,521) $296,540 $ (6,848) $699,482
------ ------ ---- ---- -------- ------- -------- -------- --------
Comprehensive income:
Net loss............... -- -- -- -- -- -- (52,745) -- (52,745)
Other comprehensive
income,
Foreign currency
translation
adjustment........... -- -- -- -- -- (91) -- -- (91)
Recognition of prior
period unrealized
losses on
investments....... -- -- -- -- -- 9,555 -- -- 9,555
------ ------ ---- ---- -------- ------- -------- -------- --------
Comprehensive (loss)
income................. -- -- -- -- -- 9,464 (52,745) -- (43,281)
Repurchase of Class A
Common Stock........... -- -- -- -- -- -- -- (30,247) (30,247)
Common stock issued under
employee plans......... 21 -- -- -- 780 -- -- -- 780
Exercise of stock
options................ -- -- -- -- 913 -- -- 724 1,637
Tax benefit relating to
employee stock
options................ -- -- -- -- 893 -- -- -- 893
------ ------ ---- ---- -------- ------- -------- -------- --------
Balance at June 30, 2000... 24,002 15,020 $240 $150 $421,507 $ (57) $243,795 $(36,371) $629,264
====== ====== ==== ==== ======== ======= ======== ======== ========
</TABLE>

See accompanying notes to consolidated financial statements.

F-5
<PAGE> 72

EXPRESS SCRIPTS, INC.

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

<TABLE>
<CAPTION>
SIX MONTHS ENDED
JUNE 30,
----------------------
1999 2000
---------- ---------
(IN THOUSANDS)
<S> <C> <C>
Cash flows from operating activities:
Net income (loss)......................................... $ 13,964 $ (52,745)
Adjustment to reconcile net income (loss) to net cash
provided by operating activities:
Depreciation and amortization........................ 30,081 43,865
Deferred income taxes................................ 4,429 (44,473)
Bad debt expense..................................... 2,223 7,291
Tax benefit relating to employee stock options....... 1,764 893
Write-down of marketable securities.................. -- 155,500
Non-recurring charges, net of cash................... 3,700 --
Extraordinary loss on early retirement of debt....... 10,741 --
Net changes in operating assets and liabilities, net
of changes resulting from acquisition............... (14,486) (12,304)
---------- ---------
Net cash provided by operating activities................... 52,416 98,027
---------- ---------
Cash flows from investing activities:
Purchases of property and equipment....................... (16,178) (26,514)
Acquisition, net of cash acquired......................... (717,886) --
Other, net................................................ -- (1,000)
---------- ---------
Net cash (used in) investing activities..................... (734,064) (27,514)
---------- ---------
Cash flows from financing activities:
Repayment of long-term debt............................... (924,770) (75,069)
Proceeds from long-term debt.............................. 1,288,815 --
Repurchase of Class A Common Stock........................ -- (30,247)
Net proceeds from issuance of common stock................ 299,312 --
Financing fees paid....................................... (25,258) --
Other, net................................................ 3,207 2,099
---------- ---------
Net cash provided by (used in) financing activities......... 641,306 (103,217)
---------- ---------
Effects of foreign currency translation adjustment.......... 36 (91)
---------- ---------
Net decrease in cash and cash equivalents................... (40,306) (32,795)
Cash and cash equivalents at beginning of period............ 122,589 132,630
---------- ---------
Cash and cash equivalents at end of period.................. $ 82,283 $ 99,835
========== =========
</TABLE>

See accompanying notes to consolidated financial statements.

F-6
<PAGE> 73

EXPRESS SCRIPTS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Financial statement note disclosures, normally included in financial
statements prepared in conformity with generally accepted accounting principles,
have been omitted in these Notes to Unaudited Consolidated Financial Statements
pursuant to the Rules and Regulations of the Securities and Exchange Commission.
However, in our opinion, such disclosures are adequate to make the information
presented not misleading when read in conjunction with the notes to consolidated
financial statements included in this prospectus and in our Annual Report on
Form 10-K for the Year Ended December 31, 1999, as filed with the Securities and
Exchange Commission on March 29, 2000.

In our opinion, the accompanying unaudited consolidated financial
statements reflect all adjustments (consisting of only normal recurring
adjustments) necessary to present fairly the Unaudited Consolidated Balance
Sheet at June 30, 2000, the Unaudited Consolidated Statements of Operations for
the three months and six months ended June 30, 1999, and 2000, the Unaudited
Consolidated Statement of Changes in Stockholders' Equity for the six months
ended June 30, 2000, and the Unaudited Consolidated Statements of Cash Flows for
the six months ended June 30, 1999, and 2000. Operating results for the three
months and six months ended June 30, 2000 are not necessarily indicative of the
results that may be expected for the year ended December 31, 2000.

2. RECEIVABLES

As of December 31, 1999 and June 30, 2000, unbilled receivables were
$416,740,000 and $450,711,000, respectively. Unbilled receivables are billed to
clients typically within 30 days based on the contractual billing schedule
agreed upon with the client. As of December 31, 1999 and June 30, 2000, we have
allowances for doubtful accounts of $17,281,000 and $21,766,000, respectively.

3. EARNINGS PER SHARE

Basic earnings per share is computed using the weighted average number of
common shares outstanding during the period. Diluted earnings per share is
computed in the same manner as basic earnings per share but adds the number of
additional common shares that would have been outstanding for the period if the
dilutive potential common shares had been issued. The difference between the
number of weighted average shares used in the basic and diluted calculation for
all years are outstanding stock options and stock warrants and any unvested
shares and shares issuable pursuant to employee elected deferral under the
executive deferred compensation plan, all calculated under the "treasury stock"
method in accordance with Financial Accounting Standards Board Statement No.
128, "Earnings Per Share".

4. ACQUISITION

On April 1, 1999, we completed our acquisition of Diversified
Pharmaceutical Services, Inc. and Diversified Pharmaceutical Services (Puerto
Rico) Inc. (collectively, "DPS"), from SmithKline Beecham Corporation and
SmithKline Beecham InterCredit BV (collectively, "SB") for approximately $715
million, which includes a purchase price adjustment for closing working capital
and transaction costs. We filed an Internal Revenue Code sec.338(h)(10)
election, making amortization expense of intangible assets, including goodwill,
tax deductible. We used approximately $48 million of our own cash and financed
the remainder of the purchase price and related acquisition costs.

F-7
<PAGE> 74
EXPRESS SCRIPTS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

The acquisition has been accounted for using the purchase method of
accounting. The results of operations of DPS have been included in the
consolidated financial statements and pharmacy benefit management ("PBM")
segment since April 1, 1999. The purchase price has been allocated based on the
estimated fair values of net assets acquired at the date of the acquisition. The
excess of purchase price over tangible net assets acquired has been allocated to
other intangible assets consisting of customer contracts in the amount of
$129,500,000 which are being amortized using the straight-line method over the
estimated useful lives of 1 to 20 years and goodwill in the amount of
$754,236,000 which is being amortized using the straight-line method over the
estimated useful life of 30 years. In conjunction with the acquisition, DPS
retained the following liabilities:

<TABLE>
<CAPTION>
(IN THOUSANDS)
----------------------------------------------------------------------------
<S> <C>
Fair value of assets acquired............................... $1,028,848
Cash paid for the capital stock............................. (714,678)
----------
Liabilities retained................................... $ 314,170
==========
</TABLE>

The following unaudited pro forma information presents a summary of our
combined results of operations and those of DPS as if the acquisition had
occurred at the beginning of the period presented, along with certain pro forma
adjustments to give effect to amortization of goodwill, other intangible assets,
interest expense on acquisition debt and other adjustments. The pro forma
financial information is not necessarily indicative of the results of operations
as they would have been had the transaction been effected on the assumed date,
nor is it an indication of trends in future results.

<TABLE>
<CAPTION>
SIX MONTHS ENDED
JUNE 30, 1999
---------------------
(IN THOUSANDS, EXCEPT
PER SHARE DATA)
<S> <C>
Total revenues.............................................. $1,961,202
Income before extraordinary loss............................ 4,143
Extraordinary loss.......................................... (6,597)
----------
Net loss.................................................... $ (2,454)
==========
Basic (loss) earnings per share
Before extraordinary loss................................. $ 0.12
Extraordinary loss........................................ (0.20)
----------
Net loss.................................................. $ (0.08)
==========
Diluted (loss) earnings per share
Before extraordinary loss................................. $ 0.12
Extraordinary loss........................................ (0.19)
----------
Net loss.................................................. $ (0.07)
==========
</TABLE>

F-8
<PAGE> 75
EXPRESS SCRIPTS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

5. MARKETABLE SECURITIES

All investments not included in a money market fund are accounted for under
Financial Accounting Standards Board Statement No. 115, "Accounting for Certain
Investments in Debt and Equity Securities." Available-for-sale securities are
reported at fair value, which is based upon quoted market prices, with
unrealized gains and losses, net of tax, reported as a component of other
comprehensive income in stockholders' equity until realized. Unrealized losses
are charged against income when a decline in fair value is determined to be
other than temporary.

We recorded a non-cash impairment charge related to our investment in
PlanetRx.com, Inc. ("PlanetRx") common stock during the second quarter of 2000
as the loss in value was deemed to be other than temporary. Therefore, any
unrealized losses associated with recording our investment in PlanetRx at
current market value that we had recorded in stockholders' equity were written
off to the current period earnings, in addition to any additional charges
necessary to write-down the value of our investment. At December 31, 1999 and
June 30, 2000, available-for-sale securities totaled $150,365,000 and
$10,270,000, respectively, with unrealized losses, net of taxes of $9,555,000
recognized in other comprehensive income during the year ended December 31, 1999
and $97,032,000, recognized in the Consolidated Statement of Operations during
the six months ended June 30, 2000, which includes $9,555,000 previously
recognized in other comprehensive income, respectively. The unrealized losses
were previously considered to be temporary, thus were reported as a component of
other comprehensive income in stockholders' equity as of December 31, 1999.
These investments consist of shares of PlanetRx common stock.

Effective July 5, 2000, we restructured our agreement with PlanetRx. Under
the restructured agreement we will retain our ownership of approximately 10.3
million shares, or 19.8%, of PlanetRx common stock and receive a one-time cash
payment of $8,000,000. Approximately $3,700,000 of the payment represents
amounts earned through the second quarter of 2000, the remainder represents a
fee for the termination of the prior contract. After this payment, no additional
cash payments will be paid to us under the restructured agreement.

6. FINANCING

Our Senior Notes are unconditionally and joint and severally guaranteed by
our wholly-owned domestic subsidiaries other than Practice Patterns Sciences,
Inc., Great Plains Reinsurance Co., ValueRx of Michigan, Inc., Diversified NY
IPA, Inc., and Diversified Pharmaceutical Services (Puerto Rico), Inc. Separate
financial statements of the Guarantors are not presented as we have determined
them not to be material to investors. Therefore, the following condensed
consolidating financial information has been prepared using the equity method of
accounting in accordance with the requirements for presentation of such
information. We believe that this information, presented in lieu of complete
financial statements for each of the guarantor subsidiaries, provides sufficient
detail to allow investors to determine the nature of the assets held by, and the
operations of, each of the consolidating groups. As of January 1, 2000, we
undertook an internal corporate reorganization to eliminate various entities
whose existence was deemed to be no longer necessary, including, among others,
ValueRx Pharmacy Program, Inc. ("ValueRx"), and to create several new entities
to house certain activities, including Express Scripts Specialty Distribution
Services, Inc. ("SDS") and ESI Mail Pharmacy Service, Inc. ("ESI MPS").
Consequently, the assets, liabilities and operations of ValueRx are incorporated
into those of the issuer, Express Scripts, Inc. and the

F-9
<PAGE> 76
EXPRESS SCRIPTS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

assets, liabilities and operations of SDS and ESI MPS are incorporated into
those of the Guarantors for 2000.

<TABLE>
<CAPTION>
EXPRESS
SCRIPTS, INC. GUARANTORS NON-GUARANTORS ELIMINATIONS CONSOLIDATED
------------- ---------- -------------- ------------ ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
AS OF DECEMBER 31, 1999
Current assets................... $ 549,374 $ 509,702 $ 7,279 $ -- $1,066,355
Property and equipment, net...... 39,036 55,776 2,761 -- 97,573
Investments in subsidiaries...... 725,468 -- 2,261 (727,729) --
Investments in marketable
securities..................... -- 150,365 -- 150,365
Intercompany..................... 463,438 (463,241) (197) -- --
Goodwill, net.................... 168 976,759 5,569 -- 982,496
Other intangible assets, net..... 22,458 160,901 61 -- 183,420
Other assets..................... 13,179 (6,493) 563 (147) 7,102
---------- ---------- -------- --------- ----------
Total assets................ $1,813,121 $1,383,769 $ 18,297 $(727,876) $2,487,311
========== ========== ======== ========= ==========
Current liabilities.............. $ 527,312 $ 563,457 $ 9,589 $ -- $1,100,358
Long-term debt................... 635,873 -- -- -- 635,873
Other liabilities................ 83,365 (33,018) 1,251 -- 51,598
Stockholders' equity............. 566,571 853,330 7,457 (727,876) 699,482
---------- ---------- -------- --------- ----------
Total liabilities and
stockholders' equity...... $1,813,121 $1,383,769 $ 18,297 $(727,876) $2,487,311
========== ========== ======== ========= ==========
AS OF JUNE 30, 2000
Current assets................... $ 788,685 $ 261,850 $ 5,207 $ -- $1,055,742
Property and equipment, net...... 93,840 15,981 2,498 -- 112,319
Investments in subsidiaries...... 725,696 -- 2,261 (727,957) --
Investments in marketable
securities..................... -- 10,270 -- -- 10,270
Intercompany..................... (46,693) 47,862 (1,169) -- --
Goodwill, net.................... 255,979 723,648 5,158 -- 984,785
Other intangible assets, net..... 59,658 103,849 31 -- 163,538
Other assets..................... 76,057 (65,841) 10 -- 10,226
---------- ---------- -------- --------- ----------
Total assets................ $1,953,222 $1,097,619 $ 13,996 $(727,957) $2,336,880
========== ========== ======== ========= ==========
Current liabilities.............. $ 781,393 $ 370,042 $ 5,450 $ -- $1,156,885
Long-term debt................... 517,908 -- -- -- 517,908
Other liabilities................ 92,850 (61,189) 1,162 -- 32,823
Stockholders' equity............. 561,071 788,766 7,384 (727,957) 629,264
---------- ---------- -------- --------- ----------
Total liabilities and
stockholders' equity...... $1,953,222 $1,097,619 $ 13,996 $(727,957) $2,336,880
========== ========== ======== ========= ==========
</TABLE>

F-10
<PAGE> 77
EXPRESS SCRIPTS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

<TABLE>
<CAPTION>
EXPRESS
SCRIPTS, INC. GUARANTORS NON-GUARANTORS ELIMINATIONS CONSOLIDATED
------------- ---------- -------------- ------------ ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
THREE MONTHS ENDED JUNE 30, 1999
Total revenues................... $ 513,958 $ 471,276 $ 11,515 $ -- $ 996,749
Operating expenses............... 485,009 465,058 11,219 -- 961,286
---------- ---------- -------- --------- ----------
Operating income............... 28,949 6,218 296 -- 35,463
Interest income (expense), net... (21,984) 145 52 -- (21,787)
---------- ---------- -------- --------- ----------
Income before tax effect....... 6,965 6,363 348 -- 13,676
Income tax provision............. 3,115 3,378 165 -- 6,658
---------- ---------- -------- --------- ----------
Income before extraordinary
loss........................ 3,850 2,985 183 -- 7,018
Extraordinary loss............... 6,597 -- -- -- 6,597
---------- ---------- -------- --------- ----------
Net income (loss)........... $ (2,747) $ 2,985 $ 183 $ -- $ 421
========== ========== ======== ========= ==========
THREE MONTHS ENDED JUNE 30, 2000
Total revenues................... $1,025,659 $ 625,470 $ 2,238 $ -- $1,653,367
Operating expenses............... 1,005,965 595,204 2,216 -- 1,603,385
---------- ---------- -------- --------- ----------
Operating income............... 19,694 30,266 22 -- 49,982
Write-down of marketable
securities..................... -- (155,500) -- -- (155,500)
Interest (expense) income, net... (11,139) (1) 3 -- (11,137)
---------- ---------- -------- --------- ----------
Income (loss) before tax
effect...................... 8,555 (125,235) 25 -- (116,655)
Income tax provision (benefit)... 3,541 (46,029) 10 -- (42,478)
---------- ---------- -------- --------- ----------
Net income (loss).............. $ 5,014 $ (79,206) $ 15 $ -- $ (74,177)
========== ========== ======== ========= ==========
SIX MONTHS ENDED JUNE 30, 1999
Total revenues................... $1,007,503 $ 873,154 $ 15,179 $ -- $1,895,836
Operating expenses............... 951,365 865,756 14,252 -- 1,831,373
---------- ---------- -------- --------- ----------
Operating income............... 56,138 7,398 927 -- 64,463
Interest income (expense), net... (26,923) 211 96 -- (26,616)
---------- ---------- -------- --------- ----------
Income before tax effect....... 29,215 7,609 1,023 -- 37,847
Income tax provision............. 11,566 5,272 448 -- 17,286
---------- ---------- -------- --------- ----------
Income before extraordinary
loss........................ 17,649 2,337 575 -- 20,561
Extraordinary loss............... 6,597 -- -- -- 6,597
---------- ---------- -------- --------- ----------
Net income (loss)........... $ 11,052 $ 2,337 $ 575 $ -- $ 13,964
========== ========== ======== ========= ==========
SIX MONTHS ENDED JUNE 30, 2000
Total revenues................... $1,932,511 $1,192,412 $ 3,953 $ -- $3,128,876
Operating expenses............... 1,887,134 1,138,206 4,479 -- 3,029,819
---------- ---------- -------- --------- ----------
Operating income (loss)........ 45,377 54,206 (526) -- 99,057
Write-down of marketable
securities..................... -- (155,500) -- -- (155,500)
Interest (expense) income, net... (23,955) (3) 1 -- (23,957)
---------- ---------- -------- --------- ----------
Income (loss) before tax
effect...................... 21,422 (101,297) (525) -- (80,400)
Income tax provision (benefit)... 9,260 (36,733) (182) -- (27,655)
---------- ---------- -------- --------- ----------
Net income (loss)........... $ 12,162 $ (64,564) $ (343) $ -- $ (52,745)
========== ========== ======== ========= ==========
</TABLE>

F-11
<PAGE> 78
EXPRESS SCRIPTS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

7. RESTRUCTURING

During December 1999, we recorded a pre-tax restructuring charge of
$2,633,000 associated with the outsourcing of our computer operations to
Electronic Data Systems Corporation. The principal actions of the plan included
cash expenditures of approximately $2,148,000 for the transition of 51 employees
to the outsourcer and the elimination of contractual obligations of ValueRx,
which had no future economic benefit to us, and non-cash charges of
approximately $485,000 due to the reduction in the carrying value of certain
capitalized software to its net realizable value. This plan was completed during
the second quarter of 2000 when remaining cash payments were made.

Also in December 1999, we recorded a pre-tax restructuring charge of
$969,000 associated with restructuring our Practice Patterns Science, Inc.
("PPS") majority-owned subsidiary and the purchase of the remaining PPS Common
Stock from management. The charge consisted of cash expenditures of $559,000
relating to stock compensation expense and $410,000 of severance payments to 9
employees. This plan was completed in January 2000.

<TABLE>
<CAPTION>
BALANCE AT BALANCE AT
DECEMBER 31, 2000 2000 JUNE 30,
1999 ADDITIONS USAGE 2000
------------ --------- ------ ----------
(IN THOUSANDS)
<S> <C> <C> <C> <C>
NON-CASH
----------
Write-down of long-lived assets.................... $ 28 $ -- $ -- $ 28
CASH
-----
Employee transition costs.......................... 1,592 -- 1,592 --
Stock compensation................................. 559 -- 559 --
Termination fees and rent.......................... 1,338 -- 946 392
------ ---- ------ ----
$3,517 $ -- $3,097 $420
====== ==== ====== ====
</TABLE>

All of the restructuring charges which include tangible assets to be
disposed of are written down to their net realizable value, less cost of
disposal. We expect recovery to approximate its cost of disposal. Considerable
management judgment is necessary to estimate fair value; accordingly, actual
results could vary from such estimates.

8. COMMON STOCK

As of June 30, 2000, we have repurchased a total of 1,265,000 shares of our
Class A Common Stock under the stock repurchase program that we announced on
October 25, 1996, of which, 790,000 shares were repurchased during the six
months ended June 30, 2000. Approximately 63,000 shares have been

F-12
<PAGE> 79
EXPRESS SCRIPTS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

utilized for stock option exercises through June 30, 2000. Our Board of
Directors approved the repurchase of up to 2,500,000 shares, and placed no limit
on the duration of the program. Additional purchases, if any, will be made in
such amounts and at such times as we deem appropriate based upon prevailing
market and business conditions, subject to restrictions on stock repurchases
contained in our bank credit facility and the Indenture under which our Senior
Notes were issued.

9. SEGMENT REPORTING

We are organized on the basis of services offered and have determined that
we have two reportable segments: PBM services and non-PBM services. We manage
the pharmacy benefit within an operating segment that encompasses an integrated
PBM service. The remaining two operating service lines (IVTx and Specialty
Distribution) have been aggregated into a non-PBM reporting segment.

The following tables present information about the reportable segments:

<TABLE>
<CAPTION>
PBM NON-PBM TOTAL
---------- ------- ----------
(IN THOUSANDS)
<S> <C> <C> <C>
THREE MONTHS ENDED JUNE 30, 1999
Total revenues............................................ $ 981,478 $15,271 $ 996,749
Income before income taxes................................ 11,470 2,206 13,676
THREE MONTHS ENDED JUNE 30, 2000
Total revenues............................................ $1,630,519 $22,848 $1,653,367
(Loss) income before income taxes......................... (121,659) 5,004 (116,655)
SIX MONTHS ENDED JUNE 30, 1999
Total revenues............................................ $1,865,914 $29,922 $1,895,836
Income before income taxes................................ 34,957 2,890 37,847
SIX MONTHS ENDED JUNE 30, 2000
Total revenues............................................ $3,084,760 $44,116 $3,128,876
(Loss) income before income taxes......................... (90,595) 10,195 (80,400)
</TABLE>

Included in PBM income before income taxes for the three and six months
ended June 30, 2000 is the non-cash write-down of $155,500,000 ($97,032,000 net
of tax) of our investment in PlanetRx (see Note 5).

F-13
<PAGE> 80

EXPRESS SCRIPTS, INC.
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 1998 AND 1999 AND
FOR THE YEARS ENDED DECEMBER 31, 1997, 1998 AND 1999

F-14
<PAGE> 81

REPORT OF INDEPENDENT ACCOUNTANTS

To the Board of Directors and
Stockholders of Express Scripts, Inc.

In our opinion, the accompanying consolidated balance sheets and the
related consolidated statements of operations, changes in stockholders' equity
and cash flows present fairly, in all material respects, the financial position
of Express Scripts, Inc. and its subsidiaries at December 31, 1999 and 1998, and
the results of their operations and their cash flows for each of the three years
in the period ended December 31, 1999 in conformity with accounting principles
generally accepted in the United States. These financial statements are the
responsibility of the Company's management; our responsibility is to express an
opinion on these financial statements based on our audits. We conducted our
audits of these statements in accordance with auditing standards generally
accepted in the United States, which require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements, assessing
the accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for the opinion expressed above.

/s/ PRICEWATERHOUSECOOPERS LLP
PricewaterhouseCoopers LLP
St. Louis, Missouri
February 4, 2000

F-15
<PAGE> 82

EXPRESS SCRIPTS, INC.

CONSOLIDATED BALANCE SHEET

<TABLE>
<CAPTION>
DECEMBER 31,
-----------------------
1998 1999
---------- ----------
(IN THOUSANDS)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents................................. $ 122,589 $ 132,630
Receivables, less allowance for doubtful accounts of
$17,806 and $17,281, respectively...................... 433,006 783,086
Inventories............................................... 55,634 113,248
Deferred taxes............................................ 41,011 32,248
Prepaid expenses.......................................... 4,667 5,143
---------- ----------
Total current assets................................... 656,907 1,066,355
---------- ----------
Investment in marketable securities......................... -- 150,365
Property and equipment, less accumulated depreciation and
amortization.............................................. 77,499 97,573
Goodwill, less accumulated amortization..................... 282,163 982,496
Other intangible assets, less accumulated amortization...... 65,765 183,420
Other assets................................................ 13,127 7,102
---------- ----------
Total assets........................................... $1,095,461 $2,487,311
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current maturities of long-term debt...................... $ 54,000 $ --
Claims and rebates payable................................ 338,251 850,630
Accounts payable.......................................... 60,247 112,731
Accrued expenses.......................................... 86,798 136,997
---------- ----------
Total current liabilities.............................. 539,296 1,100,358
Long-term debt.............................................. 306,000 635,873
Other liabilities........................................... 471 51,598
---------- ----------
Total liabilities...................................... 845,767 1,787,829
---------- ----------
Commitments and Contingencies (Notes 3, 7 and 9)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares
authorized, and no shares issued and outstanding
Class A Common Stock, $0.01 par value, 150,000,000 shares
authorized, 18,610,000 and 23,981,000 shares issued and
outstanding, respectively.............................. 186 240
Class B Common Stock, $0.01 par value, 31,000,000 shares
authorized, 15,020,000 shares issued and outstanding... 150 150
Additional paid-in capital................................ 110,099 418,921
Accumulated other comprehensive income.................... (74) (9,521)
Retained earnings......................................... 146,322 296,540
---------- ----------
256,683 706,330
Class A Common Stock in treasury at cost, 475,000 and
465,000 shares, respectively........................... (6,989) (6,848)
---------- ----------
Total stockholders' equity........................... 249,694 699,482
---------- ----------
Total liabilities and stockholders' equity........... $1,095,461 $2,487,311
========== ==========
</TABLE>

See accompanying Notes to Consolidated Financial Statements.

F-16
<PAGE> 83

EXPRESS SCRIPTS, INC.

CONSOLIDATED STATEMENT OF OPERATIONS

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
---------------------------------------
1997 1998 1999
----------- ----------- -----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C>
Revenues:
Revenues............................................... $1,230,634 $2,824,872 $4,285,104
Other revenues......................................... -- -- 3,000
---------- ---------- ----------
1,230,634 2,824,872 4,288,104
---------- ---------- ----------
Cost and expenses:
Cost of revenues....................................... 1,119,167 2,584,997 3,826,905
Selling, general and administrative.................... 62,617 148,990 294,194
Non-recurring.......................................... -- 1,651 30,221
---------- ---------- ----------
1,181,784 2,735,638 4,151,320
---------- ---------- ----------
Operating income......................................... 48,850 89,234 136,784
---------- ---------- ----------
Other income (expense):
Interest income........................................ 6,081 7,236 5,762
Interest expense....................................... (225) (20,230) (60,010)
Gain on sale of assets................................. -- -- 182,930
---------- ---------- ----------
5,856 (12,994) 128,682
---------- ---------- ----------
Income before income taxes............................... 54,706 76,240 265,466
Provision for income taxes............................... 21,277 33,566 108,098
---------- ---------- ----------
Income before extraordinary item......................... 33,429 42,674 157,368
Extraordinary loss on early retirement of debt, net of
taxes of $4,492........................................ -- -- 7,150
---------- ---------- ----------
Net income............................................... $ 33,429 $ 42,674 $ 150,218
========== ========== ==========
Basic earnings per share:
Before extraordinary item.............................. $ 1.02 $ 1.29 $ 4.36
Extraordinary loss on early retirement of debt......... -- -- 0.20
---------- ---------- ----------
Net income............................................. $ 1.02 $ 1.29 $ 4.16
========== ========== ==========
Weighted average number of common shares
Outstanding during the period -- Basic EPS............. 32,713 33,105 36,095
========== ========== ==========
Diluted earnings per share
Before extraordinary item.............................. $ 1.01 $ 1.27 $ 4.25
Extraordinary loss on early retirement of debt......... -- -- 0.19
---------- ---------- ----------
Net income............................................. $ 1.01 $ 1.27 $ 4.06
========== ========== ==========
Weighted average number of common shares
Outstanding during the period -- Diluted EPS........... 33,122 33,698 37,033
========== ========== ==========
</TABLE>

See accompanying Notes to Consolidated Financial Statements.

F-17
<PAGE> 84

EXPRESS SCRIPTS, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

<TABLE>
<CAPTION>
AMOUNT
NUMBER OF SHARES -------------------------------------------------------------------------------
----------------- ACCUMULATED
CLASS A CLASS B CLASS A CLASS B ADDITIONAL OTHER
COMMON COMMON COMMON COMMON PAID-IN COMPREHENSIVE RETAINED TREASURY
STOCK STOCK STOCK STOCK CAPITAL INCOME EARNINGS STOCK TOTAL
------- ------- ------- ------- ---------- ------------- -------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31,
1996...................... 8,974 7,510 $ 90 $ 75 $ 98,958 $ (2) $ 70,219 $(5,250) $164,090
------ ------ ---- ---- -------- ------- -------- ------- --------
Comprehensive income:
Net income.............. -- -- -- -- -- -- 33,429 -- 33,429
Other comprehensive
income, Foreign
currency translation
adjustment............ -- -- -- -- -- (25) -- -- (25)
------ ------ ---- ---- -------- ------- -------- ------- --------
Comprehensive income...... -- -- -- -- -- (25) 33,429 -- 33,404
Exercise of stock
options................. 264 -- 3 -- 4,769 -- -- -- 4,772
Tax benefit relating to
employee stock
options................. -- -- -- -- 3,174 -- -- -- 3,174
Treasury Stock acquired... -- -- -- -- -- -- -- (1,739) (1,739)
------ ------ ---- ---- -------- ------- -------- ------- --------
Balance at December 31,
1997...................... 9,238 7,510 93 75 106,901 (27) 103,648 (6,989) 203,701
------ ------ ---- ---- -------- ------- -------- ------- --------
Comprehensive income:
Net income.............. -- -- -- -- -- -- 42,674 -- 42,674
Other comprehensive
income, Foreign
currency translation
adjustment............ -- -- -- -- -- (47) -- -- (47)
------ ------ ---- ---- -------- ------- -------- ------- --------
Comprehensive income...... -- -- -- -- -- (47) 42,674 -- 42,627
Issuance of stock
dividend................ 9,239 7,510 92 75 (167) -- -- -- --
Exercise of stock
options................. 133 -- 1 -- 2,020 -- -- -- 2,021
Tax benefit relating to
employee stock
options................. -- -- -- -- 1,345 -- -- -- 1,345
------ ------ ---- ---- -------- ------- -------- ------- --------
Balance at December 31,
1998...................... 18,610 15,020 186 150 110,099 (74) 146,322 (6,989) 249,694
------ ------ ---- ---- -------- ------- -------- ------- --------
Comprehensive income:
Net income.............. -- -- -- -- -- -- 150,218 -- 150,219
Other comprehensive
income, Foreign
currency translation
adjustment............ -- -- -- -- -- 108 -- -- 108
Unrealized loss on
investment, net of
taxes of $6,000.... -- -- -- -- -- (9,555) -- -- (9,555)
------ ------ ---- ---- -------- ------- -------- ------- --------
Comprehensive income...... -- -- -- -- -- (9,447) 150,218 -- 140,771
Issuance of common
stock................... 5,175 -- 52 -- 299,326 -- -- -- 299,378
Exercise of stock
options................. 186 -- 2 -- 5,744 -- -- 141 5,887
Common stock issued under
employee plans.......... 10 -- -- 551 -- -- -- 551
Tax benefit relating to
employee stock
options................. -- -- -- -- 3,201 -- -- -- 3,201
------ ------ ---- ---- -------- ------- -------- ------- --------
Balance at December 31,
1999...................... 23,981 15,020 $240 $150 $418,921 $(9,521) $296,540 $(6,848) $699,482
====== ====== ==== ==== ======== ======= ======== ======= ========
</TABLE>

See accompanying Notes to Consolidated Financial Statements.

F-18
<PAGE> 85

EXPRESS SCRIPTS, INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
----------------------------------
1997 1998 1999
-------- --------- -----------
(IN THOUSANDS)
<S> <C> <C> <C>
Cash flows from operating activities:
Net income.............................................. $ 33,429 $ 42,674 $ 150,218
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization...................... 10,358 27,058 74,031
Deferred income taxes.............................. (834) 10,068 76,217
Bad debt expense................................... 3,680 4,583 4,989
Gain on sale of assets, net of cash paid........... -- -- (185,650)
Non-recurring charges, net of cash paid............ -- 1,467 22,281
Tax benefit relating to employee stock options..... 3,174 1,345 3,201
Extraordinary loss on early retirement of debt..... -- -- 11,642
Changes in operating assets and liabilities, net of
changes resulting from acquisition:
Receivables................................... (50,166) (35,083) (217,977)
Inventories................................... (11,444) (15,417) (54,059)
Prepaid expenses and other assets............. 1,722 756 (2,177)
Claims and rebates payable.................... 57,968 107,660 279,714
Accounts payable and accrued expenses......... 4,504 (18,537) 51,629
-------- --------- -----------
Net cash provided by operating activities................. 52,391 126,574 214,059
-------- --------- -----------
Cash flows from investing activities:
Acquisitions, net of cash acquired...................... -- (460,137) (722,618)
Short-term investments.................................. (3,550) 57,938 --
Purchases of property and equipment..................... (12,905) (23,853) (36,958)
-------- --------- -----------
Net cash (used in) investing activities................... (16,455) (426,052) (759,576)
-------- --------- -----------
Cash flows from financing activities:
Proceeds from long-term debt............................ -- 360,000 1,290,950
Repayment of long-term debt............................. -- -- (1,015,000)
Net proceeds from issuance of common stock.............. -- -- 299,378
Deferred financing fees................................. -- (4,062) (26,316)
Acquisition of treasury stock........................... (1,739) -- --
Exercise of stock options............................... 4,772 2,021 6,438
-------- --------- -----------
Net cash provided by financing activities................. 3,033 357,959 555,450
-------- --------- -----------
Effect of foreign currency translation adjustment......... (25) (47) 108
-------- --------- -----------
Net increase in cash and cash equivalents................. 38,944 58,434 10,041
Cash and cash equivalents at beginning of year............ 25,211 64,155 122,589
-------- --------- -----------
Cash and cash equivalents at end of year.................. $ 64,155 $ 122,589 $ 132,630
======== ========= ===========
Supplemental data:
Cash paid during the year for:
Restructuring charges................................... $ -- $ 184 $ 4,683
Income taxes............................................ $ 20,691 $ 17,202 $ 1,080
Interest................................................ $ 225 $ 13,568 $ 61,607
</TABLE>

See accompanying Notes to Consolidated Financial Statements.

F-19
<PAGE> 86

EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION AND OPERATIONS. We are a leading specialty managed care
company and the largest full-service pharmacy benefit management ("PBM") company
independent of pharmaceutical manufacturer ownership and drug store ownership in
North America. We provide health care management and administration services on
behalf of thousands of clients that include health maintenance organizations,
health insurers, third-party administrators, employers and union-sponsored
benefit plans. Our fully integrated PBM services include network claims
processing, mail pharmacy services, benefit design consultation, drug
utilization review, formulary management, disease management, medical and drug
data analysis services, medical information management services (which include
the development of data warehouses to combine medical claims and prescription
drug claims), disease management support services and outcome assessments
through our Health Management Services division and Practice Patterns Science,
Inc. ("PPS") subsidiary, and informed decision counseling services through our
Express Health LineSM division. We also provide non-PBM services which include
infusion therapy services through our wholly-owned subsidiary IVTx, Inc.,
operating as Express Scripts Infusion Services, distribution services through
our Express Scripts Specialty Distribution Services subsidiary, and, prior to
September 1, 1998, provided managed vision care programs through our
wholly-owned subsidiary Express Scripts Vision Corporation.

BASIS OF PRESENTATION. The consolidated financial statements include our
accounts and all our wholly-owned subsidiaries. All significant intercompany
accounts and transactions have been eliminated. The preparation of the
consolidated financial statements conforms to generally accepted accounting
principles in the U.S., and requires us to make estimates and assumptions that
affect the reported amounts of assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual amounts could differ from those estimates and
assumptions.

CASH AND CASH EQUIVALENTS. Cash and cash equivalents include cash on hand
and temporary investments in money market funds. In 1999, we changed certain
banking relationships resulting in certain cash disbursement accounts being
maintained by banks not holding our cash concentration accounts. As a result,
cash disbursement accounts carrying negative balances have been reclassified to
claims and rebates payable at December 31, 1999.

INVENTORIES. Inventories consist of prescription drugs and medical
supplies that are stated at the lower of first-in first-out cost or market.

PROPERTY AND EQUIPMENT. Property and equipment is carried at cost and is
depreciated using the straight-line method over estimated useful lives of seven
years for furniture, five years for equipment and purchased computer software
and three years for personal computers. Leasehold improvements are amortized on
a straight-line basis over the term of the lease or the useful life of the
asset, if shorter. Expenditures for repairs, maintenance and renewals are
charged to income as incurred. Expenditures which improve an asset or extend its
estimated useful life are capitalized. When properties are retired or otherwise
disposed of, the related cost and accumulated depreciation are removed from the
accounts and any gain or loss is included in income.

SOFTWARE DEVELOPMENT COSTS. During 1997, we adopted Statement of Position
98-1 ("SOP 98-1"), Accounting for the Costs of Computer Software Developed or
Obtained for Internal Use. SOP 98-1 requires the capitalization of certain costs
associated with computer software developed or obtained for internal use. Given
the limited software developed or obtained for internal use in 1997, adoption
had virtually no effect on our Consolidated Statement of Operations or our
financial position. However, the impact of SOP 98-1 on an ongoing basis will be
determined by the magnitude of computer software developed or obtained for
internal use. Research and development expenditures relating to the development
of software to be marketed to clients, or to be used for internal purposes, are
charged to expense until

F-20
<PAGE> 87
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

technological feasibility is established. Thereafter, the remaining software
production costs up to the date of general release to customers, or to the date
placed into production, are capitalized and included as Property and Equipment.
During 1997, 1998 and 1999, $1,982,000, $10,244,000 and $15,997,000 in software
development costs were capitalized, respectively, primarily due to the
integration of our acquisitions and enhancements to our information systems.
Capitalized software development costs amounted to $27,516,000 and $42,353,000
at December 31, 1998 and 1999, respectively. Amortization of the capitalized
amounts commences on the date of general release to customers, or the date
placed into production, and is computed on a product-by-product basis using the
straight-line method over the remaining estimated economic life of the product
but not more than five years. Reductions, if any, in the carrying value of
capitalized software costs to net realizable value are included in non-recurring
expense. Amortization expense in 1997, 1998 and 1999 was $622,000, $1,968,000
and $3,810,000, respectively.

MARKETABLE SECURITIES. All investments not included in a money market fund
are accounted for under Financial Accounting Standards Board ("FASB") Statement
No. 115, "Accounting for Certain Investments in Debt and Equity Securities."
Available-for-sale securities are reported at fair value, which is based upon
quoted market prices, with unrealized gains and losses, net of tax, reported as
a component of other comprehensive income in stockholders' equity until
realized. Unrealized losses are charged against income when a decline in fair
value is determined to be other than temporary.

At December 31, 1999, available-for-sale securities totaled $150,365,000,
with related gross unrealized losses, net of taxes of $9,555,000. These
investments consist of shares of PlanetRx.com, Inc. ("PlanetRx") common stock
(see Note 2). There were no marketable securities in 1998.

GOODWILL. Goodwill is amortized on a straight-line basis over periods from
10 to 30 years. The amount reported is net of accumulated amortization of
$8,114,000 and $36,317,000 at December 31, 1998 and 1999, respectively. We
periodically evaluate the carrying value of goodwill for impairment. The
evaluation of impairment is based on expected future operating cash flows on an
undiscounted basis for the operations to which goodwill relates. Impairment
losses, if any, would be determined based on the present value of the cash flows
using discount rates that reflect the inherent risk of the underlying business.
In our opinion, no such impairment existed at December 31, 1998 and 1999.
Amortization expense, included in selling, general and administrative expenses,
was $42,000, $7,863,000 and $28,203,000 for the years ended December 31, 1997,
1998 and 1999, respectively.

OTHER INTANGIBLE ASSETS. Other intangible assets consist of customer
contracts, non-compete agreements and deferred financing fees and are amortized
on a straight-line basis over periods from 2 to 20 years. Amortization expense
for customer contracts and non-compete agreements included in selling, general
and administrative expenses was $2,940,000, $4,320,000 and $25,094,000 for the
years ended December 31, 1997, 1998 and 1999, respectively. Amortization expense
for deferred financing fees included in interest expense was $609,000 and
$2,241,000 for the years ended December 31, 1998 and 1999, respectively. There
were no deferred financing charges in 1997.

CONTRACTUAL AGREEMENTS. We have entered into corporate alliances with
certain of our clients whereby shares of our Class A Common Stock were awarded
as advance discounts to the clients. We account for these agreements as follows:

PRIOR TO DECEMBER 15, 1995 -- For agreements consummated prior to
December 15, 1995, the stock is valued utilizing the quoted market value at
the date the agreement is consummated if the number of shares to be issued
is known. If the number of shares to be issued is contingent upon the
occurrence of future events, the stock is valued utilizing the quoted
market value at the date the contingency is satisfied and the number of
shares is determinable.

F-21
<PAGE> 88
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

BETWEEN DECEMBER 15, 1995 AND NOVEMBER 20, 1997 -- For agreements
entered into between these dates, we utilize the provisions of Financial
Accounting Standards Board Statement ("FAS") 123, "Accounting for
Stock-Based Compensation," which requires that all stock issued to
nonemployees be accounted for based on the fair value of the consideration
received or the fair value of the equity instruments issued instead of the
intrinsic value method utilized for stock issued or to be issued under
alliances entered into prior to December 15, 1995. We have adopted FAS 123
as it relates to stock issued or to be issued under the Premier and
Manulife alliances based on fair value at the date the agreement was
consummated.

SUBSEQUENT TO NOVEMBER 20, 1997 -- In November 1997, the Emerging
Issues Task Force of the FASB reached a consensus that the value of equity
instruments issued for consideration other than employee services should be
initially determined on the date on which a "firm commitment" for
performance first exists by the provider of goods or services. Firm
commitment is defined as a commitment pursuant to which performance by a
provider of goods or services is probable because of sufficiently large
disincentives for nonperformance. The consensus must be applied for all new
arrangements and modifications of existing arrangements entered into from
November 20, 1997. The consensus only addresses the date upon which fair
value is determined and does not change the accounting based upon fair
value as prescribed by FAS 123. We have not entered into any such
arrangements subsequent to November 20, 1997.

Shares issued on the effective date of the contractual agreement are
considered outstanding and included in basic and diluted earnings per share
computations when issued. Shares issuable upon the satisfaction of certain
conditions are considered outstanding and included in basic and dilutive
earnings per share computation when all necessary conditions have been satisfied
by the end of the period. If all necessary conditions have not been satisfied by
the end of the period, the number of shares included in the dilutive earnings
per share computation is based on the number of shares, if any, that would be
issuable if the end of the reporting period were the end of the contingency
period and if the result would be dilutive. The value of the shares of stock
awarded as advance discounts is recorded as a deferred cost and included in
other intangible assets. The deferred cost is recognized in selling, general and
administrative expenses over the period of the contract.

IMPAIRMENT OF LONG LIVED ASSETS. We evaluate whether events and
circumstances have occurred that indicate the remaining estimated useful life of
long lived assets may warrant revision or that the remaining balance of an asset
may not be recoverable. The measurement of possible impairment is based on the
ability to recover the balance of assets from expected future operating cash
flows on an undiscounted basis. Impairment losses, if any, would be determined
based on the present value of the cash flows using discount rates that reflect
the inherent risk of the underlying business. In our opinion, other than the
write-down of long-lived assets associated with our facilities consolidation,
computer operations outsourcing and Express Scripts Vision Corporation, no such
impairment existed as of December 31, 1998 or 1999 (see Note 7).

DERIVATIVE FINANCIAL INSTRUMENTS. We have entered into interest rate swap
agreements in order to manage exposure to interest rate risk. We do not hold or
issue derivative financial instruments for trading purposes. The interest rate
swaps are designated as a hedge of our variable interest rate payments. Amounts
received or paid are accrued as interest receivable or payable and as interest
income or expense. The fair values of interest rate swap agreements are based on
market prices. The fair values represent the estimated amount we would
receive/pay to terminate the agreements taking into consideration current
interest rates.

In June 1998, the FASB issued FAS 133, "Accounting for Derivative
Instruments and Hedging Activities". FAS 133 requires all derivatives to be
recognized as either assets or liabilities in the statement

F-22
<PAGE> 89
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

of financial position and to measure those instruments at fair value. In
addition, FAS 133 specifies the accounting for changes in the fair value of a
derivative based on the intended use of the derivative and the resulting
designation. The effective date for FAS 133 was originally effective for all
fiscal quarters of fiscal years beginning after June 1, 1999. However, the FASB
has deferred the effective date so that it will begin for all fiscal quarters of
fiscal years beginning after June 15, 2000, and will be applicable to our first
quarter of fiscal year 2001. Our present interest rate swaps (see Note 6) will
be considered cash flow hedges. Accordingly, the change in the fair values of
the swaps will be reported on the balance sheet as an asset or liability. The
corresponding unrealized gains or losses representing the effective portions of
the hedges will be initially recognized in stockholders' equity and other
comprehensive income, and subsequently any changes in unrealized gains or losses
from the initial measurement dates will be recognized in earnings concurrent
with the interest expense on our underlying variable rate debt. If we had
adopted FAS 133 as of December 31, 1999, we would have recorded an unrealized
gain of $6,867,000 as an asset and an increase in stockholder's equity and other
comprehensive income during 1999.

FAIR VALUE OF FINANCIAL INSTRUMENTS. The carrying value of cash and cash
equivalents, accounts receivable and accounts payable approximated fair values
due to the short-term maturities of these instruments. The fair value, which
approximates the carrying value, of our Credit Facility was estimated using
either quoted market prices or the current rates offered to us for debt with
similar maturity. The fair value of the swaps ($7,209,000 liability at December
31, 1998 for our only swap and $6,867,000 asset at December 31, 1999 for both
swaps) was based on quoted market prices, which reflect the present values of
the difference between estimated future fixed rate payments and future variable
rate receipts. The fair value of our senior note facility ($255,000,000 at
December 31, 1999) was estimated based on quoted market prices.

REVENUE RECOGNITION. Revenues from dispensing prescription and
non-prescription medical products from our mail pharmacies are recorded upon
shipment. Revenue from sales of prescription drugs by pharmacies in our
nationwide network and pharmacy claims processing revenues are recognized when
the claims are processed. When we dispense pharmaceuticals to members of health
benefit plans sponsored by our clients or have an independent contractual
obligation to pay our network pharmacy providers for benefits provided to
members of our clients' pharmacy benefit plans, we include payments from plan
sponsors for these benefits as revenue and ingredient costs or payments to these
pharmacy providers in cost of revenues (the "Gross Basis"). If we are only
administering the plan sponsors' network pharmacy contracts, or where we
dispense pharmaceuticals supplied by one of our clients, we record only the
administrative or dispensing fees derived from our contracts with the plan
sponsors as revenue (the "Net Basis").

Management services provided to drug manufacturers include various services
relating to administration of a manufacturer rebate program. Revenues relating
to these services are recognized as earned based upon detailed drug utilization
data. Rebates payable to customers in accordance with the applicable contracts
are excluded from revenues and expenses.

Retail pharmacy and mail pharmacy revenues are recognized based upon actual
scripts adjudicated and therefore require no estimation. Amounts remain unbilled
for no more than 30 days based upon the contractual billing schedule agreed with
the client. At December 31, 1998 and 1999, all unbilled receivables were
$209,334,000 and $416,740,000, respectively.

COST OF REVENUES. Cost of revenues includes product costs, pharmacy claims
payments and other direct costs associated with dispensing prescriptions and
non-prescription medical products and claims processing operations, offset by
fees received from pharmaceutical manufacturers in connection with our drug
purchasing and formulary management programs. We estimate fees receivable from
pharmaceutical manufacturers on a quarterly basis converting total prescriptions
dispensed to estimated rebatable scripts

F-23
<PAGE> 90
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

(i.e., those prescriptions with respect to which we are contractually entitled
to submit claims for rebates) multiplied by the contractually agreed
manufacturer rebate amount. Estimated fees receivable from pharmaceutical
manufacturers are recorded when we determine them to be realizable, and
realization is not dependent upon future pharmaceutical sales. Estimates are
revised once the actual rebatable scripts are calculated and rebates are billed
to the manufacturer.

INCOME TAXES. Deferred tax assets and liabilities are recognized based on
temporary differences between financial statement basis and tax basis of assets
and liabilities using presently enacted tax rates.

EARNINGS PER SHARE. Basic earnings per share is computed using the
weighted average number of common shares outstanding during the period. Diluted
earnings per share is computed in the same manner as basic earnings per share
but adds the number of additional common shares that would have been outstanding
for the period if the potential dilutive common shares had been issued. The only
difference between the number of weighted average shares used in the basic and
diluted calculation for all years is stock options and stock warrants we have
granted using the "treasury stock" method, amounting to 409,000, 593,000 and
938,000 in 1997, 1998 and 1999, respectively.

FOREIGN CURRENCY TRANSLATION. The financial statements of ESI Canada, Inc.
are translated into U.S. Dollars using the exchange rate at each balance sheet
date for assets and liabilities and a weighted average exchange rate for each
period for revenues, expenses, gains and losses. The functional currency for ESI
Canada, Inc. is the local currency and translation adjustments are recorded
within the other comprehensive income component of stockholders' equity.

EMPLOYEE STOCK-BASED COMPENSATION. We account for employee stock options
in accordance with Accounting Principles Board No. 25 ("APB 25"), "Accounting
for Stock Issued to Employees." Under APB 25, we apply the intrinsic value
method of accounting and, therefore, do not recognize compensation expense for
options granted, because options are only granted at a price equal to market
value at the time of grant. During 1996, FAS 123 became effective for us. FAS
123 prescribes the recognition of compensation expense based on the fair value
of options determined on the grant date. However, FAS 123 grants an exception
that allows companies currently applying APB 25 to continue using that method.
We have, therefore, elected to continue applying the intrinsic value method
under APB 25. For companies that choose to continue applying the intrinsic value
method, FAS 123 mandates certain pro forma disclosures as if the fair value
method had been utilized (see Note 12).

COMPREHENSIVE INCOME. During 1998, FAS 130, "Reporting Comprehensive
Income," became effective for us. FAS 130 requires noncash changes in
stockholders' equity be combined with net income and reported in a new financial
statement category entitled "comprehensive income." Other than net income, our
two components of comprehensive income are changes in the foreign currency
translation adjustments and unrealized losses on available-for-sale securities.
We have displayed comprehensive income within the Statement of Changes in
Stockholders' Equity.

SEGMENT REPORTING. During 1998, FAS 131, "Disclosures about Segments of an
Enterprise and Related Information," became effective for us. FAS 131 requires
that we report certain information, if specific requirements are met, about our
operating segments including information about services, geographic areas of
operation and major customers. The information is to be derived from the
management approach which designates the internal organization that is used by
management for making operating decisions and assessing performance as the
source of our reportable segments. Adoption of FAS 131 did not affect our
results of operations or our financial position but did affect the disclosure of
segment information (see Note 13).

F-24
<PAGE> 91
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

2. CHANGES IN BUSINESS

ACQUISITION. On April 1, 1998 we acquired all of the outstanding capital
stock of Value Health, Inc. and Managed Prescriptions Network, Inc.
(collectively known as "ValueRx") from Columbia/HCA Healthcare Corporation
("Columbia") for approximately $460 million in cash (which includes transaction
costs and executive management severance costs of approximately $6.7 million and
$8.3 million, respectively), approximately $360 million of which was obtained
through a five-year bank credit facility (see Note 6) and the remainder from our
cash balances and short term investments.

The acquisition has been accounted for using the purchase method of
accounting and the results of operations of ValueRx have been included in the
consolidated financial statements and PBM segment since April 1, 1998. The
purchase price has been allocated based on the estimated fair values of net
assets acquired at the date of the acquisition. The excess of purchase price
over tangible net assets acquired has been allocated to other intangible assets
consisting of customer contracts and non-compete agreements in the amount of
$57,653,000 which are being amortized using the straight-line method over the
estimated useful lives of 2 to 20 years and goodwill in the amount of
$278,113,000 which is being amortized using the straight-line method over the
estimated useful life of 30 years. The amortization expense from ValueRx
goodwill and customer contracts is non-deductible for income tax purposes. In
conjunction with the acquisition, ValueRx and its subsidiaries retained the
following liabilities:

<TABLE>
<CAPTION>
(IN THOUSANDS)
----------------------------------------------------------------------------
<S> <C>
Fair value of assets acquired............................... $ 659,166
Cash paid for the capital stock............................. (460,137)
---------
Liabilities retained...................................... $ 199,029
=========
</TABLE>

The acquisition has been accounted for using the purchase method of
accounting. The results of operations of DPS have been included in the
consolidated financial statements and pharmacy benefit management ("PBM")
segment since April 1, 1999. The purchase price has been preliminarily allocated
based on the estimated fair values of net assets acquired at the date of the
acquisition. The excess of purchase price over tangible net assets acquired has
been preliminarily allocated to other intangible assets consisting of customer
contracts in the amount of $129,500,000 which are being amortized using the
straight-line method over the estimated useful lives of 1 to 20 years and
goodwill in the amount of $734,485,000 which is being amortized using the
straight-line method over the estimated useful life of 30 years. In conjunction
with the acquisition, DPS retained the following liabilities:

<TABLE>
<CAPTION>
(IN THOUSANDS)
----------------------------------------------------------------------------
<S> <C>
Fair value of assets acquired............................... $1,010,159
Cash paid for the capital stock............................. (714,678)
----------
Liabilities retained...................................... $ 295,481
==========
</TABLE>

F-25
<PAGE> 92
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

The following unaudited pro forma information presents a summary of our
combined results of operations and those of DPS and ValueRx as if the
acquisitions had occurred at the beginning of the periods presented, along with
certain pro forma adjustments to give effect to amortization of goodwill, other
intangible assets, interest expense on acquisition debt and other adjustments.
The pro forma financial information is not necessarily indicative of the results
of operations as they would have been had the transactions been effected on the
assumed dates, nor are they an indication of trends in future results. Included
in the pro forma information are integration costs incurred by us that are being
reported within selling, general and administrative expenses in the statement of
operations. Additionally, the year ended December 31, 1998 includes the impact
of a write-down of assets of $1,092,184,000, $709,920,000 after tax, related to
the impairment of DPS's goodwill. If the acquisition of DPS had occurred on
January 1, 1998, goodwill on DPS's books would have been eliminated. Therefore,
the impairment charge for goodwill would not have existed. Excluding this
write-down, our pro forma net income for fiscal year 1998 would have been
$30,461, or $0.92 per basic share and $0.90 per diluted share.

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------
1998 1999
----------- -----------
(IN THOUSANDS, EXCEPT PER
SHARE DATA)
<S> <C> <C>
Total revenues.............................................. $3,449,649 $4,353,470
Income (loss) before extraordinary loss..................... (679,459) 158,526
Extraordinary loss.......................................... -- 7,150
---------- ----------
Net income (loss)........................................... $ (679,459) $ 151,376
========== ==========
Basic earnings per share
Before extraordinary loss................................. $ (20.52) $ 4.39
Extraordinary loss........................................ -- 0.20
---------- ----------
Net income (loss)......................................... $ (20.52) $ 4.19
========== ==========
Diluted earnings per share
Before extraordinary loss................................. $ (20.16) $ 4.28
Extraordinary loss........................................ -- 0.19
---------- ----------
Net income (loss)......................................... $ (20.16) $ 4.09
========== ==========
</TABLE>

SALE OF ASSETS. On August 31, 1999, we, along with YourPharmacy.com, Inc.
("YPC"), our wholly-owned subsidiary, entered into an Asset Contribution and
Reorganization Agreement (the "Contribution Agreement") with PlanetRx, PRX
Holdings, Inc. ("Holdings"), and PRX Acquisition Corp. ("Acquisition Sub").
Pursuant to the Contribution Agreement, YPC agreed to contribute certain
operating assets constituting its e-commerce business in prescription and
non-prescription drugs and health and beauty aids to Holdings in exchange for
19.9% of the post-initial public offering common equity of Holdings (the "IPO"),
and PlanetRx was also to assume certain obligations of YPC. Simultaneously with
this transaction, Acquisition Sub was to merge into PlanetRx and PlanetRx
shareholders would receive stock in Holdings, which would change its name to
"PlanetRx.com Inc." As a result of the transactions, YPC would be a 19.9%
shareholder in the new PlanetRx (formerly Holdings), which would conduct
business as an Internet pharmacy.

On October 13, 1999, the transactions described in the Contribution
Agreement were consummated, YPC received 10,369,990 unregistered shares, or
19.9%, of the common equity of PlanetRx, and PlanetRx

F-26
<PAGE> 93
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

assumed options granted to YPC employees which converted into options to
purchase approximately 1.8 million shares of PlanetRx common stock. In
connection with the IPO, we also executed a 180 day lock-up agreement that
prevents us from selling our shares until April 10, 2000. The consummation of
the transaction occurred immediately preceding the closing of PlanetRx's IPO of
common stock. Based on the IPO price of $16 per share, YPC received
consideration valued at $165,920,000 million. We recorded a one-time gain (in
other income) of $182,930,000 on the transaction, and a one-time stock
compensation expense (included in non-recurring expenses) of $19,520,000
relating to the YPC employee stock options. We are accounting for this
investment in PlanetRx on the cost method and therefore reporting our investment
on the balance sheet under the caption "investment in marketable securities" at
fair value in accordance with FAS 115 (see Note 1).

As part of our agreement, PlanetRx will pay us an annual fee of $11,650,000
and reimbursement for certain expenses of $3,000,000 over a 5 year term, which
can be extended to 10 years if we meet certain performance measures.
Additionally, we are eligible to receive an incremental fee based upon the
number of our members who placed their first order for prescription drug or
non-prescription merchandise with PlanetRx. We recorded $2,912,000 of the annual
fee and $88,000 of incremental fee in other revenue and we have reduced selling
and general administrative expenses by $750,000 for reimbursement of certain
expenses relating to our Internet initiative. As of December 31, 1999, we have
PlanetRx receivables of $5,732,000.

3. CONTRACTUAL AGREEMENTS

On December 31, 1995, we entered into a ten-year corporate alliance with
Premier Purchasing Partners, L.P. (formerly, American Healthcare Systems
Purchasing Partners, L.P., the "Partnership"), an affiliate of Premier, Inc.
("Premier"). Premier is an alliance of health care systems resulting from the
merger in 1995 of American Healthcare Systems, Premier Health Alliance and
SunHealth Alliance. Under the terms of the transaction, we are Premier's
preferred vendor of pharmacy benefit management services to Premier's
shareholder systems and their managed care affiliates and will issue shares of
our Class A Common Stock as an administrative fee to the Partnership based on
the attainment of certain benchmarks, principally related to the number of
members receiving our pharmacy benefit management services under the
arrangement, and to the achievement of certain joint purchasing goals. In
accordance with the terms of the agreement, we issued 454,546 shares of Class A
Stock to Premier in May 1996. The shares were valued at $11,250,000 using our
closing stock price on December 31, 1995, the date the agreement was
consummated, and are being amortized over the then remaining term of the
agreement. Amortization expense in 1997, 1998 and 1999 was $1,164,000,
$1,164,000 and $1,320,000, respectively. We may be required to issue up to an
additional 4,500,000 shares to the Partnership over a period up to the first
five years of the agreement if the Partnership exceeds all benchmarks. A
calculation is made on April 1 of each year to determine if a stock issuance
will be made. Premier has asserted that is has earned additional shares. We
disagree with this contention, and we are in discussions with Premier concerning
this matter. To date, we have not issued any additional shares. Except for
certain exemptions from registration under the Securities Act of 1933 ("the 1933
Act"), any shares issued to the Partnership cannot be traded until they have
been registered under the 1933 Act and any applicable state securities laws.

Effective January 1, 1996, we executed a multi-year contract with The
Manufacturers Life Insurance Company ("Manulife"), to introduce pharmacy benefit
management services in Canada. Manulife's Group Benefits Division continues to
work with ESI Canada to provide these services. Under the terms of the
agreement, we are the exclusive third-party provider of pharmacy benefit
management services to Manulife's Canadian clients. We will also issue shares of
our Class A Common Stock as an advance discount to Manulife based upon
achievement of certain volumes of Manulife pharmacy claims we process. No shares
will be issued until after the fourth year of the agreement based on volumes
reached in years

F-27
<PAGE> 94
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

two through four. We anticipate issuing no more than 474,000 shares to Manulife
over a period up to the first six years of the agreement. Except for certain
exemptions from registration under the 1933 Act, any shares issued to Manulife
cannot be traded until they have been registered under the 1933 Act and any
applicable state securities laws. In accordance with the terms of the agreement,
no stock has been issued since inception.

If Manulife has not exercised an early termination option at the end of the
sixth or tenth year of the agreement, we will issue at each of those times a
ten-year warrant as an advance discount to purchase up to approximately 237,000
additional shares of our Class A Common Stock exercisable at 85% of the market
price at those times. The actual number of shares for which such warrant is to
be issued is based on the volume of Manulife pharmacy claims we process in year
six and year ten, respectively.

Pursuant to an agreement with Coventry Corporation, an operator of health
maintenance organizations located principally in Pennsylvania and Missouri, on
January 3, 1995, we issued 50,000 shares of Class A Common Stock as an advance
discount to Coventry in a private placement. These shares were valued at $13.69
per share, the split-adjusted per share market value of our Class A Common Stock
on November 22, 1994, which was the date the agreement was consummated and the
obligation of the parties became unconditional. No revision of the consideration
for the transaction occurred between November 22, 1994 and January 3, 1995. The
shares issued to Coventry were being amortized over a six-year period. However,
due to Coventry extending the agreement for only two years, as discussed below,
instead of three years, the estimated useful life of the shares issued has been
reduced to five years and ended in 1999. Amortization expense was $114,000,
$171,000 and $171,000 for each of the years ended December 31, 1997, 1998 and
1999, respectively. Except for certain exemptions from registration under the
1993 Act, these shares cannot be traded until they have been registered under
the 1933 Act and any applicable state securities laws.

Effective January 1, 1998, Coventry renewed the agreement for a two-year
term through December 31, 1999. As part of the agreement, we issued warrants as
an advance discount to purchase an additional 50,000 shares of our Class A
Common Stock, exercisable at 90% of the market value at the time of renewal.
During 1998, we expensed the advance discount, which represented 10% of the
market value.

On October 13, 1992, we entered into a five-year arrangement with FHP, Inc.
("FHP") pursuant to which we agreed to provide pharmacy benefit services to FHP
and its members. FHP is an operator of health maintenance organizations,
principally in the western United States. In February 1997, PacifiCare Health
Systems, Inc. ("PacifiCare") completed the acquisition of FHP. As a result of
the merger, PacifiCare informed us that it would not enter into a long-term
extension of the agreement and reached an agreement with us to phase-out
membership starting in July 1997 and continued through March 1998.

In accordance with the agreement, we commenced providing pharmacy benefit
services to FHP and its members on January 4, 1993. On the commencement date and
pursuant to the agreement, we issued 400,000 shares of our Class A Common Stock
as advance discounts to FHP in a private placement. These shares were valued at
$4.13 per share, the split-adjusted per share market value of our Class A shares
on October 13, 1992, which was the date the agreement was consummated and the
obligations of the parties became unconditional. No revision of the
consideration for the transaction occurred between October 13, 1992 and January
4, 1993. The cost of the shares issued to FHP was amortized over a five-year
period ending in 1997. Amortization expense was $990,000 in 1997. No
amortization expense was recorded in 1998 or 1999.

F-28
<PAGE> 95
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

4. RELATED PARTY TRANSACTIONS

As discussed in Note 3, we have entered into a ten year corporate alliance
with Premier. Richard Norling is the Chief Executive Officer of Premier and a
member of our Board of Directors. No consideration, monetary or otherwise, has
been exchanged between Premier and us between the period September 1997 and
December 1999 (the period during which Premier is a related party with us). We
may be required to issue additional shares of our Class A Common Stock to
Premier as discussed in Note 3.

Premier is required to promote us as the preferred PBM provider to health
care entities, plans and facilities, which participate in Premier's purchasing
programs. However, all contractual arrangements to provide services are made
directly between these entities and us, at varying terms and independent of any
Premier involvement. Therefore, the associated revenues earned and expenses
incurred by us are not deemed to be related party transactions. During 1999, the
revenues that we derived from services provided to the health care entities
participating in Premier's purchasing programs was $107,538,000.

5. PROPERTY AND EQUIPMENT

Property and equipment, at cost, consists of the following:

<TABLE>
<CAPTION>
DECEMBER 31,
---------------------------
1998 1999
------------ ------------
(IN THOUSANDS)
<S> <C> <C>
Land...................................................... $ 2,051 $ 2,051
Building.................................................. 3,076 3,076
Furniture................................................. 8,336 12,873
Equipment................................................. 52,758 64,204
Computer software......................................... 37,412 55,054
Leasehold improvements.................................... 8,275 9,922
-------- --------
111,908 147,180
Less accumulated depreciation and amortization............ 34,409 49,607
-------- --------
$ 77,499 $ 97,573
======== ========
</TABLE>

F-29
<PAGE> 96
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

6. FINANCING

Long-term debt consists of:

<TABLE>
<CAPTION>
DECEMBER 31,
---------------------------
1998 1999
------------ ------------
(IN THOUSANDS)
<S> <C> <C>
Revolving credit facility due March 31, 2005 with an
interest rate of 7.94% at December 31, 1999............. $ -- $100,000
Term credit facility due April 15, 2003................... 360,000 --
Term A loans due March 31, 2005 with an interest rate of
7.94% at December 31, 1999.............................. -- 285,000
9.625% Senior Notes due June 15, 2009 with an effective
interest rate of 9.7% and interest rate lock, net of
unamortized discount of $1,146.......................... -- 250,873
-------- --------
Total debt................................................ 360,000 635,873
Less current maturities................................... 54,000 --
-------- --------
Long-term debt............................................ $306,000 $635,873
======== ========
</TABLE>

On April 1, 1999, we executed a $1.05 billion credit facility ("Credit
Facility") with a bank syndicate led by Credit Suisse First Boston and Bankers
Trust Company, consisting of $750 million in term loans, including $285 million
of Term A loans and $465 million of Term B loans, and a $300 million revolving
credit facility. The Credit Facility is secured by the capital stock of each of
our existing and subsequently acquired domestic subsidiaries, excluding PPS,
Great Plains Reinsurance Company ("Great Plains"), ValueRx of Michigan, Inc.,
Diversified NY IPA, Inc., and Diversified Pharmaceutical Services (Puerto Rico),
Inc., and is also secured by 65% of the stock of our foreign subsidiaries. The
provisions of the Credit Facility require quarterly interest payments based on
several London Interbank Offered Rates ("LIBOR") or base rate options plus an
interest rate spread. The Credit Facility contains covenants that limit the
indebtedness we may incur, dividends paid and the amount of annual capital
expenditures. The covenants also establish a minimum interest coverage ratio, a
maximum leverage ratio, and a minimum fixed charge coverage ratio. In addition,
we are required to pay an annual fee of 0.5%, payable in quarterly installments,
on the unused portion of the revolving credit facility ($200 million at December
31, 1999). At December 31, 1999, we were in compliance with all covenants
associated with the Credit Facility. In January 2000, we paid down the revolving
credit facility by $30,000,000.

Also on April 1, 1999, we executed a $150 million senior subordinated
bridge credit facility with Credit Suisse First Boston and Bankers Trust
Company. The proceeds from this facility and approximately $890 million in
proceeds from the Credit Facility were used to consummate the DPS acquisition
(see Note 2) and repay $360 million outstanding under our pre-existing $440
million credit facility. This facility was retired in June 1999, upon the
completion of our equity offering (see Note 11).

On June 16, 1999, we completed the offering of $250 million in Senior
Notes, which require interest to be paid semi-annually on June 15 and December
15. The Senior Notes also provide us an opportunity to call the debt at
specified rates beginning in June 2004. The net proceeds from the Senior Notes
offering, along with a portion of the net proceeds from the equity offering and
$23,901,000 of our own cash were used to repay $414,770,000 of the Term B loans.
In July 1999, we paid off the remaining Term B principal balance of $50,230,000.
As a result of the refinancing of the $440 million credit facility and the
repayment of the Term B loans, we recognized a $7,150,000, net of tax,
extraordinary loss from the write-

F-30
<PAGE> 97
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

off of deferred financing fees. The Senior Notes are unconditionally and joint
and severally guaranteed by our wholly-owned domestic subsidiaries other than
PPS, Great Plains, ValueRx of Michigan, Inc., Diversified NY IPA, and
Diversified Pharmaceutical Services (Puerto Rico). Separate financial statements
of the Guarantors are not presented as we have determined them not to be
material to investors. Therefore, the following condensed consolidating
financial information has been prepared using the equity method of accounting in
accordance with the requirements for presentation of such information. We
believe that this information, presented in lieu of complete financial
statements for each of the guarantor subsidiaries, provides sufficient detail to
allow investors to determine the nature of the assets held by, and the
operations of, each of the consolidating groups.

<TABLE>
<CAPTION>
EXPRESS
SCRIPTS, INC. GUARANTORS NON-GUARANTORS ELIMINATIONS CONSOLIDATED
------------- ---------- -------------- ------------ ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
AS OF DECEMBER 31, 1998
Current assets................... $ 463,818 $ 188,978 $ 4,111 $ -- $ 656,907
Property and equipment, net...... 27,375 46,817 3,307 -- 77,499
Investments in subsidiaries...... 68,198 74,297 264 (142,759) --
Intercompany..................... 363,455 (361,202) (2,253) -- --
Goodwill, net.................... 210 281,953 -- -- 282,163
Other intangible assets, net..... 11,770 53,884 111 -- 65,765
Other assets..................... 1,013 11,969 145 -- 13,127
---------- ---------- -------- --------- ----------
Total assets................ $ 935,839 $ 296,696 $ 5,685 $(142,759) $1,095,461
========== ========== ======== ========= ==========
Current liabilities.............. $ 394,553 $ 141,433 $ 3,310 $ -- $ 539,296
Long-term debt................... 306,000 -- -- -- 306,000
Other liabilities................ 779 (251) (57) -- 471
Stockholders' equity............. 234,507 155,514 2,432 (142,759) 249,694
---------- ---------- -------- --------- ----------
Total liabilities and
stockholders' equity...... $ 935,839 $ 296,696 $ 5,685 $(142,759) $1,095,461
========== ========== ======== ========= ==========
AS OF DECEMBER 31, 1999
Current assets................... $ 549,374 $ 509,702 $ 7,279 $ -- $1,066,355
Property and equipment, net...... 39,036 55,776 2,761 -- 97,573
Investments in subsidiaries...... 725,468 -- 2,261 (727,729) --
Investments in marketable
securities..................... -- 150,365 -- -- 150,365
Intercompany..................... 463,438 (463,241) (197) -- --
Goodwill, net.................... 168 976,759 5,569 -- 982,496
Other intangible assets, net..... 22,458 160,901 61 -- 183,420
Other assets..................... 13,179 (6,493) 563 (147) 7,102
---------- ---------- -------- --------- ----------
Total assets................ $1,813,121 $1,383,769 $ 18,297 $(727,876) $2,487,311
========== ========== ======== ========= ==========
Current liabilities.............. $ 527,312 $ 563,457 $ 9,589 $ -- $1,100,358
Long-term debt................... 635,873 -- -- -- 635,873
Other liabilities................ 83,365 (33,018) 1,251 -- 51,598
Stockholders' equity............. 566,571 853,330 7,457 (727,876) 699,482
---------- ---------- -------- --------- ----------
Total liabilities and
stockholders' equity...... $1,813,121 $1,383,769 $ 18,297 $(727,876) $2,487,311
========== ========== ======== ========= ==========
</TABLE>

F-31
<PAGE> 98
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

<TABLE>
<CAPTION>
EXPRESS
SCRIPTS, INC. GUARANTORS NON-GUARANTORS ELIMINATIONS CONSOLIDATED
------------- ---------- -------------- ------------ ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
YEAR ENDED DECEMBER 31, 1997
Total revenues................... $1,205,085 $ 16,107 $ 9,442 $ -- $1,230,634
Operating expenses............... 1,158,490 15,031 8,263 -- 1,181,784
---------- ---------- -------- --------- ----------
Operating income............... 46,595 1,076 1,179 -- 48,850
Interest income (expense)........ 5,821 -- 35 -- 5,856
---------- ---------- -------- --------- ----------
Income before tax provision.... 52,416 1,076 1,214 -- 54,706
Income tax provision............. 20,352 417 508 -- 21,277
---------- ---------- -------- --------- ----------
Net Income..................... $ 32,064 $ 659 $ 706 $ -- $ 33,429
========== ========== ======== ========= ==========
YEAR ENDED DECEMBER 31, 1998
Total revenues................... $1,646,807 $1,167,387 $ 10,678 $ -- $2,824,872
Operating expenses............... 1,584,731 1,139,387 11,520 -- 2,735,638
---------- ---------- -------- --------- ----------
Operating income (loss)........ 62,076 28,000 (842) -- 89,234
Interest income (expense)........ (13,943) 846 103 -- (12,994)
---------- ---------- -------- --------- ----------
Income (loss) before tax
provision................... 48,133 28,846 (739) -- 76,240
Income tax provision............. 17,903 15,377 286 -- 33,566
---------- ---------- -------- --------- ----------
Net Income (loss).............. $ 30,230 $ 13,469 $ (1,025) $ -- $ 42,674
========== ========== ======== ========= ==========
YEAR ENDED DECEMBER 31, 1999
Total revenues................... $2,257,952 $1,989,237 $ 40,915 $ -- $4,288,104
Operating expenses............... 2,140,144 1,971,696 39,480 -- 4,151,320
---------- ---------- -------- --------- ----------
Operating income (loss)........ 117,808 17,541 1,435 -- 136,784
Gain on sale of assets........... -- 182,930 -- -- 182,930
Interest income (expense)........ (54,700) 292 160 -- (54,248)
---------- ---------- -------- --------- ----------
Income before tax provision.... 63,108 200,763 1,595 -- 265,466
Income tax provision............. 34,799 72,031 1,268 -- 108,098
---------- ---------- -------- --------- ----------
Income before extraordinary
loss........................ 28,309 128,732 327 -- 157,368
Extraordinary loss............... 7,150 -- -- -- 7,150
---------- ---------- -------- --------- ----------
Net Income..................... $ 21,159 $ 128,732 $ 327 $ -- $ 150,218
========== ========== ======== ========= ==========
</TABLE>

The following represents the schedule of current maturities for our
long-term debt (in thousands):

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
-----------------------
<S> <C>
2000........................................................ $ --
2001........................................................ 42,750
2002........................................................ 57,000
2003........................................................ 57,000
2004........................................................ 62,700
--------
$219,450
========
</TABLE>

To manage our interest rate risk we entered into an interest rate swap
agreement ("swap") with The First National Bank of Chicago, a subsidiary of Bank
One Corporation, on April 3, 1998. At December 31, 1999 and 1998, the swap had a
notional principal amount of $306 million and $360 million, respectively.

F-32
<PAGE> 99
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

Under the terms of the swap, we agreed to receive a floating rate of interest on
the amount of the term loan facility based on a three-month LIBOR rate in
exchange for payment of a fixed rate of interest of 5.88% per annum. The
notional principal amount of the swap began amortizing at $27 million in April
1999, increasing to $36 million in April 2000, to $45 million in April 2001 and
to $48 million in April 2002. As a result, we have, in effect, converted $306
million of our variable rate debt under the Credit Facility to fixed rate debt
at 5.88% per annum for the first four years of the Credit Facility, plus the
interest rate spread of 2.0%.

On June 17, 1999, we entered into an interest rate swap agreement with
Bankers Trust Company. The swap will not become effective until April 2000 and
carried no notional principal amount as of December 31, 1999. Under the terms of
the agreement, we agreed to receive a floating rate of interest on the notional
principal amount based on a three-month LIBOR rate in exchange for payment of a
fixed rate of interest of 6.25% per annum. Beginning in April 2000, the notional
principal amount will be $15 million and will increase semi-annually up to an
approximate $137 million in October 2002. For the remainder of the agreement's
term, the notional principal amount will amortize until the agreement
termination in April 2005. When the swap becomes effective, we will, in effect,
convert the notional principal amount of our variable rate debt under our Credit
Facility to fixed rate debt at 6.25% per annum plus the interest rate spread.

During 1999, we entered into an interest rate lock with Bankers' Trust
Company related to our offering of $250 million Senior Notes. Upon issuance of
the Senior Notes, we received $2,135,000, which is being amortized over the term
of the Senior Notes. During 1999, interest expense was reduced by $116,000.

7. CORPORATE RESTRUCTURING

During the second quarter of 1998, we recorded a pre-tax restructuring
charge of $1,651,000 associated with closing the non-PBM service operations of
its wholly-owned subsidiary, PhyNet, Inc., and transferring certain functions of
our Vision Corporation to another vision care provider. The restructuring plan
consisted of $416,000 of cash charges associated with the severance of 61
employees and non-cash charges of $1,235,000 relating to the write-down of
long-lived assets no longer providing us benefit. We completed the remainder of
the restructuring actions during the third quarter of 1999.

During December 1999, we recorded a pre-tax restructuring charge of
$2,633,000 associated with the outsourcing of our computer operations to EDS.
The principal actions of the plan included cash expenditures of approximately
$2,148,000 for the transition of 51 employees to the outsourcer and the
elimination of contractual obligations of ValueRx which had no future economic
benefit to us, and non-cash charges of approximately $485,000 due to the
reduction in the carrying value of certain capitalized software to its net
realizable value. Completion of this plan will occur during the first quarter of
2000 when all cash payments will be made.

F-33
<PAGE> 100
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

Also in December 1999, we recorded a pre-tax restructuring charge of
$969,000 associated with restructuring our PPS majority-owned subsidiary and the
purchase of the remaining PPS Common Stock from management. The charge consists
of cash expenditures of $559,000 relating to stock compensation expense and
$410,000 of severance payments to 9 employees (of which $133,000 was paid during
December 1999). This plan was completed in January 2000.

<TABLE>
<CAPTION>
BALANCE AT BALANCE AT
1998 1998 DECEMBER 31, 1999 1999 DECEMBER 31,
CHARGES USAGE 1998 ADDITIONS USAGE 1999
------- ----- ------------ --------- ------ ------------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
NON-CASH
----------
Write-down of long-lived
assets........................ $1,235 $704 $531 $ 2,761 $3,264 $ 28
CASH
-----
Employee transition costs....... 416 184 232 2,558 365 2,425
Stock compensation.............. -- -- -- 559 -- 559
Lease termination fees and
rent.......................... -- -- -- 4,823 4,318 505
------ ---- ---- ------- ------ ------
$1,651 $888 $763 $10,701 $7,947 $3,517
====== ==== ==== ======= ====== ======
</TABLE>

8. INCOME TAXES

The income tax provision consists of the following:

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
----------------------------
1997 1998 1999
------- ------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Current provision:
Federal................................................... $19,048 $20,171 $ 26,933
State..................................................... 2,779 3,049 4,190
Foreign................................................... 284 278 758
------- ------- --------
Total current provision................................ 22,111 23,498 31,881
------- ------- --------
Deferred provision:
Federal................................................... (714) 8,694 68,627
State..................................................... (120) 1,374 7,590
------- ------- --------
Total deferred provision............................... (834) 10,068 76,217
------- ------- --------
Total current and deferred provision........................ $21,277 $33,566 $108,098
======= ======= ========
</TABLE>

F-34
<PAGE> 101
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

Income taxes included in the Consolidated Statement of Operations are:

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
----------------------------
1997 1998 1999
------- ------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Continuing operations....................................... $21,277 $33,566 $108,098
Extraordinary loss on early retirement of debt.............. -- -- (4,492)
------- ------- --------
$21,277 $33,566 $103,606
======= ======= ========
</TABLE>

A reconciliation of the statutory federal income tax rate and the effective
tax rate follows (the effect of foreign taxes on the effective tax rate for
1997, 1998 and 1999 is immaterial):

<TABLE>
<CAPTION>
YEAR ENDED
DECEMBER 31,
------------------
1997 1998 1999
---- ---- ----
<S> <C> <C> <C>
Statutory federal income tax rate........................... 35.0% 35.0% 35.0%
State taxes, net of federal benefit......................... 3.8 3.8 3.6
Non-deductible amortization of goodwill and customer
contracts................................................. -- 4.9 1.8
Other, net.................................................. 0.1 0.3 0.3
---- ---- ----
Effective tax rate.......................................... 38.9% 44.0% 40.7%
==== ==== ====
</TABLE>

F-35
<PAGE> 102
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

The deferred tax assets and deferred tax liabilities recorded in the
consolidated balance sheet are as follows:

<TABLE>
<CAPTION>
DECEMBER 31,
-------------------
1998 1999
------- --------
(IN THOUSANDS)
<S> <C> <C>
Deferred tax assets:
Allowance for bad debts................................... $ 8,013 $ 5,744
Inventory costing capitalization and reserves............. 684 185
Accrued expenses.......................................... 34,170 23,864
Depreciation and property differences..................... 6,808 7,112
Non-compete agreements.................................... 933 2,008
Net operating loss carryforward........................... -- 7,829
Unrealized loss on investments............................ -- 6,000
Other..................................................... 17 508
------- --------
Gross deferred tax assets.............................. 50,625 53,250
Deferred tax liabilities:
Gain on sale of assets.................................... -- (62,987)
Goodwill and customer contract amortization............... -- (7,942)
Other..................................................... (462) (985)
------- --------
Gross deferred tax liabilities......................... (462) (71,914)
------- --------
Net deferred tax (liabilities) assets....................... $50,163 $(18,664)
======= ========
</TABLE>

9. COMMITMENTS AND CONTINGENCIES

We have entered into noncancellable agreements to lease certain office and
distribution facilities with remaining terms from one to ten years. Rental
expense under the office and distribution facilities leases in 1997, 1998 and
1999 was $2,272,000, $3,876,000 and $11,147,000, respectively. The future
minimum lease payments due under noncancellable operating leases is as follows
(in thousands):

<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
-----------------------
<S> <C>
2000........................................................ $11,359
2001........................................................ 10,653
2002........................................................ 9,998
2003........................................................ 9,806
2004........................................................ 9,887
Thereafter.................................................. 34,479
-------
$86,182
=======
</TABLE>

For the year ended December 31, 1999, approximately 78.7% of our
pharmaceutical purchases were through one wholesaler. We believe other
alternative sources are readily available and that no other concentration risks
exist at December 31, 1999.

F-36
<PAGE> 103
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

In the ordinary course of business (which includes the business conducted
by DPS and ValueRx prior to acquiring them on April 1, 1999 and April 1, 1998,
respectfully), various legal proceedings, investigations or claims pending have
arisen against us and our subsidiaries (ValueRx and DPS continue to be a party
to proceedings that arose prior to their April 1, 1998 and April 1, 1999
respective acquisition dates). The effect of these actions on future financial
results is not subject to reasonable estimation because considerable uncertainty
exists about the outcomes. Nevertheless, in our opinion, the ultimate
liabilities resulting from any such lawsuits, investigations or claims now
pending are not expected to materially affect our consolidated financial
position, results of operations, or cash flows.

10. EMPLOYEE BENEFIT PLANS

RETIREMENT SAVINGS PLAN. We offer all of our full-time employees a
retirement savings plan under Section 401(k) of the Internal Revenue Code.
Employees may elect to enter a written salary deferral agreement under which a
maximum of 12% of their salary (effective January 1, 2000 maximum deferral is
15%), subject to aggregate limits required under the Internal Revenue Code, may
be contributed to the plan. We match the first $2,000 of the employee's
contribution for the year. Effective January 1, 2000, we will match 100% of the
first 4% of the employees' compensation contributed to the Plan. For the years
ended December 1997, 1998 and 1999, we made contributions of approximately
$909,000, $1,751,000 and $3,604,000, respectively.

EMPLOYEE STOCK PURCHASE PLAN. In December 1998, our Board of Directors
approved an employee stock purchase plan, effective March 1, 1999, that
qualifies under Section 423 of the Internal Revenue Code and permits all
employees, excluding certain management level employees, to purchase shares of
our Class A Common Stock. Participating employees may elect to contribute up to
10% of their salary to purchase common stock at the end of each six month
participation period at a purchase price equal to 85% of the fair market value
of our Class A Common Stock at the end of the participation period. During 1999,
approximately 10,000 shares of our Class A Common Stock were issued under the
plan. Class A Common Stock reserved for future employee purchases under the plan
is 240,000 at December 31, 1999.

DEFERRED COMPENSATION PLAN. In December 1998, the Compensation Committee
of the Board of Directors approved a non-qualified deferred compensation plan
(the "Executive Deferred Compensation Plan"), effective January 1, 1999, that
provides benefits payable to eligible key employees at retirement, termination
or death. Benefit payments are funded by a combination of contributions from
participants and us. Participants become fully vested in our contributions on
the third anniversary of the end of the plan year for which the contribution is
credited to their account. For 1999, our annual contribution was equal to 6% of
each participant's total annual compensation, with 25% being invested in our
Class A Common Stock and the remaining being allocated to a variety of
investment options. As a result of the implementation, we accrued as
compensation expense $797,000 in 1998 and $224,000 in 1999 as a past service
contribution which is equal to 8% of each participant's total annual cash
compensation for the period of the participant's past service with us in a
senior executive capacity. At December 31, 1999, 50,000 shares of Class A Common
Stock have been reserved for future plan contributions.

11. COMMON STOCK

The holders of Class A Common Stock have one vote per share, and the
holders of Class B Common Stock have ten votes per share. NYLIFE HealthCare
Management, Inc. ("NYLIFE HealthCare"), an indirect subsidiary of New York Life
Insurance Company, is the sole holder our of Class B Common Stock. Class B
Common Stock converts into Class A Common Stock on a share-for-share basis upon
transfer (other than to New York Life or its affiliates) and is convertible at
any time at the discretion of the holder. At December 31, 1999, NYLIFE
HealthCare and the holders of Class A Common Stock have

F-37
<PAGE> 104
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

control over approximately 86.2% and 13.8%, respectively, of the combined voting
power of all classes of Common Stock.

In June 1999, we consummated our offering of 5,175,000 shares of our Class
A Common Stock at a price of $61 per share. The net proceeds of $299,378,000
were used to retire the $150 million senior subordinated bridge credit facility
and a portion of the Term B loans under the $1.05 billion credit facility (see
Note 6).

As of December 31, 1999, we had repurchased a total of 475,000 shares of
our Class A Common Stock under the open-market stock repurchase program we
announced on October 25, 1996, although no repurchases occurred during 1999. Our
Board of Directors approved the repurchase of up to 1,700,000 shares, and placed
no limit on the duration of the program. Future purchases, if any, will be in
such amounts and at such times as we deem appropriate based upon prevailing
market and business conditions, subject to certain restrictions on stock
repurchases contained in our $1.05 billion credit facility and the Indenture
covering our Senior Notes. During 1999, we used approximately 10,000 shares
previously purchased under this program to satisfy obligations under our
employee stock option program (see Note 10).

As of December 31, 1999, approximately 10,555,000 shares of our Class A
Common Stock has been reserved for issuance to organizations with which we have
signed contractual agreements (see Note 3) and for employee benefit plans (see
Note 10).

In October 1998, we announced a two-for-one stock split of our Class A and
Class B Common Stock for stockholders of record on October 20, 1998, effective
October 30, 1998. The split was effected in the form of a dividend by issuance
of one additional share of Class A Common Stock for each share of Class A Common
Stock outstanding and one additional share of Class B Common Stock for each
share of Class B Common Stock outstanding. The earnings per share and the
weighted average number of shares outstanding for basic and diluted earnings per
share have been adjusted for the stock split except on the Consolidated Balance
Sheet and the Consolidated Statement of Changes in Stockholders' Equity.

12. STOCK-BASED COMPENSATION PLANS

At December 31, 1999, we had three fixed stock-based compensation plans,
which are described below.

In April 1992, we adopted a stock option plan that we amended and restated
in 1995 and amended in 1999, which provides for the grant of nonqualified stock
options and incentive stock options to our officers and key employees selected
by the Compensation Committee of the Board of Directors. Initially, a maximum of
1,400,000 shares of Class A Common Stock could be issued under the plan. That
amount increased to a maximum of 2,380,000 shares, with no employee being able
to receive options to purchase more than 800,000 shares.

In June 1994, the Board of Directors adopted the Express Scripts, Inc. 1994
Stock Option Plan, also amended and restated in 1995 and amended in 1997, 1998
and 1999. Reflecting the increase as of January 1, 2000, a total of 3,305,354
shares of our Class A Common Stock have been reserved for issuance under this
plan. That amount will increase annually, effective January 1, commencing on
January 1, 2000 and ending January 1, 2004, by 1% of our total outstanding
shares of Class A and Class B Common Stock on such date. Under either plan, the
exercise price of the options may not be less than the fair market value of the
shares at the time of grant. The Compensation Committee has the authority to
establish vesting terms, and typically provides that the options vest over a
five-year period from the date of grant. The options may be exercised, subject
to a ten-year maximum, over a period determined by the Committee.

F-38
<PAGE> 105
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

In April 1992, we also adopted a stock option plan that was amended and
restated in 1995 and amended in 1996 and 1999 that provides for the grant of
nonqualified stock options to purchase 48,000 shares to each director who is not
an employee of ours or our affiliates. In addition, the second amendment to the
plan gave each non-employee director who was serving in such capacity as of the
date of the second amendment the option to purchase 2,500 additional shares. The
second amendment options will vest over three years. A maximum of 384,000 shares
of Class A Common Stock may be issued under this plan at a price equal to fair
market value at the date of grant. The plan provides that the options vest over
a two-, three- or five-year period from the date of grant depending upon the
circumstances of the grant.

We apply APB 25 and related interpretations in accounting for our plans.
Accordingly, no compensation cost has been recognized for our stock options
plans. Had compensation cost for our stock based compensation plans been
determined based on the fair value at the grant dates for awards under those
plans consistent with the method prescribed by FAS 123, our net income and
earnings per share would have been reduced to the pro forma amounts indicated
below. Note that due to the adoption of the methodology prescribed by FAS 123,
the pro forma results shown below only reflect the impact of options granted in
1997, 1998 and 1999. Because future options may be granted and vesting typically
occurs over a five year period, the pro forma impact shown for 1997, 1998 and
1999 is not necessarily representative of the impact in future years.

<TABLE>
<CAPTION>
1997 1998 1999
------- ------- --------
(IN THOUSANDS, EXCEPT
PER SHARE DATA)
<S> <C> <C> <C>
Net income
As reported............................................... $33,429 $42,674 $150,218
Pro forma................................................. 32,034 38,585 142,753
Basic earnings per share
As reported............................................... $ 1.02 $ 1.29 $ 4.16
Pro forma................................................. 0.98 1.16 3.95
Diluted earnings per share
As reported............................................... $ 1.01 $ 1.27 $ 4.06
Pro forma................................................. 0.97 1.14 3.86
</TABLE>

The fair value of options granted (which is amortized to expense over the
option vesting period in determining the pro forma impact), is estimated on the
date of grant using the Black-Scholes multiple option-pricing model with the
following weighted average assumptions:

<TABLE>
<CAPTION>
1997 1998 1999
--------- --------- ---------
<S> <C> <C> <C>
Expected life of option..................................... 2-7 years 2-7 years 2-7 years
Risk-free interest rate..................................... 5.7-6.6% 4.1-5.9% 4.6-6.3%
Expected volatility of stock................................ 40% 44% 59%
Expected dividend yield..................................... None None None
</TABLE>

F-39
<PAGE> 106
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

A summary of the status of our three fixed stock option plans as of
December 31, 1997, 1998 and 1999, and changes during the years ending on those
dates is presented below.

<TABLE>
<CAPTION>
1997 1998 1999
----------------------- ----------------------- -----------------------
WEIGHTED- WEIGHTED- WEIGHTED-
AVERAGE AVERAGE AVERAGE
SHARES EXERCISE PRICE SHARES EXERCISE PRICE SHARES EXERCISE PRICE
------ -------------- ------ -------------- ------ --------------
(SHARE DATA IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
Outstanding at beginning of
year...................... 1,677 $12.56 1,702 $17.21 2,780 $28.02
Granted..................... 602 22.78 1,866 40.65 843 60.43
Exercise.................... (529) 8.80 (133) 14.71 (196) 30.28
Forfeited/cancelled......... (48) 17.56 (655) 38.82 (141) 50.35
------ ------ ------
Outstanding at end of
year...................... 1,702 17.21 2,780 28.02 3,286 35.24
====== ====== ======
Options exercisable at year
end....................... 641 800 1,391
Weighted-average fair value
of options granted during
the year.................. $ 9.91 $18.07 $32.40
</TABLE>

The following table summarizes information about fixed stock options
outstanding at December 31, 1999:

<TABLE>
<CAPTION>
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
RANGE OF ------------------------------------------------- ------------------------------
EXERCISE PRICES NUMBER WEIGHTED-AVERAGE WEIGHTED-AVERAGE NUMBER
(SHARE DATA IN OUTSTANDING REMAINING EXERCISE EXERCISABLE WEIGHTED-AVERAGE
THOUSANDS) AT 12/31/99 CONTRACTUAL LIFE PRICE AT 12/31/99 EXERCISE PRICE
--------------- ----------- ---------------- ---------------- ----------- ----------------
<S> <C> <C> <C> <C> <C>
$3.25 -- 16.50... 728 4.55 $11.74 643 $11.34
17.00 -- 28.41... 716 7.21 22.60 341 21.20
28.50 -- 42.39... 683 8.27 34.72 227 33.04
51.63 -- 55.13... 875 9.53 53.00 110 55.13
65.25 -- 88.56... 284 9.34 73.97 70 65.69
----- ------
$3.25 -- 88.56... 3,286 7.64 35.24 1,391 23.50
===== ======
</TABLE>

13. SEGMENT INFORMATION

We are organized on the basis of services offered and have determined that
we have two reportable segments: PBM services and non-PBM services (defined in
Note 1 "organization and operations"). We manage the pharmacy benefit within an
operating segment that encompasses a fully-integrated PBM service. The remaining
three operating service lines (IVTx, Specialty Distribution and Vision) have
been aggregated into a non-PBM reporting segment.

F-40
<PAGE> 107
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

The following table presents information about the reportable segments for
the years ended December 31:

<TABLE>
<CAPTION>
PBM NON-PBM TOTAL
---------- ------- ----------
(IN THOUSANDS)
<S> <C> <C> <C>
1997
Total revenues............................................ $1,191,173 $39,461 $1,230,634
Depreciation and amortization expense (1)................. 9,592 766 10,358
Interest income........................................... 6,080 1 6,081
Interest expense (1)...................................... 209 16 225
Income before income taxes................................ 52,529 2,177 54,706
Total assets.............................................. 385,330 17,178 402,508
Capital expenditures...................................... 10,670 2,235 12,905
1998
Total revenues............................................ $2,765,111 $59,761 $2,824,872
Depreciation and amortization expense (1)................. 25,466 983 26,449
Interest income........................................... 7,235 1 7,236
Interest expense (1)...................................... 20,218 12 20,230
Income before income taxes................................ 70,107 6,133 76,240
Total assets.............................................. 1,068,715 26,746 1,095,461
Capital expenditures...................................... 23,432 421 23,853
1999
Total revenues............................................ $4,222,294 $65,810 $4,288,104
Depreciation and amortization expense (1)................. 71,156 711 71,867
Interest income........................................... 5,761 1 5,762
Interest expense (1)...................................... 60,001 9 60,010
Income before income taxes................................ 259,182 6,284 265,466
Total assets.............................................. 2,479,746 7,565 2,487,311
Capital expenditures...................................... 35,895 1,063 36,958
</TABLE>

-------------------------
(1) The amortization expense for deferred financing fees ($609 in 1998 and
$2,241 in 1999) is included in interest expense on the Consolidated
Statement of Operations and in depreciation and amortization on the
Consolidated Statement of Cash Flows. The net amortization on the senior
notes discount and interest rate lock (income of $77 in 1999) is also
included in interest expense on the Consolidated Statement of Operations and
in depreciation and amortization on the Consolidated Statement of Cash
Flows.

F-41
<PAGE> 108
EXPRESS SCRIPTS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

14. QUARTERLY FINANCIAL DATA (UNAUDITED)

<TABLE>
<CAPTION>
QUARTERS
------------------------------------------
FIRST SECOND(1) THIRD FOURTH
-------- --------- -------- --------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C>
FISCAL 1998
Total revenues..................................... $371,362 $807,406 $807,319 $838,784
Cost of revenues................................... 338,492 743,557 738,544 764,403
Selling, general and administrative................ 18,826 39,266 43,153 47,745
Operating income................................... 14,044 22,932 25,622 26,636
-------- -------- -------- --------
Net income......................................... $ 9,878 $ 9,568 $ 11,303 $ 11,924
======== ======== ======== ========
Basic earnings per share........................... $ 0.30 $ 0.29 $ 0.34 $ 0.36
======== ======== ======== ========
Diluted earnings per share......................... $ 0.29 $ 0.28 $ 0.34 $ 0.35
======== ======== ======== ========
</TABLE>

-------------------------
(1) Includes the acquisition of ValueRx effective April 1, 1998. Also includes a
non-recurring operating charge of $1,651 ($1,002 after tax). Excluding this
charge, our basic and diluted earnings per share would have been $0.32 and
$0.31, respectively.

<TABLE>
<CAPTION>
QUARTERS
----------------------------------------------
FIRST SECOND(1) THIRD FOURTH(2)
-------- --------- ---------- ----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C>
FISCAL 1999
Total revenues.................................. $899,087 $996,749 $1,083,496 $1,308,772
Cost of revenues................................ 823,647 869,989 958,987 1,174,282
Selling, general and administrative............. 46,440 81,897 78,761 87,096
Operating income................................ 29,000 35,463 45,748 26,573
Extraordinary loss on early retirement of
debt.......................................... -- (6,597) (553) --
-------- -------- ---------- ----------
Net income...................................... $ 13,543 $ 421 $ 16,995 $ 119,259
======== ======== ========== ==========
Basic earnings per share
Before extraordinary item..................... $ 0.41 $ 0.20 $ 0.46 $ 3.10
Extraordinary loss on early retirement of
debt....................................... -- (0.19) (0.02) --
-------- -------- ---------- ----------
Net income.................................... $ 0.41 $ 0.01 $ 0.44 $ 3.10
======== ======== ========== ==========
Diluted earnings per share
Before extraordinary item..................... $ 0.40 $ 0.20 $ 0.45 $ 3.03
Extraordinary loss on early retirement of
debt....................................... -- (0.19) (0.02) --
-------- -------- ---------- ----------
Net income.................................... $ 0.40 $ 0.01 $ 0.43 $ 3.03
======== ======== ========== ==========
</TABLE>

-------------------------
(1) Includes the acquisition of DPS effective April 1, 1999. Also includes a
non-recurring operating charge of $9,400 ($5,773 after tax). Excluding this
amount, our basic and diluted earnings per share before extraordinary items
would have been $0.38 and $0.37, respectively.

(2) Includes non-recurring operating charges and a one time non operating gain
of $20,821 ($12,415 after tax) and $182,903 ($112,037 after tax),
respectively. Excluding these amounts, our basic and diluted earnings per
share before extraordinary items would have been $0.51 and $0.50,
respectively.

F-42
<PAGE> 109

[EXPRESS SCRIPTS LOGO]
<PAGE> 110

The information in this preliminary prospectus is not complete and may
be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is
effective. This preliminary prospectus is not an offer to sell nor does
it seek an offer to buy these securities in any jurisdiction where the
offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED OCTOBER 17, 2000.

3,000,000 Shares

[EXPRESS SCRIPTS LOGO]

Class A Common Stock

------------------------

This prospectus relates to up to 3,000,000 shares (or up to 3,450,000
shares if the underwriters' over-allotment option is exercised in full) of our
Class A common stock beneficially owned by NYLIFE LLC that may be delivered by
the Express Scripts Automatic Exchange Security Trust to holders of Trust Issued
Automatic Exchange Securities of the Trust upon exchange of such securities on
the exchange date as defined in the attached prospectus of the Trust. The Trust
Securities are being sold by the Trust in an offering described in the attached
Trust prospectus.

We will not receive any of the proceeds from the sale of Trust Securities.

Our Class A common stock votes as a single class on all matters except as
otherwise required by law, with each share of Class A common stock entitling its
holder to one vote.

In addition to this offering, NYLIFE is selling 6,000,000 shares of Class A
common stock. We will not receive any proceeds from the shares of Class A common
stock sold by NYLIFE.

Our Class A common stock is traded on The Nasdaq National Market under the
symbol "ESRX." On October 16, 2000, the last reported sale price for our Class A
common stock was $77.375 per share.

------------------------

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY OTHER REGULATORY
BODY HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY
OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.

------------------------

Joint Bookrunners

GOLDMAN, SACHS & CO. CREDIT SUISSE FIRST BOSTON

------------------------

Prospectus dated November , 2000.

A-1
<PAGE> 111

------------------

TABLE OF CONTENTS

<TABLE>
<CAPTION>
PAGE
----
<S> <C>
PROSPECTUS SUMMARY.................... 1
RISK FACTORS.......................... 8
RELATIONSHIP WITH NYLIFE.............. 14
USE OF PROCEEDS....................... 17
PRICE RANGE OF COMMON STOCK AND
DIVIDEND POLICY..................... 17
CAPITALIZATION........................ 18
SELECTED FINANCIAL AND OPERATING
DATA................................ 19
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS....................... 21
BUSINESS.............................. 33
</TABLE>

------------------

A-2
<PAGE> 112

CONCURRENT OFFERING

Concurrently with the Trust offering, NYLIFE is offering up to 6,000,000
shares of Class A common stock (or up to 6,900,000 shares if the underwriters'
over-allotment option is exercised in full). We will not receive any proceeds
from the sale of such shares of Class A common stock.

A-3
<PAGE> 113

THE OFFERING

Class A common stock offered
for delivery by the Trust... 3,000,000 shares

Common stock to be outstanding
after this offering:
Class A common stock........ 38,496,359 shares

Class B common stock........ none
------------------------------------------------------

Total common stock.......... 38,496,359 shares

------------------------------------------------------

Does not include as of September 1, 2000:

- stock options and similar equity rights
granted to employees and independent
directors to purchase 3,499,365 shares of our
Class A common stock, of which 1,162,245 were
exercisable

- 1,007,368 reserved shares of our Class A
common stock for issuance in connection with
strategic alliances with certain clients

- 269,419 reserved shares of our Class A common
stock for our Employee Stock Purchase Plan
and our Executive Deferred Compensation Plan

Use of proceeds............... We will not receive any proceeds from this
offering.

Nasdaq National Market
symbol........................ ESRX

A-4
<PAGE> 114

PLAN OF DISTRIBUTION

The Trust Securities will be distributed as described in the Trust
prospectus under the caption "Underwriting." The underwriters and certain of
their affiliates have provided, are currently providing, and expect to provide
in the future, commercial and investment banking services to us for which such
underwriters or their affiliates have received and will receive fees and
commissions.

TRUST PROSPECTUS

The Trust Issued Automatic Exchange Securities are being offered pursuant
to the Trust prospectus. This prospectus relates only to the Class A common
stock that may be delivered upon exchange of the Trust Issued Automatic Exchange
Securities. We take no responsibility for any information included in or omitted
from the Trust prospectus. The Trust prospectus does not constitute a part of
this prospectus nor is it incorporated by reference herein.

A-5
<PAGE> 115

------------------------------------------------------
------------------------------------------------------

NO DEALER, SALESPERSON OR OTHER PERSON IS AUTHORIZED TO GIVE ANY
INFORMATION OR TO REPRESENT ANYTHING NOT CONTAINED IN THIS PROSPECTUS. YOU MUST
NOT RELY ON ANY UNAUTHORIZED INFORMATION OR REPRESENTATIONS. THIS PROSPECTUS IS
AN OFFER TO SELL ONLY THE SHARES OFFERED HEREBY, BUT ONLY UNDER CIRCUMSTANCES
AND IN JURISDICTIONS WHERE IT IS LAWFUL TO DO SO. THE INFORMATION CONTAINED IN
THIS PROSPECTUS IS CURRENT ONLY
AS OF ITS DATE.

------------------------

TABLE OF CONTENTS

<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Prospectus Summary.................... 1

Risk Factors.......................... 8

Relationship with NYLIFE.............. 14

Use of Proceeds....................... 17

Price Range of Common Stock and
Dividend Policy..................... 17

Capitalization........................ 18

Selected Financial and Operating
Data................................ 19

Management's Discussion and Analysis
of Financial Condition and Results
of Operations....................... 21

Business.............................. 33

Management............................ 46

Principal Stockholders................ 50

Description of Capital Stock.......... 53

Selling Stockholder................... 55
</TABLE>

Underwriting.......................... 56

Notice to Canadian Residents.......... 59

Forward-Looking Statements............ 60

Where You Can Find More Information... 61

Legal Matters......................... 62

Experts............................... 62

Index to Financial Statements......... F-1
</TABLE>

------------------------------------------------------
------------------------------------------------------
------------------------------------------------------
------------------------------------------------------

3,000,000 SHARES

EXPRESS SCRIPTS, INC.

CLASS A COMMON STOCK

------------------------------------------------------

[EXPRESS SCRIPTS LOGO]

------------------------------------------------------

JOINT BOOKRUNNERS

GOLDMAN, SACHS & CO.

CREDIT SUISSE FIRST BOSTON
------------------------

------------------------------------------------------
------------------------------------------------------
A-6
<PAGE> 116

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

The expenses in connection with the issuance and distribution of the
securities being registered, other than underwriting discounts and commissions
(which are described in the prospectus), are estimated as follows:

<TABLE>
<S> <C>
Securities and Exchange Commission registration fee......... $218,252
Legal fees and expenses..................................... $200,000
Accounting fees and expenses................................ $ 40,000
Printing and engraving expenses............................. $250,000
NASD filing fee............................................. $ 30,500
The Nasdaq National Market listing fee...................... $ 17,500
Miscellaneous expenses...................................... $ 5,000
--------
Total..................................................... $761,252
========
</TABLE>

-------------------------

ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS

Section 102(b)(7) of the General Corporation Law of the State of Delaware
(the "Delaware Law") enables a corporation in its original certificate of
incorporation or an amendment to eliminate or limit the personal liability of a
director to a corporation or its stockholders for violations of the director's
fiduciary duty, except (1) for any breach of a director's duty of loyalty to the
corporation or its stockholders, (2) for acts or omissions not in good faith or
which involve intentional misconduct or a knowing violation of law, (3) pursuant
to Section 174 of the Delaware Law (providing for liability of directors for
unlawful payment of dividends or unlawful stock purchases or redemptions) or (4)
for any transaction from which a director derived an improper personal benefit.
Our Amended and Restated Certificate of Incorporation provides for the
elimination of the liability of our directors to the extent permitted by Section
102(b)(7) of the Delaware Law.

Section 145 of the Delaware Law provides, in summary, that directors and
officers of Delaware corporations are entitled, under certain circumstances, to
be indemnified against all expenses and liabilities (including attorney's fees)
incurred by them as a result of suits brought against them in their capacity as
a director or officer, if they acted in good faith and in a manner they
reasonably believed to be in or not opposed to our best interests, and, with
respect to any criminal action or proceeding, if they had no reasonable cause to
believe their conduct was unlawful; provided, that no indemnification may be
made against expenses in respect of any claim, issue or matter as to which they
shall have been adjudged to be liable to us, unless and only to the extent that
the court in which such action or suit was brought shall determine upon
application that, despite the adjudication of liability but in view of all the
circumstances of the case, they are fairly and reasonably entitled to indemnity
for such expenses which the court shall deem proper. Any such indemnification
may be made by us only as authorized in each specific case upon a determination
by our stockholders or disinterested directors that indemnification is proper
because the indemnitee has met the applicable standard of conduct. Article Seven
of our certificate of incorporation entitles our officers and directors to
indemnification to the fullest extent permitted by Section 145 of the Delaware
Law, as the same may be supplemented from time to time.

Article Eight of our certificate of incorporation provides that no director
shall have any personal liability to us or our stockholders for any monetary
damages for breach of fiduciary duty as a director, provided that such provision
does not limit or eliminate the liability of any director (1) for breach of such
director's duty of loyalty to us or our stockholders, (2) for acts or omissions
not in good faith or which

II-1
<PAGE> 117

involve international misconduct or knowing violation of the law, (3) under
Section 174 of the Delaware Law (involving certain unlawful dividends or stock
repurchases) or (4) for any transaction from which such director derived an
improper personal benefit.

ITEM 16. EXHIBITS

<TABLE>
<C> <S>
1.1 -- Form of Underwriting Agreement+
4.1 -- Certificate of Class A Common Stock*
4.2 -- Stockholder and Registration Rights Agreement dated as of
October 6, 2000
4.3 -- Asset Acquisition Agreement dated October 17, 2000
5.1 -- Opinion of Simpson Thacher & Bartlett
23.1 -- Consent of PricewaterhouseCoopers LLP
23.2 -- Consent of Simpson Thacher & Bartlett (included in
Exhibit 5.1)
24.1 -- Powers of attorney++
</TABLE>

-------------------------

* Incorporated by reference in our Registration Statement on Form 8-A dated May
12, 1992.

+ To be filed by amendment.

++ Filed previously.

ITEM 17. UNDERTAKINGS

The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.

Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to the directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act
and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by the final adjudication of
such issue.

We undertake that:

(1) For purposes of determining any liability under the Securities Act
of 1933, the information omitted from the form of prospectus filed as part
of this registration statement in reliance upon Rule 430A and contained in
a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or
(4) or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective.

(2) For the purpose of determining any liability under the Securities
Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial bona fide offering thereof.
II-2
<PAGE> 118

SIGNATURES

Pursuant to the requirements of the Securities Act, we certify that we have
reasonable grounds to believe that we meet all of the requirements for filing on
Form S-3 and have duly caused this Amendment No. 1 to be signed on our behalf by
the undersigned, thereunto duly authorized, in the City of Maryland Heights,
State of Missouri on October 17, 2000.

EXPRESS SCRIPTS, INC.

By: *
------------------------------------
Barrett A. Toan, President and
Chief Executive Officer

Pursuant to the requirements of the Securities Act, this registration
statement has been signed below by the following persons in the capacities
indicated on October 6, 2000.

<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
(1) Principal Executive Officer:

* President, Chief Executive October 17, 2000
--------------------------------------------------- Officer and Director
Barrett A. Toan

(2) Principal Financial Officer:

* Senior Vice President and October 17, 2000
--------------------------------------------------- Chief Financial Officer
George Paz

(3) Principal Accounting Officer:

* Vice President, Chief October 17, 2000
--------------------------------------------------- Accounting Officer and
Joseph W. Plum Assistant Secretary

(4) Directors:

* Director October 17, 2000
---------------------------------------------------
Howard I. Atkins

* Director October 17, 2000
---------------------------------------------------
Stuart L. Bascomb

* Director October 17, 2000
---------------------------------------------------
Gary G. Benanav

* Director October 17, 2000
---------------------------------------------------
Frank J. Borelli
</TABLE>

II-3
<PAGE> 119

<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
* Director October 17, 2000
---------------------------------------------------
Judith E. Campbell

* Director October 17, 2000
---------------------------------------------------
Barbara B. Hill

* Director October 17, 2000
---------------------------------------------------
Richard M. Kernan, Jr.

* Director October 17, 2000
---------------------------------------------------
Richard A. Norling

* Director October 17, 2000
---------------------------------------------------
Frederick J. Sievert

* Director October 17, 2000
---------------------------------------------------
Stephen N. Steinig

* Director October 17, 2000
---------------------------------------------------
Seymour Sternberg

* Chairman, Director October 17, 2000
---------------------------------------------------
Howard L. Waltman

* Director October 17, 2000
---------------------------------------------------
Gary E. Wendlandt

* Director October 17, 2000
---------------------------------------------------
Norman Zachary

*By: /s/ KEITH J. EBLING
---------------------------------------------
As attorney-in-fact for the
person indicated
</TABLE>

II-4
<PAGE> 120

EXHIBIT INDEX

<TABLE>
<CAPTION>
DESCRIPTION PAGE
----------- ----
<C> <S> <C>
1.1 -- Form of Underwriting Agreement+
4.1 -- Certificate of Class A Common Stock*
4.2 -- Stockholder and Registration Rights Agreement dated as of October 6, 2000
4.3 -- Asset Acquisition Agreement dated October 17, 2000
5.1 -- Opinion of Simpson Thacher & Bartlett
23.1 -- Consent of PricewaterhouseCoopers LLP
23.2 -- Consent of Simpson Thacher & Bartlett (included in Exhibit 5.1)
24.1 -- Powers of attorney++
</TABLE>

-------------------------

* Incorporated by reference in our Registration Statement on Form 8-A dated May
12, 1992.

+ To be filed by amendment.

++ Filed previously.